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VOORWOORD 
Mucoviscidose of Cystic Fibrosis (CF) is een relatief zeldzame erfelijk overdraagbare 
aandoening waarbij het kind van beide ouders een gemuteerd CF gen heeft geërfd. 
Vooral de werking van de pancreas en de longen is aangetast door ophopingen van taai 
slijm, wat aanleiding geeft tot een onvoldoende voedselopname en chronische 
longinfecties.  Een halve eeuw geleden stierven de meeste van deze kindjes in de 
kinderjaren. Door een betere en intensieve behandeling is de levensverwachting 
intussen aanzienlijk toegenomen. Wie vandaag met deze ziekte geboren wordt, mag 
hopen de leeftijd van vijftig jaar te bereiken. Hoe vroeger de diagnose wordt gesteld, 
hoe vroeger ook een aangepaste behandeling kan worden gestart. Zo vermijd je een 
lange diagnostische zoektocht voor ouders en kind, en ook – zo hoopt men – voorkomt 
men dat reeds vroegtijdig longschade optreedt, of groeiachterstand. 
Kan een systematische screening van alle pasgeborenen deze belofte waarmaken, en 
heeft ze een gunstige invloed op de levensverwachting? Maar ook de vraag wat een 
dergelijk programma als risico’s inhoudt, en wat het zou kosten. En is het dus zinvol om 
120 000 pasgeborenen te screenen om de diagnose met enkele maanden of een jaar te 
vervroegen voor een 20-tal kinderen? En zo ja, hoe doe je dit best? Dit zijn de vragen 
waarover dit rapport zich buigt. 
We wensen hierbij de multidisciplinaire equipe te danken die dit rapport grotendeels 
geschreven heeft, alsook de externe experts en validatoren die een kritische en 
waardevolle bijdrage leverden.   
 
 
 
 
 
Jean-Pierre CLOSON     Raf MERTENS 
Adjunct Algemeen Directeur     Algemeen Directeur 
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Samenvatting 
INTRODUCTIE 
MUCOVISCIDOSE 
Mucoviscidose (Cystic Fibrosis, CF) is een aangeboren ziekte die autosomaal recessief 
wordt overgeërfd. CF komt meer voor bij kaukasische bevolkingsgroepen. In België 
worden elk jaar ongeveer 35 kinderen gediagnosticeerd met CF. Om aangetast te zijn 
moeten de kinderen een ziekte veroorzakende mutatie dragen in beide genen die 
coderen voor het ‘Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)’ gen. 
Dit resulteert in een tekort aan functioneel CFTR eiwit. Dit eiwit komt vooral voor in 
de celmembraan van de luchtwegen, de gastro-intestinale tractus, de zweetklieren en de 
reproductieve tractus. De afwezigheid van functioneel CFTR eiwit verhoogt de 
viscositeit van de exocriene secreties. De meest ernstige gevallen vertonen een 
meconioum ileus de eerste dagen van het leven. De hoofdkenmerken van de ziekte zijn 
insufficiëntie van de exocriene pancreas en chronische infecties van de luchtwegen. 
Colonizatie met Pseudomonas aeruginosa komt frequent voor en gaat gepaard met een 
achteruitgang van de longfunctie.  
BEHANDELING EN OVERLEVING 
De mediane leeftijd bij overlijden van CF patiënten is sterk gestegen gedurende de 
voorbije decennia, van minder dan 5 jaar in 1950 tot 25 jaar vandaag. Voor CF kinderen 
vandaag geboren wordt een mediane levensverwachting van 50 jaar voorspeld (dit moet 
echter nog worden aangetoond). Dit komt vooral door een verbeterde 
“symptomatische” behandeling zoals die wordt opgestart en regelmatig wordt 
opgevolgd in gespecialiseerde centra bij CF kinderen vanaf een zeer vroege leeftijd. De 
behandeling omvat voedingssupplementen, het vrijmaken van de luchtwegen (oa via 
fysiotherapie van de longen), het bestrijden van luchtwegen infecties (inclusief 
intraveneuse antibiotica) en het onderdrukken van de ontsteking. Het nadeel blijft de 
omvangrijke tijdsinvestering voor deze behandelingen (ongeveer 2 uur per dag 
gemiddeld). Indien een longtransplantatie kan plaatsvinden op het juiste moment kan dit 
ook de overleving verhogen. In België zijn er zeven CF referentie centra. Ze bevinden 
zich allemaal in een universitair ziekenhuis en ontvangen sinds 1999 financiële steun van 
het RIZIV via een conventie. Deze centra behandelen de meeste CF patiënten in het 
land en registreren een aantal klinische gegevens in het Belgische CF register. 
DIAGNOSE EN SCREENING 
Patiënten met CF hebben verhoogde concentraties van natrium en chloor in hun zweet 
en een ‘zweettest’ wordt gebruikt voor de diagnose van CF bij kinderen met tekens en 
symptomen van de ziekte. In contrast met deze klassieke diagnostische benadering, 
worden bij CF NBS vooral asymptomatische pasgeborenen opgespoord. In dit geval zal  
een CF DNA test die een groot aantal mutaties kan detecteren vaak als tweedelijnstest 
worden uitgevoerd. Gezien het klinische fenotype voor een groot aantal minder 
frequente mutaties niet goed gekend is kan de diagnose van CF dus best moeilijk zijn bij 
tot 15% van de gevallen die via screening gedetecteerd worden. 
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NEONATALE SCREENING PROGRAMMA’S 
Neonatale screening programma’s voor CF zijn bestudeerd sinds 1985 en werden 
daarna geïntroduceerd in veel westerse landen of regio’s, inclusief een groot aantal 
staten in de US. In België werd tot nu geen systematisch CF NBS programma opgestart. 
Deze programma’s zijn momenteel gebaseerd op de detectie in het bloed van 
‘immunoreactief trypsinogeen’ (IRT), een merker van pancreas schade. Het nut van het 
toevoegen van een tweede merker voor pancreas schade, ‘pancreatic associated 
protein’ (PAP), is onder studie. Er is geen extra bloedafname nodig voor deze eerste 
screening test gezien gedroogde bloedspots gebruikt kunnen worden. Deze worden in 
de routine gecollecteerd bij pasgeborenen voor de detectie van aangeboren metabole 
ziekten. Zelfs gebruik makend van een zeer hoge IRT cut-off waarde, zullen de meeste 
pasgeborenen die positief testen echter geen CF hebben. Een tweedelijnstest is daarom 
nodig. In de meeste algoritmen volgt dan een DNA test op de originele bloed spot. In 
sommige programma’s wordt een tweede bloedstaal afgenomen en wordt de IRT test 
herhaald, dit om DNA testen op grote schaal te vermijden. Nochtans kan de effectiviteit 
van het programma hieronder lijden gezien het verkrijgen van een tweede staal niet 
mogelijk blijkt bij een klein deel van de doelgroep. 
ONDERZOEKSVRAGEN EN METHODES 
De volgende onderzoeksvragen werden bestudeerd: 
• Welke gegevens zijn gekend ivm de klinische voor- en nadelen van neonatale 
screening voor CF? 
• Is CF NBS kosteneffectief? 
• Welke organisatorische, ethische, legale, en budgetaire aspecten dienen te 
worden meegenomen bij de introductie van CF NBS in België. 
Het project werd grotendeels uitgevoerd door een multidisciplinair team van pediaters 
met ervaring in CF zorg, wetenschappers en experts in neonatale screening, in ethiek en 
in medisch recht. De voortgang van het project werd regelmatig geëvalueerd door 
bijkomende externe experts in CF NBS en vertegenwoordigers van de gemeenschappen 
die voor preventieve zorg verantwoordelijk zijn. 
Een systematisch literatuuronderzoek werd uitgevoerd naar de effectiviteit en de 
kosteneffectiviteit van CF NBS. De organisatorische, ethische, legale en budgetaire 
aspecten zijn gebaseerd op bijkomende verzamelde gegevens, gepubliceerde data en 
analyses van het Belgische CF register van het Wetenschappelijk Instituut voor 
Volksgezondheid. 
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VOORDELEN EN NADELEN 
Het doel van CF NBS is de grote meerderheid van de CF patiënten te diagnosticeren 
voor de leeftijd van 2 maand. Door een vroegtijdige diagnose en het instellen van een 
optimale behandeling kan de longfunctie bij CF patiënten beter bewaard worden tot het 
moment dat ze hopelijk voordeel kunnen halen uit toekomstige behandelingen die het 
basisdefect corrigeren. Een vroege diagnose zal ook een potentieel lange en kostelijke 
diagnostische lijdensweg helpen vermijden.  
DE GERAPPORTEERDE VOORDELEN 
De op studies gebaseerde ondersteuning van CF NBS is niet zo sterk als men zou 
verwachten, wetende dat er toch twee grote gerandomiseerde studies (RCTs) werden 
opgezet om CF NBS te evalueren.  Het ontwerp van de UK RCT (1985-1989) was 
ondermaats en deze studie werd daarom niet weerhouden in een recente Cochrane 
review. De Wisconsin RCT (1985-1995) had wel een correcte design en toonde een 
significant voordeel van CF NBS op het gebied van voeding en groei (gewicht en lengte). 
Op het gebied van longfunctie kon echter geen voordeel van CF NBS aangetoond 
worden op de lange termijn gezien de longen van gescreende CF babies vroeger 
gekoloniseerd werden door Pseudomonas aeruginosa in vergelijking met klinische 
gediagnosticeerde kinderen. Dit werd verklaard door een gebrek aan hygiëne-
maatregelen zoals het  gebrek aan een strikte scheiding van gekoloniseerde en niet 
gekoloniseerde patiënten in een van de twee deelnemende centra. 
De conclusies die men kan trekken op basis van klinische gegevensbanken en enkele 
cohortestudies zijn beperkt door twee redenen. Ten eerste, de “symptomatische” 
behandeling is duidelijk verbeterd over de tijd en dit had een dramatische impact op de 
overleving. Ten tweede, bij screening hebben ongeveer 15% van de gedetecteerde 
kinderen een zeer mild fenotype. Zonder screening zouden ze nooit meegeteld zouden 
worden in de CF patiëntengroep. Beide redenen maken dat de groep van gescreende 
patiënten over het algemeen een betere gezondheidstoestand hebben in vergelijking met 
historische controles die klinisch gediagnosticeerd werden. De echte bijdrage van CF 
NBS blijft daarom moeilijk om in te schatten. Op basis van de observationele data 
wordt er gesuggereerd dat CF NBS aanleiding geeft tot een verbeterde longfunctie en 
dat het de therapielast vermindert. 
Het is vermeldenswaardig dat de hoogste mediane overleving bij CF gezien wordt in 
Denemarken en Zweden, zonder screening, maar gebruik makend van dure en 
intensieve zorgprogramma’s. 
DE GERAPPORTEERDE NADELEN 
De detectie door screening van kinderen met twijfelachtige (‘equivocal’) test resultaten 
die een “variante” vorm van CF suggereren kan voor de familie onzekerheid en angst 
veroorzaken en resulteren in een potentieel onnodige behandeling zonder duidelijk 
voordeel. Dit probleem is echter nog niet afdoende onderzocht in de literatuur.  
Afhankelijk van het gekozen algoritme in het screeningsprogramma maar ook van de 
beslissing om al of niet asymptomatische pasgeborenen met een intermediaire zweettest 
verder te onderzoeken, zullen deze zogenaamde ‘equivocal’ gevallen tot 15% van de 
“CF” kinderen uitmaken die gedetecteerd worden via screening. Dit is nu het geval in 
Frankrijk. Deze gevallen geven aanleiding tot meerdere niet beantwoorde vragen. 
Bovendien zijn de voordelen van CF NBS voor kinderen met een milde vorm van de 
ziekte nooit aangetoond. Ongeveer de helft van deze gevallen zijn gerelateerd aan de 
detectie van de R117H mutatie waarvoor recent een zeer lage graad van penetratie 
werd aangetoond. Het lijkt aangewezen om het aantal van zulke ‘equivocal’ gevallen te 
beperken.  
Een ander potentieel risico verbonden aan het invoeren van CF NBS is dat artsen de 
diagnose van CF niet meer zouden overwegen bij patiënten die zich presenteren met 
suggestieve symptomen. 
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CF ZORG IN BELGIË 
De gegevens voor België zijn gebaseerd op publicaties door de CF centra en analyses 
van het Belgische CF register. Volgens internationale richtlijnen dienen kinderen bij wie 
CF vermoed wordt of die via CF NBS gedetecteerd zijn, onmiddellijk doorverwezen 
worden naar een gespecialiseerd CF centrum voor diagnose, opstarten van de 
behandeling en regelmatige opvolging. De studie van de plaats van de CF centra en de 
andere pediaters en huisartsen in de opvolging van de CF patiënten was niet 
opgenomen in de scope van deze studie. Toch moet vermeld worden dat in 2004 nog 
30% van de CF kinderen pas meer dan 2 jaar na diagnose voor het eerst doorverwezen 
werden naar een CF centrum. 
In België worden 16% van de CF kinderen reeds gedetecteerd via niet 
gestandaardiseerde lokale CF NBS programma’s. Voor sommige van deze lokale 
programma’s werd klinische follow-up na screening als een probleem gerapporteerd en 
een aparte analyse van CF kinderen gediagnosticeerd via screening bleek niet mogelijk. 
Bij de andere CF patiënten zou screening de mediane diagnoseleeftijd kunnen doen 
dalen van 10 maand naar minder dan 2 maand.  
In België bestaan er nog steeds variaties per centrum in de kwaliteit van de zorg voor 
CF. Niettegenstaande deze variatie en de afwezigheid van een georganiseerde neonatale 
screening hebben CF patiënten in België een mediane overleving die goed overeenkomt 
met die in andere westerse landen.  
Ongeveer de helft van de CF patiënten in België  zijn homozygoot voor de frequente 
F508del mutatie en 70% van de patiënten draagt deze mutatie op minstens een van de 
allelen. 
HET ALGORITME EN DE GEVOLGEN 
In lijn met de meeste CF NBS algoritmen die vandaag in gebruik zijn start het 
voorgestelde algoritme met de IRT test voor de initiële screening, gevolgd door een CF 
DNA test in IRT positieve gevallen. Indien zou beslist worden CF NBS te 
implementeren, dient rekening te worden gehouden met de bestaande infrastructuur 
voor neonatale screening die zowel voordelen alsook een aantal nadelen kan hebben bij 
de invoering van CF NBS. 
De informatiebrochures voor de ouders kunnen makkelijk aangepast worden om hen te 
informeren over het uitgebreid screening programma. Alvorens bloed afgenomen wordt 
van de pasgeborene dienen (een van) de ouders expliciete mondelinge toestemming te 
geven na het ontvangen van de nodige informatie over het uitgebreid neonataal 
screening programma, inclusief CF, en het risico op vals positieve en vals negatieve 
resultaten. Geschreven geïnformeerde toestemming is nodig indien men overweegt het 
bloedstaal ook voor onderzoeksdoeleinden te gebruiken. Het routinematig afgenomen 
bloedspot staal kan gebruikt worden voor de initiële testen (IRT en CF DNA) en 
volgens het voorgestelde algoritme zal het slechts uitzonderlijk nodig zijn een tweede 
staal af te nemen. 
Dit screening algoritme vereist echter meer standaardisatie van de methodes over de 
deelnemende laboratoria dan wat vandaag het geval is. Tevens introduceert het 
algoritme formeel een DNA test als tweedelijnstest.  
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De uitdaging van het gebruik van de 99,5 percentiel voor IRT. 
De initiële screening is gebaseerd op het gebruik van de percentiel 99,5 als cut-off 
waarde voor IRT. IRT is een eerder goedkope test om uit te voeren maar voor de 
neonatale screening laboratoria die deze test wensen uit te voeren houdt dit een 
volledige standaardisatie in van de analytische methode tussen de laboratoria (protocol, 
reagentia merk en batch, en afleesinstrument). De aankoop van een gemeenschappelijk 
systeem kan best gebeuren via publieke aanbestedingsprocedure. Het voordeel van het 
integreren van de PAP test in het algoritme is nog onder studie. Deze test zou 
potentieel het aantal DNA analyses nog verder kunnen doen dalen, en dus ook het 
aantal gedetecteerde gezonde dragers en ‘equivocal’ mutaties. Resultaten van een 
pilootstudie hebben recent geleid tot een aanbeveling door de Gezondheidsraad in 
Nederland om te starten met CF NBS op basis van IRT en PAP. 
DNA testen voor CF en gerelateerde problemen 
Volgens het voorgestelde screening algoritme, zal de tweede screening stap, een CF 
DNA test, uitgevoerd worden op ongeveer 600 bloedspot stalen (0,5% van de 
ongveer120 000 neonaten elk jaar). De mutaties die veel voorkomen in de Belgische 
bevolking zijn opgenomen in de mutatie panels van commercieel beschikbare test kits. 
Voor immigranten (en als de kost significant daalt misschien voor alle stalen in de 
toekomst) is sequencing van de CFTR allelen de meest gepast methode. Het 
laboratorium zou enkel dienen te screenen voor mutaties die geassocieerd zijn met een 
significant risico op ernstige ziekte. De voordelen van het screenen op ‘equivocal’ 
mutaties zijn niet duidelijk en de communicatie van positieve resultaten zonder klinisch 
belang zou psychologische schade kunnen veroorzaken.  De periode tussen het 
informeren van de familie van een positief screening resultaat en het onderzoek nodig 
voor een diagnose dient zo kort mogelijk te zijn. 
Het voorstellen van CF DNA analyse aan de ouders dient met de nodige 
voorzichtigheid te gebeuren, gezien uit de test soms het kan blijken dat de vader niet de 
natuurlijke vader is. Hierbij dient opgemerkt dat een ongekende fractie van de 15000 CF 
DNA testen die elk jaar terugbetaald worden in België gebruikt worden voor  
opportunistische carrier screening bij toekomstige ouders. In tegenstelling tot CF NBS, 
zijn de voor- en nadelen, de kosten en de ethische aspecten van deze opportunistische 
vorm van screening van toekomstige ouders niet goed gedocumenteerd. Het is duidelijk 
dat het nut van CF NBS grotendeels wegvalt indien beide ouders reeds negatief testten 
op CF DNA.  
De Zweettesten 
Wegens hun belang bij de diagnose en hun technische moeilijkheidsgraad zouden 
zweettesten enkel mogen uitgevoerd worden in laboratoria die strikt de internationale 
richtlijnen volgen en ISO 15189 geaccrediteerd zijn voor deze test.  
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GEZONDHEIDSECONOMISCHE OVERWEGINGEN 
Er zijn te weinig betrouwbare gegevens die als input kunnen dienen van economische 
modellen van CF NBS. Vooral het effect van screening los van de verbeterde 
behandeling over de tijd is onduidelijk. Na een systematisch literatuuronderzoek 
werden geen kosteneffectiviteitanalyses van CF NBS weerhouden die en robuust en ook 
nog actueel waren. Sommige analyses veronderstellen een verbetering in kwaliteit van 
leven bij kinderen gedetecteerd via screening, zonder dat daar echter betrouwbare 
metingen rond bestaan. Een recente kosteneffectiviteitanalyse voor Nederland was 
gebaseerd op de veronderstelling dat na CF NBS de 6% mortaliteit bij CF kinderen 
onder de 10 jaar zou dalen met 1.5%. Deze aanname is gebaseerd op mortaliteitsdata uit 
het verleden en is niet langer actueel. Momenteel is de mortaliteit bij CF kinderen 
onder de leeftijd van 10 jaar 2% in België. Veronderstellen dat na CF NBS er nog een 
daling komt met 1,5% in mortaliteit lijkt weinig realistisch.  
De budget impact van NBS CF in België werd ingeschat op €340 000 – €635 000, enkel 
gebaseerd op de kosten voor het uitvoeren van IRT, DNA, een mogelijke tweede IRT 
en de zweettesten. Een groot aantal andere items (bvb kosten voor het behalen van ISO 
15189 accreditatie, kosten voor coördinatie en supervisie, kosten voor genetische 
counseling, prijsonderhandelingen, enz.) kunnen deze budget impact schatting verhogen 
of verlagen. Gebaseerd op expert opinie kan het totale budget wellicht onder de €1 
miljoen blijven.  
Een belangrijke vaststelling is dat de reële kosten en de waarde van de RIZIV 
terugbetaling voor die activiteit sterk kunnen verschillen, zoals voor CF DNA testen 
(€150 kost t.o.v. €320 terugbetaling) en zweettesten (€126 kost t.o.v. €72 terugbetaling 
voor test in duplo). Het aantal testen in de context van CF NBS vertegenwoordigen 
voor CF DNA (n=600, plus mogelijks detective van dragers van het gen) en zweettesten 
(n = 75 pasgeborenen x 2 testen per kind) slechts een kleine fractie van de in totaal 
15000 CF DNA testen en 6400 aparte zweettesten die elk jaar terugbetaald worden, 
zelfs rekening houdend met een klein aantal klinische CF diagnoses die gemist werden 
door de screening en het testen van broers en zussen van geïdentificeerde CF kinderen.  
De budget impact voor het implementeren van CF NBS is klein in vergelijking met het 
budget dat elk jaar gespendeerd wordt voor het terugbetalen van de CF DNA testen, 
grotendeels voor het detecteren van dragers van het gen op ingestuurde stalen. Alleen 
al de terugbetaling van CF DNA testen aan de reële kost zou een jaarlijkse besparing 
opleveren van meer dan €2 miljoen, of meer dan het dubbel van het budget dat nodig is 
om CF NBS te financieren. 
CONCLUSIE 
De invoering van een programma voor CF neonatale screening programma in België zal 
een soms langdurige en dure diagnostische lijdensweg helpen vermijden en bij de CF 
kinderen die zo vroeger gediagnosticeerd worden de groei in lengte en gewicht 
bevorderen. Mogelijks is er ook een voordeel van CF NBS op longfunctie en wordt de 
therapie last minder zwaar, maar dit is niet aangetoond in RCTs. De voordelen naar 
overleving toe zijn waarschijnlijk niet langer aantoonbaar gezien de verbeterde zorg de 
vroegtijdige sterfte al sterk verminderd heeft. De voordelen van CF NBS zijn enkel 
groter dan de nadelige effecten, bvb door ‘equivocal’ CF diagnoses, indien een aantal 
kwaliteitscriteria voor screening strikt gevolgd worden. 
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AANBEVELINGEN DOOR HET KCEa 
• Alle kinderen gediagnosticeerd met CF zouden onmiddellijk na diagnose 
(gebaseerd op screening of klinisch) moeten kunnen genieten van de hoogst 
kwalitatieve zorg (die nog betaalbaar is), gezien zulke verbeterde zorg een 
dramatische impact heeft op de overleving.  
• Teneinde de kwaliteit van de zorg in de CF centra naar een uniform hoog 
niveau te brengen, dienen kwaliteitsindicatoren regelmatig te worden 
gemeten en dient de deelname aan initiatieven tot kwaliteitsverbetering te 
worden verplicht voor CF centra met een conventie. 
• Het opstarten van lokale CF NBS programma’s zonder evaluatie van 
patiëntenuitkomsten is een gemiste kans en is te vermijden. 
• De publieke financiering van twee grotendeels overlappende screening 
initiatieven dient in vraag gesteld (CF NBS programma en het lopende 
grootschalige opportunistische screenen op CF dragerschap van 
toekomstige ouders). 
• De beslissing om CF NBS te in te voeren hangt voornamelijk af van de 
balans van de voor- en nadelen. De voordelen van CF NBS zijn groter dan de 
nadelen enkel indien volgende voorwaarden strikt vervuld zijn:  
o Alvorens bloed afgenomen wordt van de pasgeborene dienen (een van) 
de ouders expliciete mondelinge toestemming te geven na het ontvangen 
van de nodige informatie over het uitgebreid neonataal screening 
programma, inclusief CF, en het risico op vals positieve en vals negatieve 
resultaten.  
o De nodige aandacht dient besteed te worden aan een optimale 
doorstroming van de informatie wanneer een zweettest aangewezen is 
bij een pasgeborene met een positief screeningsresultaat. De periode 
tussen het informeren van de familie van een positief screening resultaat 
en de diagnostische bevestiging dient zo kort mogelijk te zijn.  
o De nadelen van screening kunnen tot een minimum beperkt worden 
indien enkel gescreend wordt voor mutaties die geassocieerd zijn met 
een significant risico op ernstige ziekte.  
o Voor de via screening gedetecteerde kinderen dient de huidige 
zorgstandaard van strikte scheiding van patiënten op basis van hun 
microbiologische status te worden gegarandeerd om vroegtijdige 
kolonisatie met Pseudomonas aeruginosa te vermijden.  
o Het voorgestelde screening algoritme (gebruik van de 99.5 percentiel als 
cut-off) vereist dat de IRT testen uitgevoerd worden via eenzelfde test 
systeem en een enkele batch van reagentia voor gans België. De 
neonatale screening laboratoria dienen te beschikken over een ISO 15189 
accreditatie voor deze tests. Een gezamelijke aankoopprocedure dient te 
worden overwogen voor de aanschaf van een gemeenschappelijk 
diagnostisch systeem. 
  
                                                     
a  Alleen het KCE is verantwoordelijk voor de aanbevelingen aan de overheid.  
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o De CF DNA testen in de context van screening dienen te worden 
gestandaardiseerd en enkel te worden uitgevoerd in laboratoria die over 
een ISO 15189 accreditatie beschikken voor deze test. Bovendien moet 
de ‘test turnaround time’ het screening proces respecteren en mag niet 
meer dan 1 week bedragen. Een verlaging van het terugbetaalde bedrag 
in lijn met de reële kosten dient te worden overwogen. 
o Zweettesten mogen enkel uitgevoerd worden in laboratoria die over een 
ISO 15189 accreditatie beschikken voor deze test en die de internationale 
richtlijnen voor deze test respecteren. Een verhoging van het 
terugbetaalde bedrag in lijn met de reële kosten dient te worden 
overwogen. 
o Artsen moeten geïnformeerd worden van het belang van een vroege 
diagnose en doorverwijzing van CF patiënten en ervan bewust zijn dat 
zelfs na implementatie van CF NBS een aantal gevallen van CF nog 
steeds gediagnosticeerd moeten worden op basis van ziektetekens en 
symptomen.  
o Gezien de complexiteit van CF NBS, de nood voor standaardisatie tussen 
de centra, en de nood om de outcome van de patiënten op te volgen 
wordt de oprichting van een permanente multidisciplinaire stuurgroep 
aanbevolen. 
• Onderzoeksagenda 
o Het evalueren van de integratie van de PAP test in het screening 
algoritme gebaseerd op de resultaten van de lopende studies en de 
recente aanbeveling te starten met zulk een screening algoritme in 
Nederland. 
o Het evalueren van de beste praktijk voor de opvolging van de CF 
patiënten, met inbegrip van de rol van het CF centrum, de pediater en de 
huisarts.  
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1 GENERAL INTRODUCTION 
1.1 CYSTIC FIBROSIS 
Cystic Fibrosis (CF) is the most common lethal genetic disease in white populations 
with an incidence throughout the world of 0.25- 5 per 10 000 live births.1 In other races 
CF is also found but with a lesser frequency. The disease was first recognized as a 
separate disease entity by a pathologist in 1938.2 
CF is a complex multi-organ disease with a variable clinical spectrum. The most typical 
CF patient has pancreatic insufficiency and recurrent pulmonary symptoms together 
with an abnormal sweat test. A five-fold excess of chloride in the sweat of CF patients 
was demonstrated in 19533 and permitted the development of the sweat test4 which 
remains the gold standard diagnostic tool in CF. Although the vast majority of CF 
patients are diagnosed through the combination of classic signs and symptoms of the 
disease and corroborative laboratory results, the diagnosis is not as clear-cut in 
approximately 5% of individuals with CF. A recent Cystic Foundation Consensus Report 
summarizes current recommendations and includes detailed guidance for the diagnosis 
of both infants with positive newborn screening and older patients with less typical 
clinical picture.5 
CF is caused by a mutation in a gene that encodes the ‘Cystic Fibrosis Transmembrane 
Conductance Regulator’ (CFTR) protein, which is expressed in many epithelial cells. 
The CFTR gene6 is located on the long arm of chromosome 7. The corresponding 
protein is a chloride channel regulating ion and water balance across epithelia.7, 8 
Absence of functional CFTR results in increased viscosity of exocrine secretions. The 
hallmarks of the disease are exocrine pancreatic insufficiency and chronic lung infection.  
More than 1600 mutations have been identified (see the CFTR mutation database: 
http://www.genet.sickkids.on.ca/cftr/app). One common mutation (F508del) accounts 
for about 70% of all mutant CFTR alleles while 10-20 less common mutations represent 
a further 10-15% of all mutant alleles. 
According to their impact on the CFTR protein, mutations have been grouped into 5 
classes:9 
• Class I includes mutations which result in disruption of the CFTR protein 
synthesis and typically lead to the creation of premature termination 
codons  (G542X, W1282X …). 
• Class II mutations are associated with defective protein processing 
(F508del, N1303K …). F508del is by far the most common mutation and 
its prevalence in Belgian CF patients is 67%. These mutations result in the 
synthesis of a misfolded CFTR protein that will be almost totally degraded 
in the endoplasmic reticulum (>99% vs 75% in normal protein). 
• Class III mutations lead to the production of proteins which reach the 
plasma membrane. However their regulation is defective: they cannot be 
activated by ATP or cyclic AMP (G551D …).  
• Mutations in the two remaining classes, class IV (defective conductance: 
D1152H …) and class V (reduced function/synthesis - mainly including 
splicing mutations: 3849+10kbC→T …) produce CFTR variants with 
residual expression and/or function.   
The prognosis of a child born with cystic fibrosis in the fifties was very grim with most 
children dying before their 5th birthday from pancreatic insufficiency (PI) and 
malnutrition. In the United States, the median survival of an individual with CF is 36.5 
years, data published in 2006,10 with more than 90% of patients dying from lung-related 
disease. A recent United Kingdom report studied CF mortality in consecutive three 
year birth cohorts.11 Comparison of the 1968-1970 cohorts with recent birth cohorts 
shows that survival has increased dramatically. The median life expectancy for the CF 
population born in 2000-2003 is estimated at 50 years.  
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For babies with CF born nowadays, the disease is - although still life shortening - 
primarily a chronic disease with a high burden of therapy and complex care.  This 
should not mask the impressive list of complications of this disease, several of which are 
life-threatening. In Belgian as in several western countries close to 50% of current CF 
patients are 18 years or older. In the next decade the majority of people with CF will be 
adults. Here too, however, it is clear that this progress comes with prices:  
• a number of “new” complications are now emerging in adults, including 
high prevalence of CF related diabetes of > 30% above 30 years12 
• a high prevalence of early osteoporosis13  
• an increased incidence of digestive tract cancers14 and iatrogenic diseases.   
1.2 CF TODAY: AN EXTREMELY DEMANDING 
SYMPTOMATIC TREATMENT 
As a result of a more comprehensive approach of symptomatic treatment, the survival 
of CF patients improved markedly over the past decades. The drawback is the 
tremendous  burden of therapy: a recent US study in CF adults reported that the daily 
mean time spent on treatment activities was 108 minutes (± 58).15 A large fraction of 
these activities consists of nebulation of mucolytics and inhaled antibiotics together with 
chest physiotherapy. 
Such complex care is best implemented in specialized centres (see chapter 5), which has 
been recognized more than 40 years ago in North-America. 
Four pillars of the symptomatic treatment have long been established. They include 
nutritional repletion, relief of airway obstruction, treatment of airway infection and 
suppression of the inflammation.16 
Yet, CF is a progressive disease of which the natural course that we are just trying to 
slow still leads to the destruction of the lungs. In end-stage lung disease, life can be 
extended by lung transplantation. Recent follow-up data on transplanted CF patients 
show survival rates between 60% and 70% five to seven years after transplantation.17, 18 
It should be kept in mind that the intensity of follow-up and burden of therapy remains 
high after transplant.  CF lung disease is exchanged for post transplant disease with risk 
of bronchiolitis obliterans, opportunistic infections and post-transplant malignancy.  
The most important issue concerning transplantation is timing. Being transplanted too 
early may shorten survival, while postponing too long means that they may die while on 
the waiting list. The relative contribution of lung transplant to overall CF survival 
statistics is currently under debate.19-21 
1.3 THE FUTURE: TOWARDS A CURATIVE TREATMENT 
Advances in symptomatic treatment will continue but new approaches to therapy 
attacking the basic defect are now required to both further improve the prognosis and 
reduce the burden of the treatment. The major aim of CF search is now to find a cure. 
Since the discovery of the CFTR gene in 1989, CF has been considered a prime 
candidate for gene therapy by inhalation. However, the search for an efficient vector 
and the problem of thick mucus that forms a barrier to reach the epithelia have proved 
to be major obstacles. Additionally, host-specific immune responses generated against a 
virus-derived vector may pose a problem.22, 23 While initially promising, research has 
now been limited to few centres because of disappointing results so far.24, 25 
Two pharmacological alternative strategies are now explored,26 some examples of 
which are detailed below:  
• Circumventing the CF-related ion transport defect, by increasing chloride 
secretion and/or inhibiting excess sodium reabsorption. Several 
medications aim to restore airway surface liquid without targeting CFTR. 
Phase 2 trials of MOLI1901 and SPI-8811 are ongoing while Phase 3 trials 
of hypertonic saline, denufosol, bronchitol have begun. 
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• Developing allele-specific therapies to correct the specific defects in 
mutant forms of CFTR.    
Class I mutations are characterized by the presence of a premature termination codon 
(PTC) resulting in a truncated and often non-functional protein. Agents that suppress 
the normal proof reading function of the ribosome can overcome diseases caused by 
PTCs.  In preclinical settings high dose aminoglycosides induce such a translational 
‘read-through’ and restore protein function,27 however the potential renal and 
ototoxicity limit their clinical use. ATALUREN (formerly known as PTC124) has been 
studied in healthy volunteers and in CF.28, 29 Results of phase 2 studies have recently 
been published30 and a phase 3 study is now ongoing.  
Similarly, encouraging data have been reported using VX-770 in adults with CF and at 
least one copy of the mutation G551D. This “potentiator” is believed to help to open 
the chloride channel in CF cells. In a randomised, double-blind, placebo-controlled 
study, this agent appeared to be safe and was associated with significant improvements 
in terms of the forced expiratory volume in 1 second (FEV1), nasal potential difference 
measurements and sweat electrolytes. Two Phase 3 studies began in the summer of 
2009. 
VX-809 is a “corrector” that is expected to improve CFTR cell trafficking and its 
function as a chloride channel. A large Phase 2a trial of this compound is ongoing in 
patients homozygous for the F508 del mutation.  
1.4 CF NEWBORN SCREENING (CF NBS) IN THIS CONTEXT 
Perspectives of curative treatment have modified the objectives of CF dedicated 
physicians. An important part of the challenges they are now facing is to preserve lung 
function of many children (and a much smaller proportion of adults) by maximising 
current treatment regimens, so that they can benefit fully from future therapies that 
could correct the basic defect.31 
A number of studies using bronchoalveolar lavage (BAL) markers of infection and 
inflammation but also lung function tests and more recently computed tomography of 
the chest have documented that significant lung damage occurs very early in many, even 
asymptomatic CF infants.32-35 
Universally coupled with immediate referral to CF centres, CF NBS has expanded 
rapidly to most western countries including all US states except one within a few years. 
By permitting earlier diagnosis and optimal treatment, it has the potential to be one of 
the factors helping many patients to reach the key moment of “the cure discovery” with 
clear enough lungs. Centre-based36-38 and/or wider scale quality improvement 
initiatives39, 40 are obviously necessary too. 
1.5 PURPOSE OF THIS REPORT 
This work aimed to address the following issues around CF NBS: 
• Clinical effectiveness: summary of current evidence  
• Possible harms and how to minimize them   
• Current guidelines for implementation and care after screening 
• Belgian data: current outcome and room for improvement 
• Choosing a screening algorithm 
• Ethical and legal aspects 
• Economical aspects 
The issue of community-wide screening for cystic fibrosis carriers is beyond the scope 
of this report.  
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1.6 SEARCH STRATEGY 
The search strategy is described in detail below (Appendix 1). The electronic databases 
Medline and Embase were searched for NBS and CF, using 17 keywords. The priority of 
this step was to encompass the issues addressed in chapters 2, 3 and 4. Some specific 
aspects of other chapters necessitated the addition of articles derived from the list of 
references in relevant publications and the authors’ collection of references. Selection 
of articles and the quality appraisal was performed by two authors of this report (M. 
Proesmans and P. Lebecque).   
• For the review the effectiveness of CF NBS 55 abstracts were selected for 
which the full texts were read. In the references of these articles 19 
additional references were found as possibly relevant. For these 55+19 
references (read as full text) the following selection criteria were used: 
studies comparing outcome parameters of a screened versus a non 
screened group, RCT (1), non-RCT (2), and reports from CF registries 
(3). Additionally, systematic reviews were retrieved together with articles 
on guidelines after screening. Were not selected: non-systematic reviews, 
letters and comments, studies not specific on screening, studies not 
comparing a screened versus an non screened group.  
• Using these selection criteria 32 articles were selected for chapter 2 
(clinical effectiveness). Quality appraisal was performed for the non-RCT 
studies. For the RCTs the quality appraisal as performed by the authors of 
the Cohrane review was used. After a quality appraisal (see text and 
tables in appendix 4, four articles were rejected (detailed in section 
2.2.1.4), leaving 28 articles. 
1.7 ABOUT A FEW KEY REVIEWS 
A few references identified by the search strategy provide such an exhaustive and 
comprehensive background on the topic of CF NBS that they unavoidably serve as a 
basis for a large part of the current report and will often be cited. The reader’s 
attention is especially drawn to 5 papers,41-45 briefly commented in Appendix 2. 
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2 CLINICAL OUTCOME AFTER NEONATAL 
SCREENING 
2.1 INTRODUCTION 
Neonatal screening for CF (CF-NBS) has been in use in some areas as early as the 
seventies. Initially test quality was insufficient (measuring meconium protein levels). 
Later, ‘immunoreactive trypsinogen’ (IRT) in blood, a marker of pancreatic injury was 
introduced. Infants with CF have a raised IRT level at birth that remains elevated in the 
first weeks of life. The drawback of the IRT test is the high number of false positives. 
Combining the IRT with DNA analysis or another biochemical marker (for example 
‘PAP’ pancreatic associated protein) increases test performance. For systematic review, 
technical aspects and references on neonatal screening algorithms we refer to chapter 
6. 
Several studies have shown that starting therapy very early (also in asymptomatic 
children at time of diagnosis) improves clinical outcome and prognosis, ‘early’ being 
specified as before 2 months of age.46, 47 The median age at diagnosis for children with 
CF diagnosed on clinical ground in Belgium however is 6 months (Belgian CF registry 
data; see chapter 5). 
The rationale of CF-NBS is thus to lower the age at diagnosis and institute adequate 
treatment and follow-up also in pre-symptomatic infants. The ultimate goal is to 
improve long term prognosis. 
Knowing that CF patients are generally well nourished at birth but develop PI in 90% 
(around 60% within the first weeks of life48), delayed diagnosis will lead to severe 
malnutrition. The CF lung is normal at birth but lung disease usually develops as early as 
2 months. Pseudomonas aeruginosa (PA) infection and colonization occur in one out of 3 
undiagnosed patients. 
The aims of CF-NBS are :  
• Early treatment with pancreatic enzyme replacement therapy (PERT), diet 
and fat soluble vitamins to improve long term nutritional status  
• Early therapy to prevent and treat lung infection by close monitoring of 
sputum cultures in order to slow down progression of lung disease and to 
diminish treatment burden 49-52  
• Avoiding a diagnostic odyssey with resulting parental stress  
• Allowing genetic counselling for future pregnancies 
• Reducing burden and thus cost of treatment by preventing complications.  
NBS may however carry risks:  
• Parental stress around false positive diagnosis and dubious diagnosis 
• In order to set-up the necessary early follow-up and treatment, infants 
even when presymptomatic, may be exposed to nosocomial infections, 
and  
• Late diagnosis in initial false negative tested children (see also chapter 3.) 
In the following part we summarize existing literature on clinical outcome. Possible 
harms are reviewed in Chapter 3. 
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2.2 SUMMARY OF RELEVANT LITERATURE 
Randomized controlled trial (RCTs) are in theory the most reliable source of evidence 
for evaluating effectiveness of newborn screening. However, these trials are difficult to 
set up and large numbers of newborns need to be screened in order to have sufficient 
diagnoses to compare. Additionally, depending on the unblinding and the randomization 
procedure, the screened group (SG) may not be comparable to the clinical group (CG) 
because of missed cases in the latter: this may lead to overrepresentation of more 
severely diseased patients in the CG. Also the close monitoring of patients in RCTs can 
lessen the validity of the results. Therefore data of observational studies are valuable as 
well. Interpretation of this type of studies needs to be done with care. Even more than 
with RCT, CG and SG may not be comparable, mild cases being missed in the CG. For 
studies reporting comparison with historical controls, it is important to distinguish 
between the effect of screening versus the effect of increased awareness and improved 
diagnostic and therapeutic options over time. Finally, analysis of large patient registries 
gives information over long term evolution of SG and CG. 
There are only 2 RCTs found on CF-NBS. Each trial resulted in several reports with 
varying length of follow-up and reporting on different aspects of outcome (UK trial and 
USA Wisconsin trial). Observational data are discussed for Australia (New South 
Wales), north of France, USA (Connecticut) and Italy (Piemonte).  Registry data for UK 
and US have been published. 
Results are summarized per outcome parameter. The tables in appendix 3 summarize 
the publications separately. The quality appraisal of the non-RCT trials discussed here is 
detailed in appendix 4. The Cochrane review rejected one of the two RCTs (the UK 
trial) based because of ascertainment bias and the absence of intention to treat analyses. 
Because it concerns a very large trial, we have included the UK RCT in this document. 
We have mentioned its shortcomings and did not consider it to for the final conclusions 
on effectiveness.  
2.2.1 General overview 
2.2.1.1 Wisconsin trial 
CF- NBS was performed from 1985-1994 (initially IRT, after 1991 IRT/F508del testing). 
Only half of the positive screened children (those with odd digit number on the Guthrie 
card) were recalled for sweat testing. Data were un-blinded when the children reached 
the age of 4. CF presenting with meconium ileus (MI) at birth was excluded from the 
analysis. Follow-up data are available for 15 years. Mean age at diagnosis was 12 weeks 
(SD 37) versus 72 (SD 106) weeks. Median age at diagnosis was 7 weeks (range 4-281) 
in the screened group (SG) (n=56) versus 23 weeks (3-372) in the control group (CG) 
(n=40).53 By chance the SG differed at baseline from the CG with more PI patients (79% 
vs. 58% p=0.012) and more F508del mutations (53% homozygotes vs. 43% p=0.012) (i.e. 
more ‘severe’ mutations).54 
2.2.1.2 UK RCT trial 
From 1985-1989 infants born in Wales and West Midlands were screened with IRT on 
an alternate week basis, thus identifying 2 groups in the same area. For both groups 
babies with MI or a sibling with CF were excluded. Screened (n=58) and clinically 
diagnosed CF children (n=44) were followed annually for 4 years. Nine children 
diagnosed clinically after false-negative screen were analysed in the clinical group (CG 
44= 35+9). MI was excluded from the analysis. Mean age at diagnosis was 9.1 (SD 3.1) 
weeks for the SG versus 50.7 (SD 60.5) weeks for the CG. Median age at diagnosis was 
not reported. From a figure in the publication it can be deduced that the range was 4-22 
weeks and 5-230 weeks respectively. Follow-up was not necessarily in an accredited CF 
centre and there was no uniform treatment protocol.55 
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2.2.1.3 Methodological concerns about the 2 RCT studies 
Cochrane reviewers identified six trials potentially fulfilling search criteria of RCT or 
nearly-controlled randomized study about NBS outcomes but only two were retained 
for further analyses of data based on strict eligibility and quality criteria of Cochrane’s 
method selection.42 The first RCT is the Wisconsin CF Neonatal Screening project 
which randomly assigned 650 341 neonates born in Wisconsin during 1985-1994 to 
either a screened (n = 325 171) or control group (n = 325 170).53 The second RCT is 
the UK trial where screening took place on alternate weeks from 1985 to 1989 
(screened group: n = 230 076, control group: n = 243 510).55, 56  
From the latest published reports of these trials, Cochrane reviewers identified 108 CF 
patients (57 in the screened group, 51 in the control group) and 176 CF patients (86 in 
the screened group and 90 in the control group) respectively.42 Risks of bias of these 
studies were carefully analysed in this updated Cochrane review42 and were most 
critical for the UK trial where they included among others, a lack of consistency for an 
intention-to-screen analysis and ascertainment bias (including a too heterogeneous 
management in SG). The UK study finally was removed from the Cochrane analysis, 
which left the Wisconsin study as unique RCT validated. 
Some methodological remarks have to be made about the Wisconsin study too. First, to 
avoid a risk of lead time bias in this RCT, only data after the unblinding of the control 
group at four years of age were analysed and reported.42 Thus, some important 
comparative data before the age of 4 were considered not comparable and were thus 
not evaluated by Cochrane reviewer as for example, the demographic data in both 
groups at the time of diagnosis.53 
Another methodological issue- revealed by the unexpected high survival rate even in the 
CG (no death prior to 10 years) - needs to be considered. The Wisconsin study was 
not powered to evaluate mortality as an endpoint.57, 58 However, the absence of death 
before age 10 - unlike in the general paediatric population with CF in the respective 
time period- is most probably secondary to the close follow-up provided in this RCT 
which did not take place in the UK randomized trial.58 Thus, although the results of that 
RCT have internal validity, they may lacking external validity, which is not an uncommon 
problem with RCTs.58 The usual close monitoring of patients in RCT can lessen the 
external validity or ‘generalizability’ of results to individuals receiving care in the 
community.57 In the Wisconsin study, several aspects of this unusually close monitoring 
of infants and young children involved in this trial can be outlined. First, parents from 
both groups were well informed about CF and NBS54 and they knew that they could get 
premature access to the assignment of their child if needed. It is remarkable that 
(before unblinding) the median age at diagnosis in the CG was reduced by 13-14 weeks 
compared to ‘usual’ time-to-clinical-based diagnosis in daily practice before start of the 
trial (22-23 weeks instead of 36 weeks).53 Moreover, the median age of diagnosis 
continuously decreased along the randomization period.50, 59, 60 This does not mean that 
mothers brought numerous milder CF patients to clinical practice centre, but they 
brought clinically suspected CF patients earlier than they would have done, if 
uninformed about the disease. 
Another ascertainment bias was generated by the interventions of the coordinators of 
the study towards general practitioners (GP). GPs were regularly called and motivated 
to detect as soon as possible any false-negative of NBS or any new CF cases from the 
control group.54  
The Wisconsin Trial is however a landmark study and it should be realized that the 
above described bias concordantly could have partially masked the benefits of CF NBS. 
The same holds also true for the trend to higher proportion of pancreatic insufficient 
patients and F508del homozygote in the screened group despite the randomization 
process.54 Even more importantly, the lack of consistent patient segregation in one of 
the 2 led to a higher rate of Pseudomonas acquisition in the SG, again possibly masking 
other possible screening advantages. The latter point has such prognostic implications 
that it is further discussed elsewhere (2.3.2.6.1). 
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2.2.1.4 Other (non-RCT ) studies 
Several retrospective observational studies compare the outcome of CF patients 
diagnosed with NBS with either recent historical controls or contemporary CF patients, 
clinically diagnosed (Netherlands, Italy, France, New South Wales Australia, Connecticut 
USA).  
The oldest observational data on nutritional and respiratory parameters come from the 
Netherlands.61-63 These data concern patients born from 1973 to 1979 and diagnosed 
based on measurement of meconium protein levels, a test with even less specificity and 
sensitivity compared to IRT. Historical controls were used as comparison. Based on 
these arguments the authors decided that the relevance of these data in the context of 
current CF care is low. Results of these three reports are therefore not further 
discussed.  
Nutritional outcome has been reported for CF patients diagnosed after screening from 
1983 to 1992 in Veneto, Italy compared to CF children with a clinical diagnosis born in 
the same time period in Sicily.64 Although according to the report they were treated 
following the same protocol, the 2 regions are geographically far apart and differ 
significantly in socio-economic status, a factor known to influence clinical outcome in 
CF. For these reasons, this report is not further discussed. For the other retrospective 
observational studies included in this report a quality appraisal was performed (see 
Appendix 4). Data from these studies are discussed further in this document.  
Finally, CF patient registries provide data comparing results of screened versus 
unscreened patients (UK and US – Cystic Fibrosis Foundation (CFF) registry) (see also 
quality appraisal).  
2.2.2 Summary of effect of NBS on clinical outcome 
2.2.2.1 Growth: weight /height 
In the UK trial, no differences were found in height- or weight z-score at any age up to 
age 3.55  
In the Wisconsin trial however a clear nutritional benefit for the screened group was 
documented. In the report of 1997,53 data on 56 screened group (SG) and 48 clinical 
group (CG) children are reported. Height and weight z-scores were significantly better 
at diagnosis for SG and this advantage persisted during the 10 year follow-up (repeated 
measurements analysis) with the largest differences for weight during the first 5 years. 
Number of patients evaluated at age 10 were however only 4 (SG) and 9 (CG). A 
follow-up report54 evaluating patients until age 13, confirmed a significantly better height 
but marginally significant weight advantage in the screened group (numbers evaluated at 
age 10 being only 17 and 13). Expressing height and weight as proportion of patients 
with values below the 10th percentile (P10), showed better values for the SG. The odds 
ratio (OR) for having a weight below P10 compared to the SG was 4.12 (95% CI 1.64-
10.38) for CG patients while for height OR was 4.62 (95%CI 1.70-12.61). No 
differences in dietary intake were demonstrated. Additionally smaller head 
circumference at diagnosis was documented in the non-screened group.54 
A Cochrane review analysing the Wisconsin RCT42 concludes that severe malnutrition 
is less common among screened patients.  
IRT screen was initiated in New South Wales, Australia from 1981. CF children 
diagnosed with CF and born in the 3 years before 1981 (n=57) were compared to CF 
diagnosed after newborn screening (NS) between 1981-1984 (n=60).65, 66 Since historical 
controls are used, data have to be interpreted with care (see also quality appraisal). At 
1 year screened patients were significantly heavier but not taller, while at 5 and 10 years 
they are taller but not heavier.65 At age 15 years (n = 48 non screen and n= 52 screen) 
both groups had comparable height and weight z-scores.66 
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In a French cohort study, screened and non-screened patients born from 1989 to 1998 
from adjacent regions with comparable living standards were followed for a 10 year 
period.67 Initially NBS testing consisted of IRT, from 1995 combined IRT/DNA testing 
was used. Seventy seven CF patients diagnosed after NBS in Bretagne (Brittany) were 
compared with 36 patients clinically diagnosed in Loire-Atlantique. Patients were 
followed in a CF centre and treated according to the same protocols. Screened patients 
were significantly heavier at 1 year and 8 years and significantly taller at age 1, 3 and 5 
years. At 10 years of age, these nutritional advantages were no longer maintained. 
However, the data in the latter age group were based on very low numbers: at 10 years 
9 and 7 patients in each group respectively. 
A retrospective observational study from Connecticut, US compared a SG (n=48) and a 
CG (n=50) born between 1983 -1997 and followed in the same CF centre until 2005. 
From the 48 SG and 50 CG, 34 and 21 were evaluable. Weight and height (expressed as 
% for age) were significantly better in the SG at diagnosis and body mass index (BMI) 
was better at 10 and 15 years of age.68 
The US CF registry reported growth data for CF children. Cross sectional data analysis 
of children born between 2000 throughout 2002 and diagnosed before 12 months of 
age showed that only 9% of the SG (n=250) had a height below P3 compared to 26% of 
the CG (n=1023). Similar differences were found for weight < P3. For all CF patients up 
to age 20 years in the 2002 database (n=14647), the percentage of patients with a 
weight below P3 remained significantly lower for the SG compared to the CG in all age 
categories.69 
UK registry data were analysed for patients 1-9 year old in 2002. Data of 184 SG 
patients were compared to 950 CG patients. Lower height z-scores were found for SG 
compared to the CG but weight z- scores were comparable.70  
2.2.2.2 Vitamin status 
In the context of CF-PI, low levels of the fat soluble vitamins A, E, D are often found at 
diagnosis. Institution of PERT and vitamin substitution can correct these deficiencies. 
Long term deficiencies of vitamin A and E can lead to neurological and haematological 
abnormalities. Osteoporosis in CF patients may be related to early vitamin D 
deficiency.71 
In the Wisconsin trial α-tocopherol levels below 300 mcg/dl were present in 73% of CG 
vs. 49% of the SG (p=0.045) and this deficiency often persisted for more than 6 
months.60 This analysis only concerned PI, non-MI patients. 
An important question is the relevance of these deficiencies. The combination of lower 
head circumference with vitamin E deficiency led the Wisconsin group to investigate the 
possible effect of low α-tocopherol levels at diagnosis on later cognitive outcome. At 
age 7-16 years the ‘Cognitive Skills Index’ (CSI) measured in the CG (n= 47) and SG 
(n=42) were significantly correlated with indicators of malnutrition.72 As a whole CSI 
was not different between the CG and SG (and comparable to the normal population). 
However, after adjusting for co-variables, there was a significantly lower CSI score in 
the CG (n= 37) compared to the SG (n= 34) in the subgroup with vitamin E deficiency 
at diagnosis.73  
Apart from the older data of the Netherlands,61 a study we did not retain for this 
report, there are no data on vitamin status from other observational studies nor from 
registry data. 
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2.2.2.3 Pulmonary outcome 
Several studies have shown a relation between nutritional status and pulmonary 
outcome in CF,74, 75 suggesting that nutritional intervention may slow the decline in 
pulmonary function. CF lung disease may be present from the first weeks of life 
documented by abnormal lung function,51 presence of pulmonary inflammation and 
infection52 and early computed tomography (CT) changes.76 A study comparing patient 
data between different US CF centres report the forced expiratory volume in 1 second 
(FEV1) of children followed in 2003 and aged 6-12 years. Centres with a mean FEV1 in 
the upper quartile range had more patients diagnosed as infants based on NBS or family 
history, again suggesting that early diagnosis favourably influences pulmonary outcome.77  
In the Wisconsin trial, pulmonary function data have been documented from age 7 until 
the age of 16.78 Overall, there were no differences in lung function (LF) parameters 
between the 2 groups with most patients having a lung function within the normal 
range. The absence of a pulmonary benefit for the screened group may be explained by 
2 factors. Firstly, the screened group (SG) had more PI patients than the CG (see 
above). Secondly, the SG acquired Pseudomonas aeruginosa (PA) infection earlier and 
more frequently. Chronic PA infection is known to adversely influence outcome.79 This 
has been attributed to lack of segregation in one of the 2 centres were the children 
were followed. Even more worrying is the finding that the X-ray score (Chrispin-
Norman) although better in the SG the first 5 years, was worse compared to the CG 
after the age of 10- 12 years.80 A report on a subgroup of the Wisconsin study, only 
reporting on PI (MI excluded) (49 screened vs. 31 non screened) confirmed these 
worse X-ray scores after 10 years in the SG together with a significantly lower lung 
function. Growth advantages on the contrary persisted until age 16 years.60 
In the UK trial, X-ray scores (Chrispin-Norman) were comparable in the 2 groups at 1 
and 4 years follow-up.55.  
A Cochrane review analysing reports of the Wisconsin RCT42 concludes that at the age 
of 7 years, 88% of SG and 75% of CG had lung function parameters of at least 89% 
predicted. Over time chest radiograph scores were worse in the screened group 
(WCXR p=0.017 and BCXR p=0.041).  In screened patients PA colonization occurred 
at a younger age.  
This finding stresses the importance of strict hygienic measures to prevent 
asymptomatic children to become infected by nosocomial bacteria. Another important 
comment is that in the light of current CF treatment, spirometry is most likely not 
sensitive enough to measure differences between SG and CG especially in the first 
decade. More sensitive methods like ‘Lung Clearance Index’ may make it possible in the 
future to monitor this more closely.81  
The Australian observational data report significantly higher lung function parameters 
(forced vital capacity, FVC and FEV1) in the SG at age 5 and 10 years65 and this 
advantage was maintained at age 15 years (FEV1 12.3% higher (95%CI 2.9-21.7%; p< 
0.001) in the screened group).66 At 10 years the mean difference in FEV1 was 9.4% 
(95%CI 0.8-17.9). While in this study X-ray scores were not different at age 5 and 10 
years, Shwachman-Kulczycki score (SK score, a composite scoring system for overall 
clinical well being including the following: general activity, clinical examination, 
nutritional status, X-ray score) was 5.2 points higher (95%CI 1.2 – 9.4) in the SG.66  
Observational data from France show an FEV1 decline that was more pronounced in the 
CG although differences were not significant.67 This may be due to small patient 
numbers in the analysis, especially after the age of 5 years. Brasfield X-ray score (higher 
score means less lung disease) was found to be  significantly higher in the SG at all ages 
up to age 10, except at age 1 (p<0.05). Also the Shwachman score was better in the 
screened group at all ages (p<0.05). 
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In the observational study from Connecticut,68 FEV1 was higher at all ages in the SG 
(p=0.03) but only when controlling for age, gender, inhaled tobramycin and Pa 
colonization. In a univariate analysis, FEV1 was significantly better in SG versus CG at age 
15 (90% vs. 74% p=0.15). FEV1 decline was less in the SG between age 6-15 years 
(p=0.01). Brasfield X-rays scores and age at acquisition of PA infections were not 
different.  
For patient data in the USA CF registry, an FEV1 below 70% was 1.32 times more likely 
in CG (0.77-1.71; p=0.11) but this difference compared to the SG did not reach 
statistical significance.82 Recent cross sectional data (2002 registry data on 14 647 
patients) show an advantage for FEV1 in the SG in age category 6-10 (97% vs. 89% , p< 
0.05, CI not stated) and 11-20 years (87% vs. 82% p< 0.05, CI not stated).69  
The UK registry data (cross sectional data analysis in 2002; n=183 screen and n=950 
CG) documented no LF differences between SC and CG. X-ray scores (Northern 
score, lower is less disease) were significantly lower in the SG aged 1-3 (p=0.05) and 7-
9 years (P=0.05). Shwachman scores were higher for NS in the age range of 1-3 
(p=0.05) and 7-9 (p=0.05) years.  
2.2.2.4 Complications 
In the US CF patient registry the proportion of patients with more than 1 
hospitalisation for complications was 70% in CG versus 29% in SG (p< 0.0001). Patients 
studied were diagnosed under age 1 and born in the period 2000-2002.69 
2.2.2.5 Burden of therapy 
Burden of therapy is related to severity of CF lung disease especially when looking at 
the need for intravenous (IV) antibiotics and hospital admission.83  
In the Wisconsin trial, there was no difference in the use of intravenous or inhaled 
antibiotics, nor for the days spent in hospital per year between the groups.84 This may 
be due to the earlier acquisition of PA in a subset of the screened group.  
Most observational studies report lower treatment burden in CF patients after 
screening. 
In the UK trial, patients in the SG were on average 1.3 (sd 1.9) times admitted in 
hospital in the first year while this was 3.2 (SD 2.7) times for the CG (CI not stated; p< 
0.01).55 
In the French study, the proportion of children requiring at least one hospital admission 
before age 10 years was 86% (CG) versus 49% (P< 0.001) (SG).67 Despite this 
difference, use of IV and inhaled antibiotics was not different.  
In the UK registry data treatment burden was much higher in the CG, despite 
comparable LF. This may suggest that LF is maintained in the CG at the cost of more 
treatment burden.70, 85  
Again in the UK registry, cross sectional data on treatment intensity have been 
reported for CF patients born after 1994 and younger than 10 years (NS n=184; CG 
n=950).85 Long term therapies (prescribed for longer than 3 months) were fewer in SG 
vs. CG (2 versus 3; p=0.005). In the first 3 years of life, 42% of the CG needed IV 
antibiotics versus 20% of the SG (p=0.05). At age 7-9 the figures were 38% versus 15 % 
respectively (p= 0.05).  
In the year of diagnosis 22% (CI 18-28) of SG were hospitalized versus 64% (CI 60-67) 
of the CG according to the data of the US CF registry (OR 3.7 (95%CI 2.3-5.9) and p< 
0.001).69 
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2.2.2.6 Survival and mortality 
With improving CF care, life expectancy is progressively improving and therefore CF 
related deaths are rare before age 10 years. It is thus not easy to document favourable 
effects of NBS on mortality. 
A systematic review and analysis of all studies published between 1997 and 2003 
addressing the impact of NBS on survival in CF has been performed.86 The conclusion of 
this systematic review is that the absolute difference in mortality risk is modest in size 
(difference in mortality of 1.5 - 2 per 100 children at 10 years of age, MI excluded) and 
comparable to NBS for certain other genetic disorders.  
In the Wisconsin RCT there was no mortality in either group before age 10. In the UK 
trial there were 4 CF deaths (5% in the CG), while no deaths in the SG group before 
age 5 (MI excluded from the analysis) (p< 0.05).56 Two of the CG deaths occurred 
however before age 3 months, thus even despite relatively early diagnosis.  
In the Australian data, mortality was 9.1% and 0%, up to age 10 in the CG vs. the SG (p< 
0.05) 66. Mortality was 12% and 7% at age 15, but this was no longer statistically 
significant. 
Survival advantage after NS is also suggested by CFF registry data.87 On cross sectional 
data from 13687 registered patients born after 1986 the risk for shorter survival was 
1.76 fold higher (CI 1.24-2.48; p<0.001) for the CG vs. the SG. 82 
2.3 CONCLUSION 
Only 2 RCTs have been published (spread over several reports) comparing the 
outcome after NBS versus clinical diagnosis. NBS lowers the age at diagnosis and has 
beneficial effect on growth parameters throughout childhood. It prevents long term 
vitamin E deficiency thus possibly avoiding effects on cognition. 
A beneficial effect on pulmonary outcome has not been documented in these RCTs. 
This is in part due to the uneven distribution of PI and severe mutations with 
disadvantage for the SG. Additionally, the NBS grouped has been exposed  to risk for 
earlier PA infection with resulting  worse pulmonary course. 
With modern CF care, following guidelines in CF centred care, this harm can most 
likely be prevented.  
In several observational studies and registry analysis, a pulmonary benefit has indeed 
been documented for the SG and this was associated with lower treatment burden and 
less complications. 
Although these non RCT studies carry an inherent risk for bias, the large number of 
independent reports provides an additional argument in favour of screening, also 
concerning pulmonary outcome. 
Several sources document a modest effect on mortality.  
A very important message for a screening programme is that benefits of NBS can only 
be assured if excellent clinical follow-up is provided in accredited CF centres and 
according to international standards. Consensus guidelines of CF-NBS screening and 
follow-up after screening have been published.5, 43, 44 A consensus report specifically on 
early treatment after NBS is in preparation. 
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Key points:  
• CF NBS should be followed by immediate follow-up and appropriate 
management. 
• CF-NBS decreases the median and mean age at diagnosis. This finding has 
been confirmed by all studies on this subject, RCT as well as non-RCT. 
• Patients diagnosed by CF-NBS followed by immediate treatment and follow-
up have a long term nutritional advantage over clinically diagnosed patients. 
This has been confirmed by RCT and non-RCT. Data on the advantage for 
fat soluble vitamin status and cognitive function are based on low number of 
patients.  
• RCTs have not shown an advantage for respiratory disease after early 
diagnosis in the context of screening but this may be linked to non-
segregation of patients after screening in this trial leading to more 
Pseudomonas infections. Non-RCT and register data do however suggest 
that with current standards of care, NBS will improve pulmonary status and 
decrease the burden of therapy. 
• NBS possibly decreases CF mortality based on RCT and non-RCT data. 
Since mortality below the age of 10 years is low, these data are only based 
on low numbers of deceased CF patients. 
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3 CF NBS – POSSIBLE HARMS 
3.1 RISK FOR PSEUDOMONAS ACQUISITION 
CF NBS is universally coupled with immediate referral to a specialized CF centre. It is 
long known that without currently widely accepted standards of care, centralized CF-
care might be associated with an increased isolation rate of PA in respiratory 
secretions88, 89 as well as with outbreaks of infection with multiresistant strains of this 
pathogen.90-92 This is especially worrying as chronic PA colonization has been associated 
with the loss of nearly a third of life expectancy,93 a less favourable FEV1 and an 
accelerated decline of this parameter,94, 95 an increased treatment load affecting quality 
of life and much higher treatment costs.96  
The earlier acquisition of PA in the SG compared to the CG in one of the 2 centres 
involved in the Wisconsin RCT raised concern but was shown to be primarily due to 
absence of cohort segregation for PA positive and negative CF patients.78 Cross 
sectional data after 9 years follow-up showed a PA prevalence of 56.7 % in the SG 
versus 46.3 % in the CG, this difference not being significant. When looking at the 2 
centres separately the median PA free survival time was significantly shorter only in 1 
centre for the SG compared to the CG (52 weeks versus 234 weeks; p = 0,0003). In 
the other centre the median time to Pa acquisition was 130 weeks in the CG versus 
289 weeks in the SG.84 
This finding of earlier acquisition of PA in CF NB screened patients was not confirmed 
in subsequent studies.67, 97 In fact, several studies including long term data from the US 
CF registry suggests that the risk for acquiring PA is lower in children detected by CF 
NBS.70, 82, 98  
This is not surprising. It is actually now realized that a link between attendance at a 
centre and earlier acquisition of PA is not a fatality, neither during regular specialist CF 
care nor in the context of neonatal screening.68, 97 In reality it is largely manageable with 
a policy of patient segregation based on bacteriology (applied to ambulatory as well as 
hospitalised care), regular systematic bacteriological surveillance and early intervention 
once this organism is detected.99-103  
Such policies have been put into practice in the 6 Belgian centres studied (the 7th centre 
was not included in this study), for more than 17 years in one centre, for more than 7 
years in 4 others, and only recently in the 6th centre, contributing to a low number of 
clusters104 and a rather low (though variable in different centres) prevalence of PA in 
our country.105 Moreover, another Belgian study showed that “early” referral of CF 
patient to an accredited CF centre (defined as a delay less than 2 years) was associated 
with a significantly better FEV1 (86.7% pred. ± 19.4 vs 77.2% pred. ± 22.4, p<0.01) as 
well a with a lower prevalence of PA (17.5 % vs 36.6%, p< 0.005).106 
3.2 PSYCHOLOGICAL ISSUES 
Three detailed reviews of the psychosocial issues related to CF NBS are available,42, 107, 
108 including a very recent Cochrane review that only considered the Wisconsin trial. 
There is little data about long-term consequences. Overall, data suggest that CF NBS - 
although creating short term anxiety among parents awaiting definitive diagnostic tests - 
has the potential of reducing long-term adverse psychosocial effects resulting from 
delayed diagnosis. Persistent false beliefs (ie, vulnerable child syndrome) by parents 
about healthy children who had false-positive results are a recurring finding in NBS 
programs. Identification of children without pancreatic insufficiency or with ambiguous 
DNA and sweat test results that suggest a ‘‘variant’’ form of CF may subject the family 
to uncertainty, anxiety, and potentially unnecessary treatment without a clear 
compensating benefit. Yet this issue has not been addressed in the literature.109 The 
most commonly measured variables are knowledge, anxiety and depression.108, 110 
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3.2.1 Parental affects and NBS 
Both cohorts (with or without NBS) found the diagnosis emotionally traumatic but all 
considered NBS as an advantage.107 There has been concern about the evolution of the 
mother-baby relationship in the case of parents confronted to a pre symptomatic 
disease and/or the carrier status of their other children. NBS could mediate a rupture 
of this relationship or could induce excessive protective attitudes, designating the child 
as suffering from disease when it is not yet the case (‘Stigmatisation’). However, no such 
excessive maternal reaction has been described in CF NBS literature up to now. 
3.2.2 Parental knowledge about NBS 
One year after the communication process, 8% of family with false-positive result still 
did not fully understand that their child definitely did not have CF compared to 5% at 
the time of result. On the contrary, families with true positive result improve their 
understanding of the issue from 90% at three months to 97% at one year. These results 
are considered unsatisfactory by some108 and remarkable by others.111 In RCT, families 
with disclosed result delayed at four years (cohort group) could not manage the 
information as well as families from the screening group. Most expressed anger 
regarding hidden NBS results and worried for potential deleterious effect of the late 
diagnosis for their child’s health. The majority of families knew what a newborn 
screening program was, but there were still 22% of parents with no idea. Finally, in all 
cases, telephone call failed to correctly transmit the information compare to face-to-
face communication. Table 1 in Appendix 5 summarizes the findings of the main 
studies.108 
3.2.3 Feelings of families with a CF child : comparison between NBS and clinical 
CF diagnosis 
Diagnostic delays are experienced as extremely stressful for all parents after true 
positive CF diagnosis but particularly, for parents in screening group108 (Table 4 in 
Appendix 4). Grob et al.112 collected interviews to further investigate this issue. The 
‘disturbing’ feeling generated by NBS is well expressed by the author as “Is my sick child 
healthy? Is my healthy child sick?”. Shock and strong emotional responses are described 
in all NBS programs.108 “Reactions from the family are never the same, as a positive 
result is almost always unexpected”.113 Tables 2 and 3 in Appendix 5 summarize data 
about feeling of families at the time of diagnosis. Ways to reduce the psychological 
stress at several steps of the process are described in Figure 1 of Appendix 5. The 
period between informing the family of a positive screening test result and the definitive 
diagnostic assessment should be as short as possible. According to most algorithms, the 
crucial next step will be the sweat test. Sensitive approach around it is described in 
chapter 4 but is worth mentioning here too: it includes rapid appointment after the 
initial contact, information about the possibility of cystic fibrosis the day before the 
sweat test, contacting the families in the first three days of the week in order to avoid 
leaving them unsupported over the week-end preceding the test, provision of the 
results of the sweat test by the lead CF physician within one hour or two.114 
3.2.4 Psychological impact of false positive screening test 
Depression and potentially strong emotional shock have been reported at the 
announcement of an increased IRT level. However, this feeling quickly resolved in false-
positive results and parents did not experience stress anymore three months later.108 
43% of parents expressed depressive feelings while waiting for sweat test results and > 
70% suffered from anxiety.111 Such feelings almost always fully resolve after 
announcement of results of the normal sweat test. There is no publication of mother-
baby relationship disruption due to NBS. Anxiety is the predominant psychological side 
effect. Parents of babies with a low Apgar score at birth are at risk to keep on worry 
despite normal sweat test (they have concerns about their child’s health because of the 
‘bad’ entry in the life). The potential psychological harm effects of ‘unexplained’ false-
positive NBS results directly impact on parents’ acceptance of being screened or not as 
carrier.111 
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3.2.5 Feelings of families with a child having an inconclusive diagnosis 
No study specifically assessed this issue. Tluczek describes feelings of these parents as a 
combination of feelings similar to the true-positive group and to the false-positive 
results when diagnosis is finally ruled out.115 Anxiety is not milder but decreases along 
the time, while they observe their child is doing well despite inconclusive results. 
Emphasis is made to definitely avoid pronouncing the name “cystic fibrosis” in front of 
the parents until the diagnosis is clearly established or excluded. “Suspected CF” seems 
more appropriate than “inconclusive case” for reducing the feeling of ‘uncertainty’ 
which always increases parental anxiety. These parents are not numerous and the 
feeling of being misunderstood and isolated is high since they even cannot share their 
experience with parents of definitive CF diagnosis. 
3.2.6 Psychological impact of disclosing carrier status 
According to the literature, three considerations may justify a CF NBS process with 
DNA analysis resulting in the identification of healthy carriers:107  
• A protocol without DNA analysis would identify much more false positive 
results than number of carrier status. 
• Family can get the information through appropriate genetic counselling 
and use it in reproductive planning.  
• The generation of false-positive cases is the inevitable price some families 
will have to pay to enable screening programmes to operate. 
In his review, Hayeems compared the effect of disclosing carrier results induced by NBS 
for sickle cell anaemia and cystic fibrosis.111 A ‘CF carrier’ is first ‘flagged’ as positive in 
the screening protocol unlike other screened genetic diseases. Doing so, we are the 
first responsible of child ‘stigmatisation’. As stated by the author, “it is not surprising 
that parents are stressed while awaiting sweat test results”. The result of the screen 
should be given in a thoughtful and empathetic manner in order to reduce anxiety which 
is a common side effect generated by CF NBS in parents of a child being revealed as a 
carrier (Table 5). One year after the announcement of CF carrier status, stress score 
and parent's worrying about their child are still significantly different from other parents 
with 10% of parents thinking about this result once a week or more and nearly 30% of 
parents worrying about the health of their child. The first community-wide newborn 
screening programs for CF started in 1981, in New Zealand and New South Wales. Yet, 
studies assessing the impact at various ages (childhood, adolescence, adulthood) of being 
detected as a carrier are still lacking. From the child's perspective, there is a consensus 
that the knowledge of being a carrier is not of direct and immediate benefit, and as the 
child could not decide whether he/she wished to be tested, this can be considered as a 
violation of the “right-not-to know”. Finally, parental CF DNA analysis can be offered to 
identify the carrier parent or to distinguish the 1-carrier couple from the 2-carrier 
couple. This issue should be addressed sensitively, because parental testing can result in 
detection of misattributed paternity. 
3.3 DELAYED DIAGNOSIS IN CASE OF FALSE NEGATIVE NBS 
The true incidence of false negative NBS is very difficult to assess. The quality of the 
associated surveillance program and issues related to difficult cases are critical. 
Increasing the number of mutations looked for when IRT/DNA algorithms are used 
improve the sensitivity of the program. In the Wisconsin program (IRT/DNA protocol 
with a panel of 23 CFTR mutations)116 and without taking into account false-negative 
inherent to technical issues or administrative reasons, at least 3.8% of CF patients will 
be missed. Even after excluding patients with meconial ileus, a rare patient homozygous 
for the F508del mutation may present with a neonatal IRT level below the 95th 
percentile. 
So the message to be delivered to primary care physicians is clear: “Not all cases of CF 
will be detected through CF NBS and any patient with suggestive symptoms should be 
investigated accordingly”.117 
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Two papers116, 117 highlight possible troublesome situations, including:  
• meconial ileus: true-false negative IRT levels in some CF newborns with 
meconial ileus and a CF diagnosis should be excluded in these cases, 
regardless of IRT values.  
• blood transfusions: their effect on IRT are unclear. A repeat sample 
should therefore, be taken after a minimum of 72 hours has elapsed. As 
white cells are removed prior to transfusion, misleading results with 
mutation analysis are unlikely.  
• viral infection leading to fever and acute gastroenteritis or respiratory 
illness has sometimes been associated with a falsely negative screening 
result.  
• falsely negative results have also been reported in some premature or 
small for dates babies.  
• some seasonal variation of IRT dosages which might also be due in part to 
reagent lot.  
• black newborns may have higher IRT levels  
Trivial risk factors for “non-screening” include baby changes from maternity to intensive 
care soon after birth or transfers to another hospital and modifications of parent’s 
address or no phone number to reach parents for giving results. Such babies should be 
clearly identified as “non-screened for CF”. 
3.4 INCONCLUSIVE NBS RESULTS 
3.4.1 Diagnosis of CF: the grey zone is increasing 
CF NBS is a screen, not a diagnostic test, and thus only identifies newborns at risk for 
CF. 
At the present time, false positive and false negative are unavoidable, inasmuch as it is 
increasingly realized that the diagnosis of CF itself might be difficult. 
In 1998, a CFF consensus about the diagnosis of CF stated that although the vast 
majority of persons with CF are diagnosed through classic signs and symptoms of the 
disease and corroborative laboratory results, the diagnosis was not as clear-cut in 
approximately 2%.118 Ten years later, an update of this consensus extended this grey 
zone to 5% to 10% of individuals with CF.5 It is in fact expected to be even larger in 
infants identified through CF NBS as many of them (± 50%) are asymptomatic. This 
makes reliable assessment of specificity and sensitivity of CF NBS programs difficult. 
Debate is still ongoing around terms such as “atypical CF”, “non-classic CF”, “CFTR 
dysfunction”, “CFTR related disorder” and most appropriate algorithms. In practice, the 
wide range of CF phenotypic variability is increasingly recognized. Of note, the last CCF 
consensus report5 recommends a diagnosis of CF to be made in any patient carrying 2 
CF-causing mutations in trans, regardless the results of the sweat tests. Using these 
criteria, 47% (28/59) of a group of patients classified under the terms “CFTR 
dysfunction” according to a diagnostic algorithm formulated and then validated by an 
international group of experts after a European consensus conference119, 120 should be 
considered as CF. 
All current CF NBS protocols rely on IRT as the primary test and on sweat test for 
confirming or excluding the diagnosis of CF. Determining the cut-off neonatal IRT is 
thus the first crucial issue. As seasonal and reagent lot variations of this dosage have 
been documented,116 it seems more meaningful to use a floating IRT cut-off adjusted 
daily to an IRT percentile rather than a fixed cut-off (such as 65 μg/L in France).  
After an abnormal IRT value is identified, most NBS programs perform DNA testing to 
identify known CFTR gene mutations (IRT/DNA strategy), while other programs repeat 
the IRT measurement.43 Various combinations of these two are also possible.  
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Increasing the number of mutations in the initial panel aims to improve the sensitivity of 
the program (ie lower rate of false negative). Drawbacks include increased costs and 
identification of a larger number of healthy carriers.  
Doing so while including some mutations of uncertain clinical significance can further 
increase the sensitivity of the program but will be associated with lower specificity and 
detection of an increased number of equivocal cases (implying additional costs for 
assessment and at times for follow-up, possible psychological harms, difficult genetic 
counselling and unwarranted treatment). On the other side, it has the potential to 
improve our knowledge of the severity of a number of mutations. 
3.4.2 Mutations of uncertain significance 
The pathogenic potential of the vast majority of CFTR mutations is unclear or unknown. 
This is most often related to their rareness. According to the CFF, only 23 mutations 
have been demonstrated by direct or empirical evidence to cause sufficient loss of 
CFTR function to confer CF disease and thus can be recommended as conclusive 
genetic evidence for diagnostic purposes.5 This list includes several class IV or V 
mutations that can be associated with rather mild (though often very variable) 
phenotype and at times intermediate (or more rarely even normal) sweat chloride 
values. Most patients who are compound heterozygotes for a Class I, II or III / Class IV 
or V mutation are pancreatic sufficient. A recent European consensus suggested a list of 
34 CF-causing mutations but acknowledged that 6 of them (among which R117H-5T and 
R117H 7T) could at times be associated just with a CFTR-related mono-symptomatic 
disorder (congenital bilateral absence of the vas deferens (CBAVD), idiopathic 
pancreatitis …).121 Seven of the added mutations were class I, II or III. Table 1 provides 
a list of these mutations. 
Table 1. CF‐causing mutations according to the CFF consensus5 and a 
European consensus121 
Class I,II or III Class IV or V 
1078delT F508del 2789+5G→A * 
1717-1G→A G542X 3849+10kbC→T 
1677delTA G551D A455E 
1898+1G→A G85E D1152H 
2184delA I507del L206W 
2184insA N1303K R117H 
3120+1G→A R1158X R334W 
3659delC R1162X R347P 
621+1G→T R553X TG13-T5 
711+1G→T R560T  
711+3A→G S549N  
E822X W1282X  
 
*usually PI; Underlined: mutations common to both lists; Bold: mutations mentioned only in the 
European list; Italic: mutations mentioned in the European list as at times causing CF disease, at 
times resulting in a CFTR-related disorder. 
There are several ways to try to list the most common problematic mutations. Yet, it 
should also be emphasized that a substantial phenotypic variability exists and constitutes 
a well acknowledged limitation of this approach. Modifiers genes, environmental factors, 
quality of care, medical non compliance can all contribute to this variability. 
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3.4.2.1 Mutations that can be associated with milder forms of the disease 
Several studies have looked at the effects of genotype on phenotype. The largest study 
on the impact of class IV or V mutations investigated in 15 651 patients enrolled in the 
US CFF Registry.122 Median age at death for patients carrying at least 1 class IV or V 
mutation was 37.6 years while it was 24.2 years for the high-risk CFTR genotype group 
(p<0.001). Given the considerable variation in the CF phenotype that occurs between 
patients with the same CFTR genotype, the authors stressed that this finding is of little 
value at the individual level. 
A few studies focusing on specific mutations support the conclusion that they are 
“globally” associated with a milder (though variable) form of the disease. Such mutations 
include A455E,123 3849+10kbC->T,124, 125 2789+5G->A,125 D1152H,126, 127 R334W,128 
3272-26A->G,129 as well as R117H and 5T that will be discussed later. 
3.4.2.2 Mutations that can be associated with suggestive symptoms of CF and 
borderline (30-60 mmol/L) or normal (<30 mmol/L) sweat chloride values  
According to the literature, the Class V mutation 3849+10kbC→T and the Class IV 
mutation D1152H seem to be the most common of these mutations.120, 123-126, 130-133 
Interestingly, compound heterozygotes for a severe CFTR mutation and R117H were 
reported to have abnormal sweat chloride values in most cases (78%) when a 5T allele 
was present, and in a few cases only when the background was 7T.134 In addition, sweat 
tests in 56 CF NBS infants carrying the F508del/R117H genotype (almost always on the 
7T background), yielded normal (<30 mmol/L) sweat chloride values in almost half of 
the cases and intermediate (30-59 mmol/L) results in 46%.135 
Table 2. Mutations that can be associated with suggestive symptoms of CF 
and normal or intermediate sweat chloride values beyond neonatal period 
Sweat chloride values (mmol/L)  
30-59 mmol/L < 30 mmol/L 
3849+10kbC→T                                           
D1152H, L206W, R117H-7T  
R117H-5T, 5T, 3272-26A→G, S1235R, D945L, G149R, R1070W, 
R117C-7T, G91R, S977F, S945L, L165S, L159S, 
3849+10kbC→T    
D1152H 
R117H-7T 
R117H-5T 
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3.4.2.3 Mutations that are clearly overrepresented in CF screened infants as compared 
with those identified in CF patients diagnosed on the basis of clinical symptoms 
Figure 1. Mutations that are clearly overrepresented in CF screened infants 
as compared with those identified in CF patients diagnosed on the basis of 
clinical symptoms 
 
French authors compared the frequency of mutations identified in CF patients on the 
basis of clinical symptoms (2000) and in the first 808 CF newborns identified through 
the national CF NBS program implemented in 2002-2003 (A. Munck et al. Personal 
communication). 
The 2 main findings are that:  
• 2 mutations with specific ethnic distribution were identified more often 
(Y1222X: Reunions Island; 3120+1G→A: Black Africa). Diagnosis of CF in 
these patients was probably often overlooked before CF NBS.  
• R117H was identified 33 times more often through CB NBS as this 
mutation was included in the initial panel of mutations.  
3.4.2.4 Mutations that are clearly overrepresented in patients with monosymptomatic 
CFTR related disease 
Among these disorders, CBAVD is by far the best studied. A review of data concerning 
449 men with CBAVD concluded that about 16% of them were carriers of two CFTR 
changes and roughly half were heterozygotes for one CFTR change many of whom 
(67%) have the 5T variant on the chromosome not carrying the CFTR mutation.136 
While the frequency of the 5T allele is estimated at 5-10% in the general population, 
roughly one quarter of CBAVD patients carry this variant. When looking at the 
genotypes of CBAVD patients carrying two CFTR mutations, it was evident that the 
R117H mutation which was found in almost half of the cases was grossly 
overrepresented. Desideri-Vaillant et al. 137  investigated 291 CBAVD patients and 
showed that 25% of them carried 2 mutations, 22% carried one CFTR mutation and the 
5T allele in trans, 19% carried only a CFTR mutation or only the 5T allele. Seventy 
different mutations were identified, most differing from those seen in the CF population. 
R117H was found in 7% of the cases.137 Another study of 182 CBAVD patients showed 
that 83% of them carried 2 mutations and 8.8% carried only one.138  
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Here, the 5T variant was considered as a mutation and accounted for 17% of the 
detected CFTR changes. The frequency of R117H in this study was much lower (3.02%), 
similar to that of D1152H (3.3%) and L997F (3.02%). L206W and R347H were found in 
1.92% and 1.37% of the cases, respectively. 
The reasons for the discrepancies between these studies are unclear but it can be 
concluded that R117H is overrepresented in patients with CBAVD. 
3.4.2.5 Mutations that are overrepresented when a diagnosis of CF is made in 
adulthood (> 18 y) 
A recent cross-sectional study of 9 766 new diagnoses of CF reported to the US CFF 
Registry between 1995 and 2005 compared features of patients diagnosed before 
(91.7%) or after (8.3%) 18 years of age.139 It showed that adults present with commonly 
described CF respiratory disease (PA infection and reduced lung function) but have 
lower sweat chloride values and lower frequency of F508del mutation. Median age of 
adult diagnoses was 33 years with a first FEV1 around 69% predicted. 54.8% of them 
were pancreatic sufficient. When available, sweat chloride values were lower than 60 
mmol%L in 24 % (!) of patients and lower than 40 mmol/L in 11 %. 
By contrast, in the 2005 Cystic Fibrosis Foundation Patient Registry, only 3.5% of 
patients with a diagnosis of CF had a sweat chloride value <60 mmol/L, and only 1.2% 
had a value <40 mmol/L.140 Table 2 is adapted from this paper and lists the 10 most 
commonly reported non-F508 del mutations, as the prevalence of the remaining were 
extremely low. All except two (W1282X: class I, L206W: class II) are class IV or V 
mutations. 
Table 3. CFTR Mutation frequency (%) in patients diagnosed ≥ 18 years of 
age 137   
 Class Diagnosis ≥ 18years % 
(n=655) 
Relative frequency in 
patients diagnosed in 
adulthood * 
F508de II 74.1 (485) X 0.84 
R117H IV 15.6 (102) X 6 
3849+10kbC->T V 7.8 (51) X 4.8 
D1152H IV 6 (39) X 30 
W1282X I 4.6 (30) X 2.1 
2789+5G->A V 3.5 (23) X 3.9 
R334W IV 3.2 (21) X 8 
A455E IV (V?) 2.4 (16) X 4.8 
L206W II 1.1 (7) X 5.5 
I148T  IV 0.9 (6) X 0.4 
R347H IV 0.9 (6) X 4.5 
 
*for each of these mutations, the frequency was significantly different according to the age at 
diagnosis (< or ≥ 18y). 
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3.4.2.6 Mutations for which a low penetrance has clearly been demonstrated 
When found in trans with a severe CFTR mutation, the 5T allele usually results in 
normal phenotype. Yet, it may be associated with CBAVD or recurrent pancreatitis. 
Very few cases have been reported of adults who were either compound heterozygotes 
for the F508del mutation and 5T141, 142 allele or homozygous for the 5T allele on a TG11 
or TG12 and M470V background143 and presented with late respiratory symptoms 
suggestive of CF, abnormal or intermediate sweat chloride values and abnormal nasal 
potential. Given its frequency in normal subjects (5-10%), it is clear that the penetrance 
of this variant is very low. The molecular basis for this has been described.143, 144 
Recent work from French authors convincingly demonstrated that the penetrance of 
the R117H mutation was very low too.135 It is known that its severity is modulated by 
the polypirimidine variant in the intron 8 acceptor splice site (T7 or T5) in cis with 
R117H. However, only 4% of 173 individuals carried the F508del/R117H mutation 
combined with the 5T allele (96% carried 7T). In this series, 37% of the subjects were 
identified through CF NBS. The median age at diagnosis of the 121 remaining patients 
was high (30 years, IQR 26-34 years). Most of them (89.3%) were males as CBAVD led 
to the identification of this genotype in 74.4% of this group. The penetrance of classical 
CF for the F508del/R117H-7T genotype was estimated at 0.03% and that of severe CF 
in adulthood at 0.06%. 
3.4.3 How important is the problem? 
In every CF NBS program based on the IRT/DNA strategy, the importance of equivocal 
cases is strongly related to the choice of the mutations looked for. According to the 5-
year French experience, as much as 15% of CF NB screened infants belong to this 
category, with R117H accounting for more than half of the cases.145 In the 
Massachussets program, 11% of detected infants fall in this diagnostic dilemma 
category146 and R117H is often involved too.44 
Such inconclusive cases raise unanswered questions. Definitely informing parents 
whether or not their infant will develop signs and symptoms of CF is currently 
impossible. This ambiguity is likely to generate psychological harmful effects but no 
study aimed to assess them. Genetic counselling is very difficult too. Panels of experts 
have provided recommendations for the clinical follow-up of these infants5, 147 but these 
have still to be validated. 
In Australia where all but one state only include class I, II or III in the initial panel of 
mutations, only 1-2% of infants with a positive NBS result (defined as neonatal IRT 
>99th percentile and at least one CFTR mutation) are reported to have a borderline 
sweat test (Cl: 30-59 mmol/L).148 According to the Australasian consensus, repeat 
clinical assessment and sweat testing at 3-6 months of age is recommended but it is 
considered that parents need closure of the issue and should not be left with the 
lingering doubts about a diagnosis of CF. “Missing” some infants who may not have 
clinical evidence of CF for many years may be the price to pay but is deemed an 
acceptable limitation of a program that is by nature a screening program. 
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3.4.4 The case of R117H 
There is no doubt that compound heterozygotes for a severe CF mutation and R117H 
may present symptoms of CF (usually with pancreatic sufficiency). This risk is higher 
when a 5-thymidine sequence in the intron 8 is found in cis with R117H. Though very 
rarely, symptoms of CF have also been reported on a 7T background149, even at times in 
young children.150, 151 In such cases, the sweat test may yield normal, intermediate or 
abnormal results though the latter is rare with the 7T background. Association of 
R117H and 5T seems very unusual in France (but could be more frequent in UK and 
Australia).135 The French experience also shows that  
• R117H accounts for the majority of equivocal cases following CF NBS 
implementation in this country  
• the penetrance of classical CF or severe CF in adulthood for the genotype 
F508del/R117H -7T is very low (less than 1%). 
3.4.5 Trying to limit the number of equivocal cases? 
Population-based newborn screening for CF is not a comprehensive diagnostic program. 
By definition, any newborn screening programme will miss some infants with the disease 
in question. Which children it is permissible to miss is open for debate. Most current 
CF NBS programs are based on an IRT/DNA strategy. Whether to include so-called 
mild CF mutations (mainly classes IV and V) in the panel of screened mutations remains 
controversial for several reasons that include the implications of making a genetic 
diagnosis of CF in newborns who might not become symptomatic for years, if at all. 
Most of the controversy is around the R117H mutation. While current US consensus is 
that it is worth gaining knowledge by regular follow-up of compound heterozygotes 
carrying this mutation,5 French authors convincingly plead for its withdrawal from the 
initial panel.135, 152 The Australian approach is even more pragmatic148 and suggests that 
inconclusive diagnoses are not acceptable and that CF NBS should only focus on class I, 
II or III mutations. 
3.5 KEY POINTS 
• Applying standards of good care for CF infants detected by CF NBS is crucial 
to avoid early Pseudomonas acquisition. If well applied this should result in 
less Pseudomonas acquisition in CF NBS patients as compared to patients 
detected on the basis of clinical symptoms. 
• Psychological side effects of CF NBS seem mild and acceptable but sensitive 
communication is essential. There is little data about long-term 
consequences. The impact of equivocal case has not been studied.  
• It should be made clear for the physicians that not all cases of CF will be 
detected through CF NBS so that any patient with suggestive symptoms will 
still need appropriate investigations.  
• Depending on the choice of the algorithm including the decision to 
investigate whether or not asymptomatic infants with intermediate sweat 
chloride values, equivocal cases may represent – as in France - up to 15 % of 
“CF” infants detected by a NBS program. Such cases raise several 
unanswered questions. In addition, the benefits of CF NBS for mild forms of 
the disease have not been established. Roughly half of these cases are related 
to the R117H mutation for which a very low degree of penetrance has 
recently been demonstrated. It seems wise to try to limit the number of 
such equivocal cases. 
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4 CONSIDERATIONS FOR IMPLEMENTATION. 
4.1 GUIDELINES FOR IMPLEMENTATION OF CF NEWBORN 
SCREENING PROGRAMS – “NO SYSTEM IS STRONGER 
THAN ITS WEAKEST LINK”. 
Several guidelines for implementation of CF NBS have been published43, 44, 148 as well as 
an updated CFF consensus about the diagnosis of CF taking into account specific aspects 
related to NBS.5 In addition, an in-depth critical assessment of the wide-scaled French 
experience is now available.45 Appendix 6 Tables 1 and 2 summarize important 
information derived from the Australasian148 and French45 experiences. Tables 3-5 are 
tables of contents of the US and European guideline papers,5, 43, 44 allowing to easily 
locate valuable information. These documents resulted from workshops organized by 
the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society respectively. 
No data are available concerning the methodology used by the panel of experts. 
In addition, a flowchart and 5 tables of particular interest derived from these articles are 
presented in Appendix 6. They detail : 
• The diagnostic process for screened newborns5 – Flowchart 1. 
• Components of successful CF NBS programs5 – Table 6.  
• Workgroups topics for successful CF NBS programs5 – Table 7.  
• Items to be recorded for quality control5 – Table 8.  
• Recommendations for counselling about positive NBS results43– Table 9. 
• Recommendations for counselling parents when NBS identifies carrier 
infants43 – Table 10. 
The goal of NBS has been defined to harvest over 90% of truly afflicted cystic fibrosis 
cases permitting their entry into a treatment programme in the first 2-month window 
but without alarming the families of healthy babies.44, 153  
At the present time, such an ideal CF test does not exist. Numerous false positives will 
be identified before sweat testing and it remains critical to minimize the risk of either a 
wrong diagnosis or an ambiguous result. In addition, false-negative tests are unavoidable 
too, which stresses the need for primary care physicians to remain vigilant. Regardless 
of CF NBS results, a diagnosis of CF should still be considered and excluded by 
appropriate evaluation including sweat testing whenever a patient presents with a 
positive family history or suggestive clinical symptoms.5 Among these, meconial ileus 
(which can be associated with low neonatal IRT levels) or a history of prenatal 
echogenic bowel, pancreatic insufficiency, chronic cough and bronchiectasis are 
especially worth mentioning. 
4.1.1 Determining the spectrum of CF disease to be identified by the CF NBS 
program 
Carefully determining the spectrum of CF disease that a NBS program will aim to 
identify is one of the first essential tasks. It has major implications regarding the choice 
of any IRT-DNA algorithm, its sensitivity and specificity, the number of equivocal cases 
to be managed (see chapter 3) and costs. Early detection of mild forms of the disease 
may raise unresolved questions in terms of genetic counselling for example. Moreover, 
its benefit is not established. Accordingly, there is an emerging consensus that programs 
using an IRT-DNA algorithm should focus on mutations commonly associated with 
severe lung disease. Australian authors even suggested that only class I, II or III 
mutations should be looked for.148 
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In practice however, this complex issue remains controversial. It is usually accepted that 
IRT-DNA algorithms should include a panel of mutations detecting at least 80% of 
mutations in a selected population. Data from the Belgian registry show that it would be 
difficult to reach this level without including some Class IV or V mutations. This seems 
acceptable in some cases. It is now recognized that a few well-studied CF mutations 
which globally result in a rather mild phenotype such as D1152H,126 A455E,123 2789+ 5 
G→ A and 3849 +10kb C→T125 are in fact associated with a broad clinical spectrum 
quite commonly including early lung disease. Moreover, though these patients are often 
diagnosed later, severe lung disease with chronic colonization by PA at the time of 
diagnosis is not uncommon.126, 139, 154 The case of the R117H (class IV) mutation has been 
discussed in detail in chapter 3. It is suggested that this mutation should not be included 
in the initial panel of mutations. Though currently recommended,5, 147 extensive 
investigation of asymptomatic infants with elevated IRT (D3), 1 CFTR mutation and 
repeatedly intermediate sweat chloride values is also debatable as even if they are found 
to carry 2 CFTR gene changes, most of them are unlikely to develop significant 
respiratory symptoms in early childhood. 
4.1.2 Defining an operational network 
Algorithms will be discussed in chapter 6. Whatever the choice, guidelines recommend 
to clearly identify and assemble those who will have operational responsibility, typically 
including all of the CF centre directors and a CF newborn screening coordinator for 
each screening centre. The role of the primary care physician and the regional 
paediatrician, if any, should also be defined. 
Pathway for result notification should be well defined as illustrated in Figure 2 which 
summarize the current Australian approach.148 
Figure 2.  Pathway of notification and follow-up of positive results from NBS 
for CF (Australia). 
 
* Approach in New Zealand is to recall all infants with one or two mutations for sweat test 
before referral to CF physician. 
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Belgium is a very small country with a limited number of well-established accredited CF 
centres (n=7, academic hospitals) and neonatal screening programs (n=6: St-Jan Bruges, 
UCL St-Luc Brussels, CHU Liège, PCMA Antwerp, ULB Erasme Brussels, UZ Ghent). 
This should facilitate greatly CF NBS implementation. The diagnostic pathway for CF 
could be similar to the existing pathways for metabolic disorders detected using 
neonatal screening. 
Flowcharts 2-5 in Appendix 6 suggest a model of operational network, based on the 
experience abroad, which could be considered in our country and specify the respective 
interactions between neonatal screening labs, CF Centres and a supervising structure 
that should be implemented. Note that in contrast to France where the nearby CF 
centre is alerted if case of a screen positive result, in Belgium according to the proposed 
protocol the pediatrician of the maternity will be alerted, who will inform the parents.   
4.1.3 Sweat tests. 
The sweat test is a key component of any NBS protocol for CF. False-negative results 
and anxieties created by false-positive results are known to be common in hospitals 
without large experience and engagement in quality-assurance programs. The test might 
be especially challenging in this age group and has to be performed and interpreted 
according to specific guidelines.5, 148, 155-157 Around 4 weeks of age, sufficient sweat can 
generally be collected. Because of the anxiety experienced by families when they learn 
of a positive NBS result, bilateral sweat sampling is recommended if the baby is at least 
2 kg and more than 36 weeks gestation at birth.5 Tests resulting in insufficient sweat 
samples should be repeated. In Belgium, it is already a mission of the 7 accredited 
centres to provide accurate diagnosis for CF and it seems wise to perform all these 
diagnostics tests in such centres, inasmuch as it will be their tasks to communicate 
adequately about the results and to initiate a treatment without delay if a CF diagnosis is 
confirmed. If exceptions are to be considered then care should be taken to ensure that 
adherence to specific requirements for sweat testing required for accreditation is 
actually met and that referral to a CF centre is not delayed.  
As for all technical aspects of CF NBS programs (IRT, DNA analysis), quality control is 
necessary. In the US, it is recommended that NBS positive newborns undergo sweat 
testing only at a Cystic fibrosis Foundation-certified laboratory. Specific accreditation is 
mandatory.5, 156 Of note, it is not considered appropriate to perform the sweat test 
using conductivity.156 Specific requirements such as a very low incidence of insufficient 
(QNS) samples (below 5% for patients older than 3 months), positive and negative 
controls with every sweat analysis run and documenting sweat testing proficiency (three 
specimens mailed twice a year to laboratories and feed-back provided concerning their 
performance) are especially worth mentioning. Such external quality assessment 
structure for sweat tests is currently lacking in Belgium. Finally, current reimbursement 
of sweat test in our country is notoriously insufficient. 
4.1.4 Communication 
Optimized communication is also considered essential at all steps of the process,43, 44, 148, 
158, 159 which should be fluent. For instance, the UK Newborn screening program centre 
states that the newborn screening laboratory must initiate clinical referral within 24 
hours of the mutational analysis results being received and that a baby must be seen 
within five working days of the specialist centre being informed of positive screening 
results.160 Sensitive approach around the sweat test includes rapid appointment after the 
initial contact, information about the possibility of cystic fibrosis the day before the 
sweat test, contacting the families in the three first days of the week in order to avoid 
leaving them unsupported over the week-end preceding the test, provision of the 
results of the sweat test by the lead CF physician within one hour or two.114 The 
appropriateness of genetic counselling is also of great importance, not only as a vital 
part of follow-up care but also for parents of infants identified as healthy carriers. A 
recent French study emphasized that a sweat test should be arranged for all first-degree 
siblings of screened babies diagnosed with CF (even if older children are symptom-free) 
with gene analysis prescribed only in case of a positive sweat test result.161  
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The latter recommendation (the law in France does not allow to perform genetic 
testing in a child, ie sibling, less than 18 years of age unless it provides personal benefit) 
aims to avoid early identification of children with genotypes of uncertain significance but 
should presumably be restricted to asymptomatic children. The US guidelines also 
recommend a sweat test for any half-siblings who have signs or symptoms of CF or who 
have 2 parents known to be carriers.44 
4.1.5 Quality assurance 
In this context of rapidly expanding CF NBS programs, quality assurance is now a major 
issue. Integrated screening programs are recommended, which include centralization of 
outcome data from all CF centres and allow a monitoring structure to evaluate and 
modify screening algorithms if needed.45, 117, 156 In France, this surveillance committee is a 
small, well-funded structure derived from the Association Française pour le Dépistage 
et la Prévention des Handicaps de l'Enfant (AFDHPE, French Association for the 
Screening and Prevention of Infants Handicaps) which is mandated by the Ministry of 
Health to organize CF NBS within the same framework as other screening tests. It 
includes a senior CF physician working part time (one day/week) and centralizing data 
from the 22 regional associations. They provide the following data on a quarterly basis 
to the national structure: 1. Data on each “positive IRT test” (ie IRT value, date of 
sampling, genetic finding, sweat test result, conclusion of the centre) and 2. Summary 
items form completed by the CF centre physician (date of initial consultation at CF 
centre, CF status of the child, and in case of confirmed CF: family history for CF, 
personal symptoms). Reimbursement of IRT laboratories (n=23) and CFTR laboratories 
(n=9) is performed quarterly after the national structure has checked the the adequacy 
of the IRT results/sampling. In addition, the monitoring structure is also collecting 
through a yearly questionnaire to the accredited CF centres data on false-negative cases 
diagnosed on the basis of clinical symptoms. A questionnaire is also sent to the regional 
associations in charge of collecting IRT values. The national structure has a technical 
committee with quarterly meeting. One person is responsible for IRT evaluation and 
one for molecular testing. It also plays an important role in adjusting IRT cutoff values to 
maintain the percentage of positive screens at around the 0.5% target and continuously 
trying to improve the algorithm. For example, from February 2010 a prospective study 
has started to assess in 500 000 newborns within one year the possible role of PAP 
measurements – in parallel to the current algorithm – with the main objective to reduce 
the rate of carrier detection. 
A further step towards quality assurance has recently been reported by North-
American authors who comprehensively tracked and rated 112 potential errors in the 
whole CF NBS programs. It appeared that 60 % of the most serious potential errors are 
related to communication challenges.162 Table 4 summarizes the very concrete critical 
points identified in this study. The authors generated a list of 120 of potential errors 
throughout the whole CF NBS program, each of which was then rated on a 1 to 10 
scale for severity, occurrence probability, and detectability. The product of these is the 
Risk Priority Number or RPN *. Of note, two of the 7 most severe identified problems 
are related to the role of primary care physicians. 
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Table 4. Most severe potential problems of CF NBS programs identified by a 
comprehensive approach 
  RPN * 
1 parents misunderstand genetic counselling information 203 
2 missed babies due to neonatal intensive care unit transfer 180 
3 IRT cutoff errors leading to false negative outcome 165 
4 babies with confusing or similar names 160 
5 primary care physicians not understanding NBS results and being unable to 
accurately explain them to parents 
159 
6 birth hospitals entering the wrong data, i.e., clerical errors 158 
7 primary care physicians understanding the NBS results but not how to 
communicate properly without a scripted message 
157 
8 babies never screened 153 
9 nurses or lab technicians obtaining and processing the wrong NBS card 153 
10 false negative NBS test results 148 
4.1.6 The issue of false-negative screens 
Even in well-implemented CF NBS programs, this issue remains difficult. This is in part 
related to the grey-zone of diagnosis such as discussed in chapter 3 (3.4.1). It is also 
very dependent on the choice of the algorithm. Anyway it is important to try to limit 
the delay for clinical diagnosis in case of a false negative screen. The medical community 
should be made clear that  
• screening is not a diagnosis  
• even if an algorithm is chosen aiming to mainly identify severe forms of 
the disease, a few of them will still be missed (see Chapter 3.3) in addition 
to usually milder phenotypes.  
This implies that any patient with suggestive symptoms should still be investigated 
appropriately regardless of NBS results. An even more specific information could be 
delivered to primary care physicians and adult pulmonologists about milder, yet at times 
very progressive, forms of the disease that are more likely to present in adulthood and 
will probably have be missed by such a CF NBS program. Educational tools are to be 
developed for this. The Belgian CF Association (ABLM, BVSM) can play a role in this 
context, by contributing to share relevant information. 
In addition, tracking these false-negative patients is an important component of quality 
assessment of the program. The small number of accredited CF centres in Belgium 
(n=7) and the high degree of CF care centralization already achieved in our country 
should facilitate their identification and notification to a monitoring structure. 
4.2 GUIDELINES ON CARE AFTER SCREENING 
CF centre care and the availability of necessary medications are essential prerequisites 
before the introduction of NBS programmes. Both are met in Belgium. Clearly defining 
practical modalities ensuring rapid referral of CF screened infants to specialist CF 
services is a crucial part of any CF NBS program. All newborns identified by NBS should 
be managed according to internationally accepted guidelines.102, 163, 164 
The implementation of a dedicated CF NBS programme shifts the focus of CF health 
care from control of disease manifestations in symptomatic children to health keeping in 
a pretty large proportion of presymptomatic infants. In the future, this is likely to 
involve some specific recommendations. Expert opinions on the clinical management of 
infants identified following CF NBS are in the process of being collected, through a 
modified Delphi methodology.165 A general agreement on aspects of standard care is 
likely to be reached but the lack of an evidence-base approach will make it difficult to 
produce definitive statements. Unresolved issues need to be tackled through the 
implementation of specifically designed longitudinal studies and randomized clinical 
trials.43, 164 
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Key Points 
• Current guidelines for implementation of CF newborn screening programs 
invariably stress the importance of carefully considering each step of the 
process, keeping in mind that  “No system is stronger than its weakest link”. 
It is also necessary to identify and assemble those who will have operational 
responsibility.  
• Carefully determining the spectrum of CF disease that a NBS program will 
aim to identify is one of the first essential tasks.   
• Physicians should understand the limits of the screening and remain vigilant 
to identify false-negative cases: suggestive symptoms should still lead them 
to suspect a diagnosis of cystic fibrosis.   
• Quality assurance programs for the sweat test remain a key component of 
any CF NBS program. 
• Optimized communication at all steps of the process should be fluent. 
• Centralization of outcome data from all CF centres should allow a 
monitoring structure to evaluate and modify screening algorithms if needed 
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5 BENEFITS FOR THE BELGIAN CF PATIENTS 
Benefits of CF NBS are supported by a number of mostly observational studies and have 
been reviewed in chapter 2. There is no reason to suspect that these findings would not 
apply to the Belgian CF population. Based on ‘real life data’ using the Belgian CF registry, 
we further discuss here how the project of NBS could improve outcome for Belgian CF 
patients (ie excluding benefits related to genetic counselling) and how to optimize this 
ultimate goal. 
The Belgian CF Registry started in 1998 and was based on the US model. It is now for 
years a well-established tool,166-170 estimated to cover more than 90% of Belgian patients 
with CF. From 2006, the Registry is sponsored by the National Institute for Health and 
Disability Insurance (INAMI-RIZIV) and has been transferred to the Operational 
Direction of Public Health and Surveillance, the scientific serve of Health Services 
Research of the Institute of Public Health (IPH). An annual report is provided to the 
accredited centres. The supply of data by centres is obligatory and directly impacts on 
their funding. It is supervised by a board consisting of physicians from all CF centres and 
scientific collaborators of the IPH. For the year 2007, a first public version of the annual 
report was available on request (http://www.iph.fgov.be/epidemio/epien/index20.htm).  
Selected data from this report are listed in Table 5. 
Table 5. Annual Belgian CF Registry report (2007, public version) - Selected 
data.   
Demographics n 1057 
 Median age (years) 17.4 
 M (Males)  (%) 51.4 
 Adults (≥ 18 years) (%) 49.3 
 Patients ≥ 40 years (%) 7.3 
 Deaths reported 8 
Diagnosis New diagnoses 32 
 Median age at diagnosis 7 months 
 Diagnosis < 1year of age (%) 66 
 Diagnosis > 18 years of age (%) 7 
Anthropometry Height <P3 – children – M  (%)  12.6 
 Height <P3 –  children – F  (%) 9.2 
 Weight <P3 -  children – M  (%)  12.5 
 Weight <P3 – children – F (%) 14.3 
 BMI < 18.5 – adults – M (%) 21 
 BMI < 18.5 – adults – F (%) 18.9 
Spirometry FEV1 < 70% pred. : moderate to severe lung disease  (%) *  
  6-11 years (n:192) 7.9 
  12-17 years (n:161) 19 
  18-29 years (n:272) 54.4 
  ≥ 30 years (n:140) 65 
Treatment Pancreatic enzymes (%) 87 
 Insulin therapy (%) 9.7 
 ≥ 1 treatment with IV antibiotics in 2007 – children (%) 27.9 
 ≥ 1 treatment with IV antibiotics in 2007 – adults (%) 48.5 
 Number of lung transplants performed in 2007 17 
Genetics Patients homozygous for the F508del mutation (%)  47.9 
* excluding lung transplanted patients 
Some additional data are available from a published Belgian multicenter study.106 
The following items will be considered: 1) earlier diagnosis 2) earlier referral to a CF 
centre 3) optimizing quality of CF care in Belgium. 
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5.1 EARLIER DIAGNOSIS 
5.1.1 How important is it ? 
Early diagnosis is associated with improved outcome and a recent study is especially 
worth mentioning.46 Using the United Kingdom Cystic Fibrosis Database, this 
retrospective cross-sectional analysis looked at the outcome of 990 patients 
homozygous for the F508 del mutation, attending specialist CF centres, and 1 to 10 
years of age between 2000 and 2010. The study compared subjects diagnosed via NBS 
with subjects diagnosed via clinical symptoms at an early age (before 2 months) or at a 
later age (after the age of 2 months). Two meaningful analyses were performed. When 
compared to late clinical diagnosis via symptoms (median age at diagnosis 9 months), CF 
NBS led to improved growth, reduced morbidity and lower treatment burden for at 
least the first ten years. Early clinical diagnosis via symptoms (before the age of 2 
months) resulted in a nutritional status that was as good as the one in patients 
diagnosed via NBS but was still associated with an increased treatment burden. As up to 
and including 2002, a reactive rather than proactive approach was used in the treatment 
of CF in the United Kingdom, treatment burden was a reasonable and justifiable 
surrogate marker for increasing disease severity (ie, lower SK score) rather than poor 
pulmonary function, which may manifest later. Of interest, the benefits of early diagnosis 
could even have been underestimated in this study as the percentage of patients with at 
least 3 positive PA cultures was similar in the three groups while more recent studies 
suggest that optimal centralized care should nowadays result in a lower rate of chronic 
colonization by PA (see Chapter 3.1). 
An important conclusion of this landmark article is that making the diagnosis before the 
age of 2 months - which is achievable by CF NBS - can be considered as a critical 
objective. 
5.1.2 International data about age at diagnosis 
Specific information about age at diagnosis is available from several large national 
registries. 
In 2000, median age at diagnosis in Australia (where 70% of cases were already 
diagnosed through the NBS) was 1.8 months. Corresponding values in UK (20% of 
infants screened), France and US (smaller proportions of screened infants) were 4, 4 
and 6 months respectively.171 
A more refined analysis was available in the USA for the years 2000-2002.69 The median 
age at diagnosis was 2 weeks for screened babies and 14 ½ months for those clinically 
diagnosed (excluding meconium ileus). Corresponding values in the UK were 1 and 6 
months respectively.85 
In France, systematic newborn screening was introduced in 2002 and implicated in all 
centres by the end of 2003. Very recent results of this nationwide CF NBS program 
show that the median age at effective referral in CF centres for 987 screened CF infants 
was as low as 35 days. Interestingly enough, 54 % of them were already symptomatic 
(digestive complaints: 69%, growth failure: 44%, respiratory symptoms: 24%) but 
without CF NBS many of them would have gone through the well described long and 
sometimes traumatic journey to a diagnosis.172 These data prove that NBS can reduce 
the median age at diagnosis to below 2 months of age. 
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5.1.3 Current age at diagnosis in Belgium 
The Belgian CF registry data report 2007 (N=1057) shows that the median age at 
diagnosis is 7.03 months overall.170 These data include 16.2 % of the subjects in whom 
the diagnosis was made via newborn screening because several Belgian hospitals 
implement systematic neonatal screening using IRT on a local basis. The data also 
include 13.8% of subjects in whom the diagnosis is made at birth because of meconium 
ileus. Omitting these subjects from the calculations would thus increase the median age 
at diagnosis. If one excludes all subjects in whom the diagnosis is made after the age of 
10 years (thereby excluding subjects with milder disease forms, but also some late 
diagnoses of patients with classical severe forms of disease hence ‘missed diagnoses’) 
the median age at diagnosis is 4.4 months and thus still double the ’necessary age for 
benefit’ of 2 months. If, from these subjects with diagnosis before age 10 years one 
excludes 16 % of the cohort with diagnosis made via NBS, the median age at diagnosis 
rises to 6.9 months and if one further excludes 14% presenting with meconium ileus the 
median age at diagnosis rises to 9.5 months. The analysis was then further refined to 
include only subjects F508del homozygous diagnosed via symptoms before the age of 10 
years and excluding subjects presenting with meconium ileus (n=92). Their median age 
at diagnosis was 7.7 months. 
When limiting the analysis to subjects with a new clinical (i.e. through symptoms) 
diagnosis of CF up to the age of 10 years in the last 5 years of data collection (n=135) 
the median age at diagnosis was 10.9 months and when restricting this analysis further 
to subjects homozygous for F508 del (n=35) the median age at diagnosis was 7.3 
months. In the latter analysis subjects presenting with meconium ileus are also excluded. 
A very strict way of assessing subjects with potential benefit by NBS in the Belgian 
population is by evaluating the age at diagnosis in all subjects homozygous for F508del in 
the registry (N=492) diagnosed through symptoms, and excluding those presenting with 
meconium ileus at birth (n=93): the median age at diagnosis is then 8.5 months. In 256 
subjects the diagnosis was later than age 2 months and taking into account their specific 
ages at diagnosis a total of 8086 patient months of benefit can be gained in the Belgian 
population. If looking only at the 82 subjects diagnosed in the last 10 years the median 
age was 5.8 months, amongst them 66 diagnosed after 2 months with 1950 patient 
months in excess of the benefit. 
The above-mentioned 16.2% proportion of Belgian CF patients diagnosed by CF NBS 
could suggest that some useful information can be derived from a comparison of this 
group and unscreened patients. For several reasons however, this is not the case. Little 
is known about these local programs: different algorithms have been used, these local 
initiatives were not structurally funded and some have evolved over time. Most 
importantly, no data about quality control is available. 
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5.2 EARLIER REFERRAL TO A CF CENTRE. 
5.2.1 How important is it ? 
CF NBS is universally coupled with immediate referral to a specialist centre. Guidelines 
and international consensus all emphasize that this is a key point for a program to be 
efficient.43, 44 The French experience is of particular interest in this context. Ten years 
ago, it was apparent that the outcome of CF patients in France was less favourable than 
in the US and other European countries with similar economic status but with an 
organized CF care systems. For instance, the median life expectancy, median age at 
death and number of pregnancies in CF women all were lower in France.173 French 
experts in the field then pleaded for CF NBS implementation but this was subordinated 
to the creation of a network of CF Resource and Skill Centers, allowing the 
multidisciplinary approach to this complex disease with standardized follow-up 
protocols.173, 174 
Even outside the context of CF NBS, early referral to a specialist healthcare centre is 
considered as an important prognostic factor as highlighted in consensus reports on 
optimal management of CF.102, 175, 176 Though this is long supported by a number of 
common sense reasons and has been mentioned as a model for the management of 
complex diseases,177 most published studies concerning the impact of this centralization 
on lung disease are either biased due to comparison with historical controls, and/or 
probably underpowered.63, 178-182 Two studies avoid these pitfalls. 
Mahadeva et al.89 compared two groups of adults who had either received continuous 
care from paediatric and adult CF centres (n=50) or had received neither paediatric nor 
adult centre care for their CF (n=36). Excluding body mass index as a covariate, FEV1 
was significantly better in the first group. 
More recently, a Belgian retrospective multicenter study clearly showed that earlier 
referral of children suffering from CF to specialist care is associated with a significant 
pulmonary benefit.106 This work should have been conducted by the Belgian CF Registry 
team but this proved impossible at the time (2003) so the directors of 6 out 7 
accredited centres accepted to supply their data. This carefully designed study 
demonstrated that children referred early (defined as patients referred less than 2 years 
after the diagnosis) had a better FEV1 (86.7% pred.±19.4 vs 77.2% ± 22.4, p=0.01) and a 
lower prevalence of PA (17.5% vs 38.6 %, p<0.05) than patients referred later. Assuming 
a mean annual decline in FEV1 of 1–3%, a 10% difference in this major outcome variable 
between “early” and late referred children at a mean age of 13 years is impressive and is 
likely to have survival implications. 
5.2.2 Room for improvement in Belgium 
In Belgium, several centres have for quite some time now been functioning according to 
the North American model organization of care. A further crucial step in this regard 
occurred in 1999 when seven CF centres were officially accredited and financially 
supported by the national health system. All are based in academic hospitals. Centres 
had to fulfil a number of qualitative criteria (facilities and resources) closely derived 
from the Cystic Fibrosis Trust's 1996 guidelines.183 A minimum of 50 patients on full 
care was required. Shared care is not considered as an option in this small country. The 
last annual report of the Belgian CF Registry included data of about 1057 patients at the 
end of the year 2007170 and all these patients were at least known in an accredited CF 
Centre (which provided the data). An independent listing of CF patients known by the 
Belgian CF Association was similar, confirming the high coverage of the Belgian Registry. 
This is an encouraging point but cannot mask the fact that at the end of 2003, the delay 
between the age at diagnosis and the age at referral to a CF Centre still exceeded 2 
years in 31% of patients.106 Obviously, implementing CF NBS coupled with a sine qua 
non immediate referral to a specialized centre will result in substantial reduction of this 
delay. 
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5.3 OPTIMIZING QUALITY OF CF CARE IN BELGIUM 
5.3.1 Caveat : comparing data from different countries is difficult. 
Numerous methodological issues make it difficult to compare results of national 
registries and actually will seriously dent many of such comparisons. 
These include (but are not limited to): 
• The coverage or exhaustivity of a registry, an item which might be difficult 
to assess and is not always available 
• The choice of reference equations used to normalize anthropometric and 
spirometry data (several sets can be used and they are not even always 
specified)  
• The type of subjects included in the registry: an increasing number of 
patients with milder forms of the disease are now being identified in some 
countries (children as well as adults),184 through wide access to CFTR 
gene sequencing and nasal potential difference measurements, or via CF 
NBS.  An example of the latter is the increasing percentage of genotypes 
including the R117H mutation in the French CF Registry.185 This allowed 
French authors to study a large group of such patients, demonstrating a 
very low classical-CF penetrance of this mutation186 and supporting the 
suggestion that this mutation should be withdrawn from the panel of 
CFTR mutations used for screening purpose in this country.152  
• A lack of uniform definitions of many clinical conditions (ie hepatopathy, 
CF related diabetes, pulmonary exacerbation …)  
• Differences in set-up (longitudinal versus cross-sectional)  
• Differences in age stratification (in UK, adults are defined as patients ≥ 16 
years …)  
• Issues related to quality control and missing data  
• In or exclusion of lung transplanted patients (“another disease”)  
• Bacteriology: crucial differences in frequency of sampling and  laboratory 
practice in isolating and reporting pathogenic organisms  
• Spirometry: FEV1 has been recorded as the last value of the year, the best 
value of the year, the mean value of the year, the average of the best value 
for each quarter of the year … Normal FEV1 has been defined as ≥ 80 or 
90% of the predicted value in different registries  
• Wide heterogeneity of CFTR mutations throughout the world  
There is an obvious need for standardization in data collection if we are to compare 
different registries meaningfully. It has recently been suggested that evaluating cohorts 
on the basis of the presence or absence of pancreatic insufficiency could help to 
overcome some of the current limitations.166 Limiting analysis to patients homozygous 
for the F508 del mutation could be even “cleaner”. 
5.3.2 Selected data 
Overall, Belgian data compare very well with those from other western countries. 
Reliable, well-established national CF registries with a high coverage are scarce. Such 
registries, all originate from countries with a high level quality of care in this field. This is 
confirmed as preliminary data continues to appear in congresses from other European 
or even developing countries: their outcomes (variables) are clearly less favorable. On 
the other hand, it is to be mentioned that detailed yearly data from Canadian and 
Scandinavian national registries are lacking, even though the latter are known to have 
the best results in the world. 
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In order to circumvent some of the above mentioned drawbacks of registry data, a few 
indicators have been chosen. It should be realized that improvement in the median age 
and proportion of adults over time can is indeed correlated both to increased survival 
and to new diagnoses in adults. However, continuous improvement is clearly 
documented on a very wide scale in the US Registry over the past 4 decades using the 
same items, median life expectancy and anthropometric as well as spirometric data, and 
this has been true before the recent development of new tools for diagnosing milder 
forms of the disease and CF NBS. In addition Kulich et al.187 specifically addressed this 
issue, taking advantage of the huge amount of data from this registry which is estimated 
to contain information about at least 85% of patients diagnosed with CF in the United 
States. In-depth statistical analysis of the whole cohort and specific subgroups provided 
evidence that most of the observed improvement in survival among CF children was 
related to progress in care.  
Comparisons with data from the US Registry are especially meaningful as the Belgian 
Registry was initially based on its model. 
5.3.2.1 Median age of patients (Belgium vs other countries) 
Table 6 summarizes published data from 6 well established national registries. 
Table 6.  Median age of CF patients in 6 industrialized countries.   
Country Year Estimated population 
(millions) 
Number of 
patients 
Median 
age (yrs) 
Ref 
UK 2004 60 7046 16.4 188 
France 2006 63 4994 15 185 
Australia 2005 20 2472 15.3 189 
Belgium 2003 10.5 860 16 167 
Belgium 2005 10.5 950 17 168 
Belgium 2006 10.5 1036 17 169 
Belgium 2007 10.5 1057 17.4 170 
Ireland 2007 4.3 1170 17 190 
Germany 2007 82 4926 17.2 39 
 
5.3.2.2 Proportion of adults (Belgium vs other countries) 
Another index of survival is the proportion of patients now reaching adulthood. This 
percentage is steadily increasing in western countries where it is expected that within 
the next few years most patients will actually be adults. This is already the case in 
Scandinavia (unpublished data). 
Table 7. Proportion (percentage) of adult patients (≥ 18 y) in selected 
western countries. 
 Belgium USA France Germany Sweden Australia Canada Ireland 
Year         
1999 36.4    45191    
2000 38.4 38.7192       
2001 35.3 39.5193       
2002 39.6 40.2194     47.6195  
2003 40.5  40196       
2004 42.7 41.8197       
2005 44.0 43198 40.7199 43.440   41.1189    
2006 48.4169 44.6200 41.3186      
2007 49.3170  44.4201   47.6191    49190 
These data are in keeping with those derived from a recent report of the European 
Cystic Fibrosis Society (ECFS) concerning a few national registries with high rates of 
exhaustivity (Table 8).202. 
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Table 8. Proportion of adult patients (≥ 18 y) in selected western countries at 
the end of 2006.202 
 Denmark Belgium Israel Germany Ireland Czech 
Republic 
N 438 1.036 447 4.894 830 470 
≥ 18 yrs (%) 52.3% 48% 46.8% 46.6% 45.3% 38.3% 
 
5.3.2.3 Proportion of children (6-<18y) with a normal FEV1 (≥ 90% predicted) 
(Belgium vs US). 
As the respiratory course has a major impact on the prognosis of CF and FEV1 is as yet 
the best marker, the proportion of CF children with a “normal” FEV1 is an index of 
great interest. In 2003, this percentage was 45.2 in US196 and 51.7 in Belgium,167 using 
the same reference values by Knudson.203 The difference between the 2 countries is in 
fact somewhat underestimated as the mean of best FEV1 per quarter was retained in US 
while the last value of the year (fall or winter) is used in Belgium. Unfortunately this 
proportion is no longer detailed in the more recent annual reports of US Registry. 
5.3.2.4 Median FEV1 in selected age groups (Belgium vs Denmark and Germany). 
Detailed FEV1 data of non transplanted patients by the end of 2006 (according to 
Wang204 & Hankinson205) were available for 3 European countries in the report of the 
ECFS 202 and are summarized in Table 9. 
Table 9. Median FEV1 % predicted values for selected age groups in 
Denmark, Belgium and Germany (at the end of 2006).  
Age group Median FEV1 (% pred.) 
 Denmark Belgium Germany 
10-14 yrs 102 93 88 
15-19 yrs 98 78 74 
20-24 yrs 84 72 63 
25-29 yrs 73 59 56 
 
5.3.2.5 Comparison of recent anthropometric data of children 2-3 years old in French 
and Belgian CF Registries. 
In France, CF NBS is fully implemented from 2004. While writing this chapter, we 
wondered whether there could be a difference in anthropometric data of young 
children (2-3 years since Centers for Disease Control (CDC) reference values for BMI 
below 2 years of age are not available) in the French and Belgian registries. The CF 
Registry coordinators from these 2 countries kindly accepted to provide the requested 
mean data within a few days. Pancreatic sufficient patients were excluded from analysis 
as well as patients diagnosed after meconium ileus. Belgian infants diagnosed by CF NBS 
were excluded too. 120 French children 2-3 y old by the end of 2006 were compared 
to 53 Belgian children 2-3 y old by the end of 2007, 2006 and 2005. These data 
demonstrate a nutritional advantage in the French (screened) patients (Table 10).  
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Table 10. Recent anthropometric data of pancreatic insufficient 2‐3 
years‐old children without meconium ileus (after exclusion of the NBS 
Belgian patients): France vs Belgium. 
 FRANCE BELGIUM P 
N 120 53  
Mean age (years) 2.42 2.43  
Mean age at diagnosis 
(months) 
<2 7.6  
Height Z score 0.02 (± 0.92) -0.57 (± 0.87) <.0011 
Weight Z score -0.36 (± 0.86) -0.93 (± 1.26) <0.001 
BMI Z score -0.46 (±  0.88) -0.74 (± 1.43) NS 
 
Data are presented as mean (± SD).  
5.3.3 Scandinavia : the best outcomes without NBS programs. 
Even though published data are limited, Scandinavian countries are currently considered 
as the reference in terms of outcomes for CF patients.202, 206 It should be emphasized 
that good outcome in Denmark and Sweden is achieved without CF NBS. This cannot 
be attributed to less severe genetic background since Denmark is reporting the highest 
percentage of patients homozygous for the F508 del mutation. Data are lacking to 
explore in-depth the factors involved and such analysis is well beyond the scope of this 
work. Yet, it demonstrates that improving the quality of care is very important. Possibly, 
key features of these ‘success’ countries include very high economic status, a long 
tradition of centres of reference, more frequent visits to the centres (monthly), a very 
aggressive and costly approach for patients chronically colonized by PA (2 weeks 
hospitalization quarterly for intravenous antibiotic treatment) in Denmark, cultural 
importance of physical exercise, attention to nutritional status (Sweden). … 
5.3.4 Quality of CF care in industrialized countries is heterogeneous 
5.3.4.1 A long known fact & Selected examples 
Large differences between outcomes variables obtained from the different centres have 
been recognized for a long time.207 
A few striking illustrations of this heterogeneity are provided by recent data from the 
2007 US Registry,201 allowing for comparisons between centres: 
1. mean FEV1 (% predicted) for CF children 6-17 years - : national average: 
92.6%, range: 75-103 % (reference values : Wang204 & Hankinson205 
2. percent with BMI < 5th Percentile for CF patients 2-20 years - national 
average: 52.7, range: 32-83 
3. MRSA infection rate – national average: 21.2%, range: 6 -42% 
Other recent similar features can be derived from the CF German Registry where a 
quality management program with an overall coverage of 82% for the year of 2005 
confirmed considerable difference between centres in terms of key parameters39. For 
instance, the percentage of children (6 - <18 years) with an FEV1 above 80% of the 
predicted value (according to Zapletal208 ranged from 20 to 100% in centres treating less 
than 50 patients and from 35% to 100% in larger centres. Globally, the mean FEV1 in 
this age group was 88% of the predicted value. 
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5.3.4.2 A reality in Belgium too 
A recent Belgian multicenter study confirms wide differences in outcome between the 
reference centres in our small country.106 Neither the climate, nor the distance to the 
centre, nor the genetic heterogeneity could be relevant in Belgium. The role of 
socioeconomic factors cannot be excluded, yet the quality of the social security system 
of this country is expected to limit their impact. A comprehensive attempt to identify 
specific care patterns associated with better outcome was beyond the scope of this 
study. 
5.3.4.3 An opportunity for quality improvement initiatives 
Differences between outcomes variables obtained from different centres are now 
drawing considerable attention as they may provide an opportunity to develop quality 
improvement initiatives.39 
The Epidemiologic Study of Cystic Fibrosis (ESCF) was an observational database 
collecting prospective information from a large number of CF patients. North American 
data from 1995 through 1996 were analyzed in order to identify care patterns 
associated with better respiratory outcomes.209 The 194 participating sites all cared for 
at least 50 patients. They were ranked on the basis of median values for FEV1 within 
each of three age groups (6 to 12 years, 13 to 17 years, and > 18 years). The study 
confirmed substantial differences in lung health across different CF care sites. For 6-12 
yrs children, mean values of FEV1 (% predicted according to Knudson203 were 93% and 
74% in upper and lower quartiles respectively. Corresponding values for children 13-17 
yrs were 85 and 62%. Patients who were treated at higher ranking sites had more 
frequent monitoring of their clinical status, measurements of lung function, and cultures 
for respiratory pathogens. These patients also received more interventions, particularly 
IV antibiotics for pulmonary exacerbations. 
A more recent ESCF study led to the identification of a link between better lung 
function in 6 to 12 year-old children and clinical care patterns in infants in previous 
years.77 
Patient registries are essential to identify significant differences in clinical state and 
outcomes. A recent comprehensive editorial emphasized the importance of collecting 
very reliable data for quality management.210. This necessitates complete datasets 
probably through obligatory (as in Belgium) rather than voluntary supply of data, 
standardisation of sampling moments and procedures but also for regular audits of the 
centres by the registration committee. The latter has still to be implemented in Belgium. 
The author also underlines the importance of structure indicators evaluating the care-
delivery system (“Is the dedicated team appropriate?” – the answer to this question has 
funding implications) and process indicators (including a number of important items such 
as the quality of microbiological evaluations, local policies for segregation of patients on 
a bacteriological basis …). 
This should lead to sharing expertises and eventually facilitate a more standardized and 
efficient approach177, 211-213 with the ultimate goal being the improvement of the services 
delivered to patients. This fits in the scope of the cystic fibrosis quality assurance 
project in Germany.39, 40 A few key interrelated outcome parameters such as BMI, FEV1 
and PA infection rate can be used to qualitatively describe the results achieved by 
different centres. Benchmarking diagrams have been derived. Auditing and quality 
groups have then been created to enable CF centres “to learn from the best”, an option 
currently endorsed by the new European CF Registry organised by the European CF 
Society (ECFS) and Euro Care CF. It has been suggested that such data could also serve 
as a basis for political action in the health care system. 
Centre-based quality improvement using a clinical microsystems approach might also be 
helpful.36-38 Involving a number of critical components (ie assessment of care processes, 
standardization of care, patient involvement, communication, developing a culture of 
continuous improvement …) it has been shown effective in improving pulmonary 
function of pediatric patients at the US CF centre of the Akron Children’s Hospital.36 
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Key-points 
• Implementing a systematic CF NBS program in Belgium has the potential to 
lower the median age at diagnosis in patients with typical CF but without 
meconium ileus from about 10 months to less than 2 months.  
• Immediate referral to a specialized CF centre after CF NBS is required to 
have early access to optimal care. Both CF NBS and immediate referral 
have been shown to improve the outcome of CF patients.  
• A number of methodological issues flaw comparisons between different 
national registries. Nevertheless, it might be derived from current data that 
the quality of care in CF patients in Belgium is already high on average. 
• Considerable variability of outcomes between centres has long been 
documented and is also observed in Belgium. It offers an opportunity for 
promoting quality improvement initiatives which would help to maximize 
the benefits from CF NBS. The Scientific Institute of Public Health could 
play pivotal role in this context. 
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6 SCREENING STRATEGIES 
6.1 LITERATURE 
We identified numerous recent reviews and guidelines dealing with CF NBS strategy. 
Three health technology assessment studies were published.110, 214, 215 There is no 
universally agreed approach to screening for CF. The primary studies are 
heterogeneous (strategy, IRT cut off values, number and type of mutations analysed, CF 
prevalence) and results in term of sensitivity, specificity and predictive values are difficult 
to compare. Several studies have been conducted to compare strategies. They were 
reviewed in 2007.216 
A document that describes European best practice guidelines for CF NBS was recently 
published.43 This working document is a true state-of-the-art democratic consensus 
among experts with respect to guidelines for CF NBS. 
Indeed, these guidelines were obtained as follows. Altogether, 37 experts in the field of 
CF NBS from different countries of Europe and the United States were invited to 
participate. They were divided in working groups. Each of these working groups had 
pre-conference consultations and drafted a preliminary document. A meeting was then 
organized in Garda, Italy, on March 28–29, 2008, in which 31 of the 37 experts 
participated. The individual working groups had then formal discussions within their 
working group and concluded a working document. In a next phase, all participants took 
part in a general discussion of all working documents and reached a group consensus. 
Post-conference consultations were then performed in subsequent months by all 
participants to generate the final consensus guidelines for CF NBS.43 This document, 
containing a chapter devoted to strategies, is thus an excellent basis for evaluating, and 
possibly setting up, a CF NBS program in Belgium. 
6.2 DESCRIPTION OF THE VARIOUS PROTOCOLS 
Screening allows the detection of children with an elevated risk for CF. Screening is thus 
not a diagnostic test.  
A screening test is valid if it detects most people with the target disorder (high 
sensitivity) and excludes most people without the disorder (high specificity), and if a 
positive test usually indicates that the disorder is present (high positive predictive 
value). 
Multiple protocols and algorithms are used to screen newborns for CF. In Europe, 
more than 25 screening programs have been developed, with quite marked variation in 
protocol design.43 An algorithm for a standard CF NBS procedure is shown in  Figure 3. 
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Figure 3. Standard CF NBS procedure 
 
Some mutations like 3849 + 10 Kb C>T or R117H may be associated with sweat chloride 
values < 30 mmol/L. Reproduced from 43. 
A referral is given to Figure 4 (taken from 43), which is included as Figure 4 in this KCE 
report. Figure 6 referred to in the above flowchart is included as Figure 8 in this KCE 
report. 
CF NBS protocols currently used in Europe are shown in Table 10. This reflects (1) the 
ethnic mix of populations, (2) the structure of current NBS protocols (for instance the 
ability to organize a second heel prick test), and (3) variations in healthcare provision 
and resources. While harmonization of protocols is desirable, it is not realistic to hope 
for a single European scheme, and probably this is not desirable. However, it is 
important to compare rigorously the performance of different available protocols, in 
order to find the protocol best suited for a given region or country in Europe. 
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Table 11. CF NBS protocols used in Europe  
Areas Average 
screened 
population 
per year 
2nd 
tier 
3rd 
tier 
4th 
tier 
Specifics 
Two-tier protocols 
Liguria (I) 12,000 ST – –  
Three-tier protocols 
Czech Rep 76,000 MUT ST – PS; Feb 2005–Nov 2006 
Emilia Romagna 
(I) 
40,000 rIRT ST –  
Calabria (I) 18,000 rIRT ST 
MUT 
–  
Lombardy (I) 98,000 MUT 
rIRT 
ST – rIRT if bIRT > 97.5° centile 
MUT if bIRT > 99° centile 
Marche (I) 14,000 MUT 
 
rIRT 
ST – PS; rIRT if bIRT > 97.5° centile MUT if 
bIRT > 99.8° centile 
Tuscany (I) 33,000 MP 
rIRT 
ST –  
Piedmont (I) 39,000 MUT 
rIRT 
ST – PS; rIRT if bIRT > 98.6° centile 
MUT if bIRT > 99.6° centile 
Lazio 1 (I) 28,000 rIRT ST 
MUT 
–  
Lazio 2 (I) 37,000 MUT 
rIRT 
ST –  
Sicily (I) 54,000 MUT 
rIRT 
ST –  
Austria 77,000 rIRT ST –  
Catalunya (SP) 83,000 rIRT MUT 
ST 
–  
Castilla-Leon 
(SP) 
18,000 rIRT 
MUT 
ST   
Galice (SP) 21,000 rIRT MUT 
ST 
– PS 
Wales (UK) 34,000 MUT ST   
Dresden (GER) 15,000 MUT   Since January 2008 IRT PAP 
Heidelberg 
(GER) 
40,000 MUT 
PAP 
ST  PS (started April 2008) 
Russia 1,300,000 rIRT ST   
The 
Netherlands 
180,000 
PAP MUT 
 
PS (started 1-1-2008) 
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Areas Average 
screened 
population 
per year 
2nd 
tier 
3rd 
tier 
4th 
tier 
Specifics 
Four-tier protocols 
France 809,000 MUT rIRT ST rIRT if MUT-tive and bIRT > 100 μg/l 
Poland 210,000 MUT 
SEQ 
ST   
England (UK) 655,000 MUT rIRT 
 
MUT 
ST rIRT if 1 mutation at MUT or bIRT 
> 99.9th centile 
Expanded MUT if one mutation at first 
panel 
Northern 
Ireland (UK) 
24,000 MUT rIRT 
 
MUT 
ST rIRT if 1 mutation at MUT or bIRT 
> 99.9th centile 
Expanded MUT if one mutation at first 
panel 
Scotland (UK) 58,000 MUT rIRT 
 
MUT 
ST rIRT if 1 mutation at MUT or bIRT 
> 99.9th centile 
Expanded MUT if one mutation at first 
panel 
Veneto 56,000 MUT rIRT ST rIRT if MUT and MP-tive and bIRT twice 
the cutoff 
Trentino Alto-
Adige (I) 
 
MP 
  
 
 
Notes:  
- 1st tier is always IRT (bIRT).  
- abbreviations: rIRT = IRT resampling; MUT = genetic analysis by mutation-specific tests; MUT 
SEQ = genetic analysis by sequencing of exons (6 regions of the CFTR gene, recently upscaled to 
.. regions of the CFTR gene, Norek A. personal communication); MP = meconium proteins 
dosage; ST = sweat test; NA = not available; PS = pilot study; PAP = pancreatitis associated 
protein. 
- more than one test per tier is considered if tests are performed at the same time. 
Modified and updated from 43, 217, 218. 
All current protocols are multi-stage testing and rely on IRT as the primary test and on 
a sweat test for confirming or excluding the diagnosis of CF. Intermediate tiers are 
required to achieve an acceptable combination of sensitivity and specificity and are 
nearly always used. These tiers may either consist of a further analysis on the first blood 
spot (CFTR mutation or Pancreatitis-associated protein), or a second IRT test on 
another blood spot collected later on, or various combinations of these three. Each of 
these protocols have their own advantages and drawbacks. 
6.2.1 IRT issues 
Serum immunoreactive trypsine (IRT) levels are raised in neonates with CF compared 
with unaffected neonates due to back leakage from blocked pancreatic exocrine duct. A 
single IRT protocol involves measurement of IRT on a heel prick blood sample during 
the first week of life, followed by a DNA test or sweat chloride test in infants with 
elevated IRT levels to confirm the diagnosis. It has been used in the early years of 
newborn screening for CF. Since elevated IRT levels during the first week of life are not 
only found in infants with CF but also in healthy infants (ethnicity, CF carrier status and 
perinatal health), the major problem associated with this protocol is its low positive 
predictive value due to a high number of false positives.110 It is now generally accepted 
that a single IRT stage is not an adequate screening strategy.  
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6.2.1.1 IRT cut offs 
The initial IRT centile cut-off has the greatest effect on NBS performance, and therefore 
optimization of cut-off levels depends on the relative importance attached to sensitivity 
and, particularly, specificity. Early experience with the two-stage IRT–IRT protocol219, 220 
showed that a good sensitivity can be achieved with a 99.5th centile cut-off, although 
the use of a lower cut-off (e.g. 99th centile) is also common.221 A retrospective study of 
false-negative cases suggests that when the sample is taken relatively late (day 5), 
lowering the cut-off would have little effect on sensitivity (Heeley, unpublished data 
taken from Castellani43). Furthermore, the use of low IRT cut-offs around the 95th 
centile, prior to mutation analysis, reduces the positive predictive value of a single CFTR 
allele with regard to making a subsequent diagnosis of CF. 
The range of cutoff values (min-max) reported to the Newborn Screening Quality 
Assurance Program is very large for IRT (32/170 ng/mL whole blood).222 This is a 
reflection both of differences between IRT tests being marketed and the between-lot 
variations. Unfortunately, no standardized reference material is available for this 
important test. 
In general, a policy of replication in duplicate should be adopted for all samples with IRT 
values above a preliminary threshold, usually set 10 ng/ml below the final cut-off.43 This 
is to minimize effects of volumetric variability of the punched discs, day-to-day variation 
in IRT assay calibration, and to detect contamination of the sample with faeces or 
possibly sample misidentification. 
6.2.1.2 Quality control 
There are significant differences among commercially available IRT assay kits in terms of 
the value assigned to the initial cut-off and possibly also in the rate of decline of 
measured IRT in positive cases during the first few weeks of life.223, 224 This could result 
in a different IRT cut-off for different kits. Despite such variability, all the current 
commercial IRT assays seem to produce satisfactory results. However, this should not 
pose any problem since in a given lab cut-off centiles are used. The performance of the 
various commercially available IRT assays is shown in Table 12.222  
The total coefficient of variation (CV = SD / mean) reaches more than 50% for some 
brands of IRT around cut-off. However the averages within lab CV remains at 
acceptable levels. 
Since commercially available trypsin preparations differ between companies and batches 
in immunoreactivity (see 6.2.1.7 IRT1/IRT2 isoforms), protein concentration, or tryptic 
activity, the production of quality control material for IRT assays is extremely difficult.225 
Traditional external quality assurance (EQA) schemes are of limited use for calibrating 
IRT assays used in screening since there is too much volumetric variability in the control 
spots themselves and in the calibrant spots used to construct the standard curve. A 
large number of spots assayed in several different daily runs would be needed in order 
to produce accurate results. 
An alternative approach is to use the population distribution of IRT values to monitor 
assay performance. Centile plots of IRT results from routine screening are useful as a 
retrospective check on assay calibration, and will detect quite small differences between 
individual batches or between different laboratories.226 This overcomes difficulties 
associated with prepared blood spots and, provided that a sufficient number of results is 
available (at least over 2000), has greater statistical validity than EQA based on relatively 
few blood spots.226 
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Table 12. IRT : 2008 Quality Control Data Summaries of Statistical Analyses 
(ng IRT/mL whole blood) (adapted from 222) 
METHOD N Mean Average 
Within 
Lab SD 
Average 
within lab 
CV (%) 
Tot SD Tot CV 
(%) 
Y-
Interc
ept* 
Slope 
Lot 791 – Assayed 16.1 ng/mL blood 
MP Biomedicals ELISA 20 29.4 3.1 11 10.6 36 1.7 1.4 
Delfia 419 16.1 2.4 15 2.9 18 -0.3 1.1 
AutoDelfia 1043 16.9 1.7 10 2.0 12 -1.7 1.2 
Bio-Rad Quantase 90 13.2 2.7 20 4.5 34 -2.4 0.9 
Bioclone ELISA 29 13.1 1.6 12 1.9 15 -7.1 0.9 
Other 29 16.5 2.0 12 2.1 13 1.6 0.9 
Lot792 Assayed 38.8 ng/mL blood 
MP Biomedicals ELISA 20 55.5 9.5 17 18.5 33 1.7 1.4 
Delfia 409 40.3 4.6 11 5.8 14 -0.3 1.1 
AutoDelfia 1043 43.4 4.2 10 5.0 12 -1.7 1.2 
Bio-Rad Quantase 90 31.2 4.4 14 16.4 53 -2.4 0.9 
Bioclone ELISA 30 28.1 2.5 9 6.3 22 -7.1 0.9 
Other 30 38.6 5.6 15 9.0 23 1.6 0.9 
Lot793 Assayed 69.2 ng/mL blood 
MP Biomedicals ELISA 20 86.5 10.6 12 11.7 14 1.7 1.4 
Delfia 410 74.8 7.9 11 10.6 14 -0.3 1.1 
AutoDelfia 1058 81.7 8.4 10 10.3 13 -1.7 1.2 
Bio-Rad Quantase 88 55.0 7.4 13 26.6 48 -2.4 0.9 
Bioclone ELISA 30 52.2 12.3 24 16.7 32 -7.1 0.9 
Other 30 67.5 6.5 10 8.9 13 1.6 0.9 
Lot 794 – Assayed 133.7 ng/mL blood  
MP Biomedicals ELISA  20  190.7  17.6  9 41.7  22 1.7  1.4  
Delfia  408  140.3  13.4  10 17.3  12 -0.3  1.1  
AutoDelfia  1068  155.3  14.1  9 18.2  12 -1.7  1.2  
Bio-Rad Quantase  86  115.4  21.3  18 51.7  45 -2.4  0.9  
Bioclone ELISA  29  122.8  27.2  22 48.3  39 -7.1  0.9  
Other  30  128.1  12.3  10 24.7  19 1.6  0.9  
*Estimated by performing a weighted linear regression analysis of mean reported concentrations 
versus enriched concentrations and extrapolating the regression to the Y-axis. 
6.2.1.3 Age at sampling 
The age at which the blood samples are taken seem to have little direct effect on the 
effectiveness of screening. Some US programs sample on day one of life and report 
reasonable results, as does the relatively late day 5 sampling.54, 224 The introduction of 
CF screening does not require a change in current blood sampling practice except for 
additional emphasis on avoiding fecal contamination. 
6.2.1.4 Stability of IRT in blood spots 
IRT in dried blood spots is stable over the short term, but it is not advisable to rely on 
a screening result from a sample that has been significantly delayed in transit. When 
stored for 10 weeks in dark at room temperature and in a dry location inside a 
cardboard box, ‘Guthrie’ blood samples from normal babies lose approximately two-
thirds of their IRT as measured by Sorin® reagents, which measure mainly trypsinogen 
and give a screening cut-off ~ 80 ng/ml.227 When samples are stored at + 4 °C for 4-8 
months, using the Boehring RIA-gnost® neonatal trypsin kit (which detects both trypsin, 
trypsinogen and inhibited forms of the enzyme), with a screening cut-off of 
approximately 900 ng/ml,228 samples from babies with non-CF hypertrypsinaemia lost 
approximately 25% of their activity after 4 months, and almost 45% after 8 months. 
Unlike samples from normal neonates, samples from CF cases showed a bimodal decay 
curve suggesting a different mix of IRT species. 
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6.2.1.5 Non-CF causes of increased IRT 
A wide variety of physiological or medical conditions have been associated with 
hypertrypsinaemia in the neonatal period. Increased IRT has been noted in trisomies 
13.82, 229 Perinatal stress has also been reported to be a significant factor in 
hypertrypsinaemia,230 and a cohort of 372 sick infants on the neonatal intensive care 
ward had significantly increased blood-spot IRT compared to normal infants irrespective 
of the diagnostic category.231 However, neonatal infection as such was reported not to 
have any effect.232 Elevated IRT levels have been found in association with congenital 
infections, renal failure and bowel atresia223 and in a case of nephrogenic diabetes 
insipidus.233 
In the absence of any of the common CF-causing mutations, and particularly if the 
mutation panel has a sufficiently high population specific detection rate in the newborn 
ethnic group, the likelihood of CF in such cases is low. 
The population distribution of blood IRT concentrations in the newborn period is 
slightly higher in babies of North African parentage234 and in African-Americans235 than 
in babies of North European origin, which should be taken into consideration if 
newborns have an ethnic origin from these regions. 
6.2.1.6 IRT in special situations 
A tendency for CF neonates with meconium ileus to have IRT values within the normal 
range was noted early in the history of newborn screening, though its basis is 
obscure.145, 224, 236 
Hyperechogenic bowel on ultrasound imaging in utero in the second trimester of 
pregnancy may indicate CF, with risk of the disease in the fetus ranging from 1.5% to 
25% depending on the grade of echogenicity observed.237, 238 
Neonates presenting with meconium ileus, who have had hyperechogenic bowel in 
utero, should be regarded as high risk and should be investigated independently, in 
parallel with the normal NBS process. 
6.2.1.7 IRT1/IRT2 isoforms 
There are several molecular forms of IRT; the 2 major forms secreted by exocrine cells 
of the pancreas are trypsinogen 1 (cationic trypsinogen or IRT1) and trypsinogen 2 
(anionic trypsinogen or IRT2).239, 240 A multiplex method with specificity for 2 isoforms 
of IRT has been described and has performance comparable to that of a standard IRT 
method and the advantage of improved standardization by detection of the 2 
isoforms.241   
6.2.2 Screening algorithms 
Some examples of intermediate tiers strategies are shown in Figure 4. A comparison of 
the main used protocols is presented in Table 13. 
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Figure 4. Three examples of intermediate tier strategies.  
 
the cut-off for resampled IRT is lower than the cut-off for IRT at birth.  
if IRT at birth exceeds a cut-off higher than the one used to start the procedure, the protocol 
proceeds to resampling even though no mutations were detected. Reproduced from 43. 
Table 13. Comparison of different CF screening strategies (adapted from 
Wilcken216) 
Strategy Countries/ 
references 
Likely benefits Likely drawbacks 
IRT/IRT Austria, part of 
Italy, part of USA 
Good specificity and 
sensitivity after second test 
No genetics testing - No 
carriers detected 
Need for repeat blood sample 
Poor specificity first test: thus, more 
families with anxiety 
Need for second IRT cut off 
IRT/DNA Merelle 2006 Single sample 
Good sensitivity 
 
Lower specificity 
Unwanted carrier identification 
Unwanted detection of mild CF 
Increased cost 
IRT/DNA/failsafe 
step 
 
Comeau, 2004 Single sample 
Increased sensitivity 
compared with IRT/DNA or 
IRT/DNA/IRT strategies 
Increased number of sweat tests 
 
IRT/DNA/IRT UK, Irland, 
Scotland, France 
Increased specificity 
compared with IRT/DNA 
Reduced number of sweat 
tests 
 
Repeat blood sample for a small 
number of babies 
False-negative result possible if no 
mutations detected, or if second IRT 
is normal (2 severe mutations, one 
undetected) 
Some carriers are identified, and 
offered genetic counselling. 
Some of these could have another 
mutation 
IRT/PAP Sarles 2005 
Pilot studies 
Holland, 
Germany 
Single sample 
Same or equal sensitivity than 
IRT/DNA 
Cheap 
Easy to implant 
No sample splitting 
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6.2.2.1 IRT/IRT 
The concentration of blood/serum IRT declines with age much faster in false positive 
cases than in infants with CF,242 and therefore raised IRT at about one month of age has 
a high positive predictive value. Most programs select a slightly lower cut-off for this 
second sample. 
The rate of decline of IRT in babies with CF is variable. In the CF group as a whole, IRT 
is still increased at one year of age,243, 244 but such patients typically have non-detectable 
levels of IRT by the age of five years.243-245 However, a significant proportion of CF 
patients show a more rapid decline in IRT: Rock246 found that of 24 neonates who were 
positive on the initial screen, 10 had IRT values below the cut-off in samples taken 
between 41 and 62 days of age. Retrospective genotyping of babies with a raised IRT 
value in the initial sample, but an IRT value below the cut-off in a second sample taken 
at 27 days of age, showed that approximately 1% of these were compound 
heterozygotes for the F508del mutation and another CFTR mutation, the majority being 
R117H.247 
This was the initial protocol adopted by most screening programs in Australia, New 
Zealand, Europe, and the US.248 
A major disadvantage of this protocol is that a second blood sample will be required 
from 1 in 200 to 250 of all babies screened. A considerable number of unaffected babies 
will be subjected to a sweat test, generating a great deal of parental anxiety.248, 249  
Other disadvantages of CF screening protocols with an algorithm requiring a second 
sample are possible delays to obtain this additional sample or cases where no sample is 
obtained.250 
6.2.2.2 IRT/DNA 
Cystic fibrosis is caused by mutations in the CFTR (ABCC7) gene.6, 251 The most 
common mutation is F508del, previously termed ΔF508, which accounts for 
approximately two thirds of all CFTR alleles in patients with CF, with a decreasing 
prevalence from Northwest to Southeast Europe.252, 253 The remaining third of alleles 
are substantially heterogeneous, with fewer than 20 mutations occurring at a worldwide 
frequency of more than 0.1% (http://www3.genet.sickkids.on.ca/cftr/app and 
www.who.int/genomics/publications/en/ ). Some mutations can reach a higher frequency 
in certain populations, due to a founder effect in religious, ethnic or geographical 
isolates.254, 255 The combinations of these mutations mostly explain at least 90% of all 
mutant CFTR genes in Northern- and Western European countries.  
Although the majority of CFTR mutations have been associated with European-derived 
populations,252 there are also CFTR mutations in non-European populations, such as 
African and East Asian populations,256 but no alleles have reached the high frequency of 
F508del. 
At this moment, more than 1600 mutations have been identified in the CFTR gene and 
additional mutations are continuously found and updated in the Cystic Fibrosis Genetic 
Analysis Consortium (CFGAC) database (http://www3.genet.sickkids.on.ca/cftr/app). 
Missense mutations account for 42%, frameshift mutations for 15%, splicing mutations 
for 12%, nonsense mutations for about 10%, inframe insertions/deletions for 2%, large 
insertions/deletions for 3%, promoter mutations for 0.5%, and sequence variations 
which are not predicted to be disease-causing for 15% of all alleles. De novo mutations 
and uniparental disomy of chromosome 7 bearing a mutated CFTR gene are exceptional 
events. 
It is generally advised in Europe to screen for all mutations that are found at an 
incidence of at least 0.5% in the mutant CFTR genes from which the tested individual 
originates.43, 121, 257  
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Most NBS protocols use a panel of the most common CF-causing mutations only on 
samples with a raised IRT.257 Homozygotes and compound heterozygotes can be 
assessed promptly. Management can then often be initiated in the first three weeks of 
life. It is mandatory to confirm the findings of the DNA test with a confirmatory positive 
sweat test.  
Infants carrying only one identified mutation proceed in the protocol, usually through a 
sweat test, in order to distinguish affected individuals from carriers. DNA-testing should 
always be linked to genetic counselling in order to provide sufficient advice to the family 
and eventually offer testing of the index case's relatives if they are within the 
reproductive age. 
A second tier NBS panel should be designed in order to include well known CF-causing 
mutations represented in the local CF population, including those alleles frequently 
occurring in ethnic minorities. However, population genetic calculations based on the 
Hardy–Weinberg law provide evidence that increasing mutation coverage much above 
80% has little effect on the proportion of CF patients in whom no CF-causing mutation 
is found (false negative rates). One should also keep in mind that the number of 
unaffected carriers detected keeps increasing in proportion to the mutation detection 
rate (Figure 5). In areas with ethnic diversity and a tendency to marry within ethnic 
groups, the Hardy–Weinberg equation does however not apply. Here, increasing the 
number of mutations, i.e. including the ethnic specific mutations, has a clear benefit on 
screening performance. Additionally, in such areas there is also an ethical and political 
dimension to ensure that minority groups are not disadvantaged. 
Figure 5. Effect of CFTR mutation coverage on yields of CF patients and CF 
carriers.  
 
The data shown are calculated using the Hardy–Weinberg equation for a population where 0.5% 
of the initial screened samples are sent for a single-stage mutation analysis. It is assumed that 
carriers for all the mutations examined are over-represented to the same extent as carriers of 
F508del. Reproduced from 43. 
It is still a matter of discussion whether the R117H mutation should be included in a 
second tier NBS panel or not. R117H can be in cis, i.e. on the same parental allele, with 
a stretch of either 5 or 7 thymidines located in intron 8, conventionally named T5 or 
T7.258 These polymorphic tracts affect the extent of correct splicing of CFTR exon 9: T5 
stretches give rise to less efficient splicing than T7.259-261 Thus, R117H-T5 will result in 
less functional CFTR than R117H-T7.260 In clinically diagnosed CF patients populations, 
when found in compound heterozygosity with a CF-causing mutation R117H-T5 
generally results in pancreatic sufficient CF, whilst R117H-T7 may result in a mild form 
of CF, obstructive azoospermia, or no disease at all.121 In the French NBS program,145, 
262, 263 up to 7% of the newborns who had an elevated IRT test and two CF alleles were 
compound heterozygous for R117H-T7 and a CF-causing CFTR mutation, a much 
higher proportion than in the CF population diagnosed clinically.152 These children have 
shown no major signs of CF in their pediatric lifespan, although the longterm outlook is 
difficult to predict and there are reports of significant chest involvement with this 
genotype and manifestations of CF disease in adulthood.149  
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But all by all, when a baby is found to be compound heterozygous for R117H-T7 and a 
CF-causing CFTR mutation, without any signs of clinical CF symptoms, it is much more 
likely that the child does not develop pediatric CF disease. In a follow-up study of 184 
F508del/R117H individuals it was concluded that the R117H mutation should be 
withdrawn from mutation panels in CF screening programs.135 
There are indications that in a small fraction of patients, CF or CF-like disease may be 
caused by mutations in (a)nother gene(s) than CFTR.264, 265 There is evidence that 
mutations in the subunit genes coding for the amiloride sensitive epithelial sodium 
channel may explain disease in a minority of these patients by a monogenetic 
mechanism, an oligogenetic system with CFTR (CF carriers), or even a polygenetic 
system.266-268  Additional studies are needed, and currently it is not appropriate to 
screen for mutations in other genes than CFTR.  
Functional studies are needed to determine if a CFTR mutation is a CF-causing mutation 
rather than a variant. For more than 80% of the more than 1600 different CFTR 
mutations, functional studies have not been performed. Although the pathological 
consequences of nonsense mutations and frameshift mutations can be accurately 
predicted (representing about 25% of all CFTR mutations identified), the functional 
consequences of the remainder cannot be accurately predicted. Such mutations might 
be found when the complete CFTR gene is analyzed for the presence of mutations, such 
as by sequencing. Up till now, many clinicians therefore advise to perform mutation-
specific testing only of mutations of which the CF-causing status has been clearly 
established.  
To overcome this problem, the CFTR project (Garry Cutting, personal communication, 
http://www.genet.sickkids.on.ca/cftr2ComingSoon.html )269 has been set up. The goal of 
the  CFTR2 project is to assess the disease liability of CFTR mutations that have been 
reported in CF patients. The CFTR2 database currently has clinical data on 1099 
mutations that occur in about 40 000 CF patients.  A committee of CF clinical experts 
approved the clinical data set obtained for every patient using uniform criteria.  Sweat 
chloride level was selected as the primary metric. The first application of this project 
has been to study mutations that occur in 9 or more patients worldwide. These 160 
mutations account for 96% of the CF alleles in CFTR2.  To complement clinical 
evidence of CF pathogenicity, the CFTR2 team is evaluating the functional consequences 
of the 160 mutations using 4 steps: 1) the nature of the mutation 2) studies of mutation 
effect on RNA splicing 3) studies of mutation effect upon CFTR processing and function 
and 4) absence in “non-CF” CFTR genes (CFTR genes in normal subjects).  The results 
of the aforementioned methods are also being used to construct an algorithm that 
predicts the disease liability of the 160 mutations.  The development of a predictive 
algorithm will provide an objective assessment of disease liability that will be used to 1) 
corroborate clinical and functional data, 2) evaluate the disease potential of the 
remaining rare mutations and 3) enable prediction of disease causing potential of 
mutations discovered after the CFTR2 project has been completed.   
In a second phase, the number of mutations will be extended to 260 mutations, i.e. 
mutations that occur in 5 or more patients worldwide and that account for 98% of the 
CF alleles in CFTR2. 
This CFTR2 database will thus be of utmost importance in future genetic counselling.  
Sequencing technologies are indeed rapidly evolving and it is predicted that by 2015 a 
complete human genome can be sequenced for less than 1000 €.270 It is therefore very 
likely that complete sequencing of a gene may become the standard genetic test format 
in the near future. Moreover, such sequencing tests might be offered by private 
companies (outside Belgium) in which genetic tests simply can ordered through the 
internet, e.g. by families in which the newborn had a positive IRT test, but in whom only 
1, or even no, CF-causing mutation was found. In the end, professionals of a Belgian CF 
NBS screening program then still have to deal with this potential problem of 
problematic counselling. 
 
56  Cystic Fibrosis Neonatal Screening KCE Reports 132  
Given the decrease in sequencing cost, sequencing of the CFTR gene in IRT-positive 
newborns in Belgium from other ethnic minorities, may become a reasonable option in 
the future. Indeed, screening for ethnic mutations of other countries than the country in 
which the individual currently lives and in which the screening is performed is practically 
not feasible. Sequencing may be a valuable practical and economical option in these 
individuals. An alternative would be to use another biological marker like PAP (see 
below). 
It should be noted that there are currently already CF NBS screening programs in place 
in which sequencing of the majority of the CFTR gene, or even the complete CFTR 
gene, is performed. In these populations, the spectrum of CF-causing CFTR mutations is 
very heterogeneous so that mutation-specific tests do not reach a sufficient sensitivity, 
such as in Poland218 and in the state of California in the US because of the many Latin-
American immigrants.271 
Requirements regarding parents' consent to potential genetic analysis at the moment of 
the blood collection vary from country to country but may be very onerous.272 Usually 
an “opt out” scheme is utilized at maternity wards that explains the entire CF NBS 
scheme, including the potential of a secondary “CFTR-gene specific” genetic test. We 
refer to chapter 8 for a detailed discussion. 
Compared to an IRT/IRT algorithm, an IRT/DNA protocol is associated with increased 
sensitivity, specificity, and positive predictive value and has the advantages of an earlier 
diagnosis and of eliminating the need for a second blood sample. A potential 
disadvantage of DNA analysis is unwanted carrier identification which results in the 
increase in the number of unaffected infants referred for a sweat test.249  
6.2.2.3 IRT/DNA/IRT 
To address the drawbacks of the IRT/DNA protocol, the IRT/DNA/IRT protocol which 
includes a second IRT measurement after DNA testing, significantly reduced the 
number of second IRT tests compared to the IRT/IRT protocol and also the number of 
(negative) sweat tests.248 This protocol is used in France and UK (England) with some 
differences as shown respectively in Figure 6 and Figure 7. 
Figure 6. French protocol (from45) 
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Figure 7. UK protocol (from 117) 
 
Cut-off 0 :  approximately 10 ng/ml less than cut-off 1 (typically a value of 60 ng/ml) ; Cut-off 1: 
99.5th centile (70 ng/ml) ; Cut-off 0 : approximates to 0.1 % (120 ng/ml) 
• In both programmes the cut-off for the sweattest is > 60 mmol/l for CF 
diagnosis, < 30 mmol/l for normal and from 30 to 60 mmol/l for 
inconclusive result.  
• In both programmes, replications in duplicate for all samples with an IRT 
above a preliminary threshold, set 10 ng/ml below the final cut-off. 
The main differences between these two protocols are: 
• Number of mutations screened: 30 in France and 4, extended to 29 or 31 
if one mutation found initially, in the UK. However, it should be noted 
that these 4 mutations have a much higher sensitivity in the UK than in 
other European populations, which makes a two-phase mutation 
screening protocol less feasable in most European populations. 
• Different attitudes if one mutation is found: sweat test in France, and 
second IRT in the UK. 
6.2.2.4 IRT/PAP or IRT/PAP/DNA 
The use of the pancreatitis-associated protein (PAP) as a second tier, or even combined 
with IRT in the first tier is being explored. This approach would avoid the issues raised 
by CFTR mutation analysis or the need for a second blood sample. PAP measurement is 
technically feasible on the same sample as other neonatal screenings tests 
(phenylketonuria, hypothyroidism). CF neonatal screening with PAP alone performs 
similarly to screening with IRT alone, with less carrier detection. Combining PAP with 
IRT for CF neonatal screening may be as efficient as an IRT/DNA strategy, but would be 
cheaper and would result in a lower number of CF carriers. If obtaining informed 
consent for DNA testing poses ethical or practical problems, the PAP/IRT strategy 
would be an alternative to the IRT/DNA strategy.  
It should be noted that the use of the IRT/PAP approach will allow one to detect 
patients with ethnic-specific mutations in ethnic minorities. This is an issue for countries 
and/or large cities with multiple ethnicities.  
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A combined IRT+PAP assay kit is being developed and pilot studies are in progress in 
the Netherlands273, Germany274, 275, France, Australia,276 and in Belgium.277 In the 
Netherlands, the results of a pilot trial recently resulted in a recommendation of the 
Health Council of the Netherlands to start CF NBS using IRT+PAP 
(http://www.gezondheidsraad.nl/en/publications/neonatal-screening-cystic-fibrosis), thus 
avoiding many of the ‘equivocal’ CF cases seen when CF DNA tests are used as second 
line screening test. 
6.3 DIAGNOSIS THROUGH CF NEONATAL SCREENING 
Screening tests identify apparently healthy individuals who have a high probability of 
having a specific disorder, which justifies a subsequent diagnostic procedure.278 
Following a positive NBS for CF, a major component of the subsequent assessment is a 
sweat test, which can usually distinguish between true and false positives. Despite 
recognition of the CFTR gene defect, the sweat test is still considered by consensus 
groups as the ‘gold standard’ for a diagnosis of CF. Infants with a positive NBS test and a 
raised sweat chloride (above 60 mmol/L) are considered to have a diagnosis of CF, even 
in the absence of any clinical features.5, 119 
After a positive screening test result is reported, the time to diagnostic assessment 
should be as short as possible. This requires efficient cooperation between screening 
laboratories, maternity units, community health care providers and CF centers. It is 
essential that these pathways are established before implementation of a CF NBS 
program. In particular, attention should be given to ensure that the assessment and 
sweat testing are carried out promptly to minimize parental stress, which is known to 
be extreme in the period following an abnormal screening test result.279 
6.3.1 Sweat test 
The sweat test is a key component of any NBS protocol for CF, providing a 
physiological confirmation of the screening result, or reassurance that a carrier is not a 
compound heterozygote with an as yet unidentified CFTR mutation. However, sweat 
testing in this age group is challenging and has to be performed according to specific 
guidelines.5, 280  
The following must be taken into account when undertaking a sweat test in infants 
following a positive screening result: 
• Sweat chloride concentration is the “gold standard” analytical measure to 
confirm a diagnosis of CF in NBS positive infants. With rare exceptions, a 
diagnosis of CF can be made when chloride levels exceed 60 mmol/L, and 
excluded when they are below 30 mmol/L.5, 119 Results which are not 
physiologically compatible should be questioned (i.e. chloride or sodium 
> 150 mmol/L). 
• Sweat collection and analysis should be performed in a laboratory with 
adequate experience. International standards suggest that a laboratory 
should be undertaking at least 50 tests per year.156, 280 
• When using a 2 × 2-inch gauze or filter paper, the minimum sweat weight 
should be 75 mg. When using the coiled capillary system (MacroductTM), 
the electrodes and stimulation area are smaller and the minimum 
acceptable sample is 15 μL (calculated to ensure a rate of sweat secretion 
greater than 1 g m− 2 min− 1). A macoduct system is the preferred method 
for a NBS programme: less sweat is needed for a correct analysis and the 
succes rate will be higher. However, the cost of this system will increase 
the cost of the sweattest. 
• Sweat testing can be performed by the age of two weeks in newborns 
weighing 3 kg or more.280 Neonates must be normally hydrated and with 
no significant signs of systemic illness. When clinically indicated, it can be 
performed in term infants after 7 days of age, but with a higher probability 
of insufficient sweat collection. 
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• Collecting sweat from two sites is preferable as this reduces the number 
of insufficient samples and provides internal validity. Sweat should be 
collected for not more than 30 min and not less than 20 min. Insufficient 
sweat collections should not be pooled; the test should be repeated. 
• Sweat sodium is also elevated in CF but is less discriminatory when 
compared to chloride, and therefore should not to be used for the 
diagnosis of CF.156 
• Sweat conductivity should not be used to confirm a diagnosis of CF. 
• Some CFTR mutations that are clearly CF causing (in particular, 
3849 + 10 kb C > T) can be associated with normal or equivocal sweat 
electrolyte values. 
• Following sweat collection, chloride analysis should be undertaken 
promptly (preferably immediately) in order to reduce the waiting period 
for the family. 
• NBS programmes use a sweat test cut-off value of > or = 60 mmol/L for a 
CF diagnosis.5 Lower values for sweat tests have however been reported 
in CF newborns. Therefore infants with an intermediate sweat test (30-59 
mmol/L) and 1 mutation detected should proceed to sequencing. Some 
reports advise an even lower cut-off for intermediate values of 24 
mmol/L.281  
The sweat test thus remains a key component in establishing a diagnosis of CF in infants 
with a positive NBS result. Sweat collection in infants is challenging, and must be 
performed according to specific guidelines. 
6.3.2 Inconclusive diagnosis 
The majority of affected infants recognised through NBS have a clear diagnosis of CF 
(i.e. two CF-causing mutations in trans or one recognised CF-causing mutation and a 
sweat chloride level above 60 mmol/L).5 However, in a small but significant number of 
cases the diagnosis is equivocal, specifically when CFTR mutations with unclear 
phenotypic consequence are detected or when one mutation is found and sweat 
chloride levels are in the intermediate range (i.e. between 30 and 60 mmol/L). 
The ECFS CF NBS Working Group has produced a consensus with regard to the 
evaluation and management of infants with an equivocal diagnosis following CF NBS.147 
Initial statements were agreed based upon a systematic review of the literature, and 
formed the basis of a modified Delphi methodology282 to achieve a Europe-wide 
consensus. Contributing clinicians, biochemists and geneticists were asked to express 
their opinions on the statement. Their options were either to agree, disagree or state 
that they felt unable to comment. If they disagreed they were asked for comments or 
alternative suggestions. Consensus was established if more than 80% of respondents 
agreed with a particular statement. 
Figure 8 illustrates the pathway developed through the consensus process. Highlighted 
(shaded) boxes are discussed below. 
Repeat sweat test 
Sweat collection and analysis should be repeated in an experienced laboratory. 
Extended DNA analysis 
Further DNA analysis of the CFTR gene should be guided by the type of screening 
protocol (i.e. protocols that initially only examine a limited panel of CFTR mutations 
would continue promptly further DNA analysis with an extended panel of population 
specific mutations). The extent of DNA analysis should reflect the level of clinical 
suspicion. Care should be taken to avoid a situation where mutations are recognized 
with an unclear pathogenic potential (e.g. missense mutations identified by sequencing of 
the CFTR gene). Infants recognized to be compound heterozygotes for R117H should 
have further characterization of the poly T variant region for the presence or absence 
of the 5T background.144, 261 
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Baseline clinical assessment 
Although infants with CF may have little or no symptoms in the first months of life, it is 
essential to carefully search for clinical features associated with the diagnosis of CF. 
Clinical evaluation should be done in a CF clinic, and include assessment of non-
respiratory (e.g. fecal elastase examination) and respiratory disease (airways culture and 
chest radiograph) signs of the disease. Further investigations may be indicated as 
determined by the clinical symptoms. 
Figure 8. Diagnostic algorithm for inconclusive diagnoses following CF NBS. 
Reproduced from Mayell.147 
 
Evidence of ion transport defect 
A number of electrophysiological techniques are available to demonstrate the salt 
transport defect that characterizes CF. Some of these tests are technically challenging in 
neonates/infants, and they are currently undertaken only in few specialist centers 
worldwide. Thus far, none have the validity of sweat testing or CFTR genotype analysis, 
but may provide useful additional information in equivocal cases (Table 13). Intestinal 
current measurements do not detect mild or atypical CF disease. 
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Table 14. Electrophysiological diagnostic techniques. 
Test Technical details 
What it involves for the 
infant 
Availability 
Nasal Potential 
Difference (PD) 
Ion transport across airway 
epithelium can be assessed by 
measuring the baseline PD. The 
impact on the PD of perfusing 
different solutions and drugs 
provides further information to 
differentiate CF from non-CF 
recordings. 
The exploring electrode is 
placed in the nose. A 
reference electrode is placed 
either subcutaneously or 
over abraded skin on the 
forearm. Solutions are 
perfused into the nose and 
can be swallowed. 
Very few centres are able 
to undertake this 
measurement in infants 
although it is more widely 
available in older children 
and adults. 
Intestinal 
Current 
Measurements 
(ICM) 
A biopsy is mounted in the 
laboratory in a device (Ussing 
chamber) that enables 
measurement of transepithelial 
ion transport. Various aspects of 
ion transport can be examined. 
Biopsy of rectal mucosa. This 
procedure is painless and 
well tolerated by young 
infants. Does not require 
general anaesthesia or 
sedation. 
This technique requires a 
dedicated laboratory 
service with highly skilled 
technicians. Available in 
limited number of centres 
in Europe. 
Small bowel 
biopsy 
Similar measures of 
transepithelial transport 
processes can be undertaken in 
the laboratory on upper gastro-
intestinal (GI) mucosal biopsies. 
Upper GI biopsy; requires 
general anaesthesia in most 
cases. 
Limited (only currently 
available in Sheffield, UK; 
contact Prof Chris 
Taylor). 
Reproduced from 147. 
6.4 INTERNATIONAL RECOMMENDATIONS  
6.4.1 Australasian paediatric respiratory group (2005)  
The Australasian paediatric respiratory group established a consensus statement.148 The 
diagnosis of CF can be made in an infant who has been identified by newborn screening 
with an IRT >99th percentile and has: 
Two confirmed CFTR mutations that are known to be associated with CF, or one 
mutation and a sweat Cl- of 60 mmol/l, or one mutation, a sweat Cl- 30–59 mmol/l, and 
recognized clinical features. 
6.4.2 Cystic Fibrosis Foundation Consensus Report (2008) 
This document5 is a practical guide intended to facilitate the implementation of CF NBS, 
with a specific chapter about the algorithms. The choice between IRT/IRT and IRT/DNA 
should be done in function of the goals of the program, the means, the demography, and 
the clinical care programs.  
6.4.3 European best practice guidelines (2009) 
This working document43 is a true state-of-the-art democratic consensus among experts 
in Europe with respect to guidelines for cystic fibrosis neonatal screening. For the 
experts, there is little evidence to support the use of IRT alone as a second tier, 
without involving DNA mutation analysis. However, if IRT/DNA testing does not lead 
to the desired specificity/sensitivity ratio in a population, a screening programme based 
on IRT/IRT may be used.  
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6.4.4 Newborn screening of cystic fibrosis in France (2009) 
Several recommendations are included in the Haute Autorité de Santé (HAS) report on 
CF NBS,45 obtained after five years of screening with a IRT/DNA/IRT algorithm. They 
include: evaluation of the interest for the patient because the potential  identification of 
CF heterozygotes; reevaluation of the panel of the screened mutations; evaluation of a 
strategy involving a PAP step. 
6.4.5 Laboratory Guide to Newborn Screening in the UK for Cystic Fibrosis 
(2009) 
This document117 is a detailed guide for the laboratories which provide a newborn 
blood spot screening service for CF in UK. The pre-analytical, analytical and post-
analytical steps are described. The chosen protocol is a IRT/DNA/IRT algorithm. 
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7 BELGIAN SITUATION 
All screening programs are intended to maximise diagnosis of CF, to minimize second 
heel pricks, unnecessary sweat tests, diagnostic delay, detection of unaffected CF 
heterozygotes and diagnosis of very mild form of CFTR defect, and finally to allow for 
the fact that a clear diagnosis is not always possible. The choice of strategy will depend 
upon population genetics, costs, and the weight placed on the different aims: maximal 
sensitivity, minimal or no resampling needed, rate of unwanted CF carrier detection, 
and reduced numbers of sweat tests.  
7.1 CURRENT SCREENING INFRASTRUCTURES 
There are approximately 120 000 births per year in Belgium. The screening programs 
are under the authority of the regional communities. There are 3 newborn screening 
centres authorized by the French community; and 3 by the Flemish community. Dried 
capillary or venous blood samples (on Whatman 903 filter paper) are obtained from 
newborns at the age of 3 to 5 days. These are sent to one of the screening laboratories 
where the various screening analyses are performed. CF screening should be fully 
integrated within the existing blood spot screening programs and based on the same 
screening laboratory populations. Local studies for CF NBS are ongoing.277  
7.2 CHOICE OF A STRATEGY 
The proposed CF NBS algorithm (Figure 9) and the expected patient numbers as shown 
below is mainly based on the French algorithm, taking into account the neonatal 
screening situation in Belgium and the fact that appropriate CF DNA kits are available. 
The aim is to limit as much as possible the number of ‘equivocal’ cases detected. Recent 
data from the Netherlands suggest that IRT-PAP based screening may be an alternative, 
even further reducing the number of CF DNA analyses and the number of ‘equivocal’ 
cases, as presented in Figure 11. 
Given the fact that the number of IRT-positive (high) newborns who are found to carry 
no CF-causing CFTR mutation is still considerable, the easier and cheaper rIRT-test is 
preferred over the sweat test.   
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Figure 9. Proposed Belgian CF NBS algoritm 
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7.2.1 IRT measurement 
The same sample used for the current neonatal blood sampling taken at 3-5 days of life 
will be used for the first tier IRT. 
We propose a cut-off of 99.5th percentile that gives a good sensitivity, and the use of a 
policy of replication in duplicate for all samples with IRT values above a preliminary 
threshold, set 10 ng/ml below the final cut-off as recommended.43 However, the amount 
of IRT measured will vary from lab to lab, and therefore the cutoff should be set 
accordingly to reach the 99.5th percentile cutoff of the respective labs. It means that 
approximately 600 newborns will be positive for IRT and will need CFTR mutation 
testing each year. 
The screening laboratories have to participate to an external quality assessment 
scheme. 
When using the IRT-IRT protocol, a second blood sample is asked to all newborns with 
a elevated IRT (≥ 70 ng/ml). This is done by sending a letter to the pediatrician of the 
maternity where the child was born. It is their responsibility to contact the parents and 
to make sure a second sample is being taken. If the parents do not respond, a second 
reminder is send, before the file will be closed.  
When looking at the data from the Brussels region in 2009,277 a second sample was 
obtained in 85% of the cases which means that 15% of the newborns with an elevated 
IRT are not followed up and might be at risk to develop symptoms of CF. Moreover, 
when looking at the age of sampling of the control sample, the mean age is 36 days, 
ranging from 11 days to 167 days, with 27 days as median. These data confirm that CF 
screening protocols where the algorithm requires a second sample have limitations as 
obtaining the sample may lead to a considerable delay or no sample may be obtained. 
7.2.2 Belgian genetics 
With respect to the second tier CFTR mutation test, it is generally advised to screen for 
all mutations that are found at an incidence of at least 0.5% in the mutant CFTR genes 
from which the tested individual originates.43, 121, 257 However, the ethnic origin of a 
newborn is not always known. It is therefore advised to test a European panel of 
mutations, i.e. the most common mutations found in Europe.  
Table 15. CFTR mutation spectrum in Belgium. 
Mutation N Fraction 
Cumulative 
Fraction 
F508del 1367 0,695 0,695 
G542X 53 0,027 0,722 
N1303K 50 0,025 0,748 
1717-1G>A 28 0,014 0,762 
3272-26A>G 22 0,011 0,773 
R117H 22 0,011 0,784 
S1251N 22 0,011 0,796 
2789+5G>A 17 0,009 0,804 
R553X 14 0,007 0,811 
W1282X 14 0,007 0,818 
A455E 13 0,007 0,825 
R1162X 11 0,006 0,831 
I507del 11 0,006 0,836 
2183AA>G 10 0,005 0,841 
L927P 10 0,005 0,846 
3849+10kbC>T 7 0,004 0,850 
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394delTT 7 0,004 0,854 
E60X 7 0,004 0,857 
W401X 6 0,003 0,860 
poly-T-tract 6 0,003 0,863 
3659delC 5 0,003 0,866 
D1152H 5 0,003 0,868 
G920R 5 0,003 0,871 
R334W 5 0,003 0,873 
3120+1G>A 4 0,002 0,875 
G85E 4 0,002 0,877 
Y913C 4 0,002 0,879 
1078delT 3 0,002 0,881 
4218insT 3 0,002 0,883 
711+1G>T 3 0,002 0,884 
I336K 2 0,001 0,885 
1497delGG 2 0,001 0,886 
2184delA 2 0,001 0,887 
3272-1G>A 2 0,001 0,888 
2750delAG 2 0,001 0,889 
E656X 2 0,001 0,890 
G458V 2 0,001 0,891 
G551D 2 0,001 0,892 
L165S 2 0,001 0,893 
L227R 2 0,001 0,894 
Q1313X 2 0,001 0,895 
R1070W 2 0,001 0,896 
R347P 2 0,001 0,897 
S1255P 2 0,001 0,898 
Y1092X 2 0,001 0,899 
other mutations 33 0,017 0,916 
total characterized CFTR genes 1801 0,916   
characterized CFTR genes, but mutation not known 
to BMR 2 0,001   
CFTR genes without identified mutation 165 0,084   
missing CFTR genes 104 0,053   
total CFTR genes 2072     
Total CFTR genes - CFTR genes without identified 
mutation or missing CFTR genes 1966 1,000   
Taken from the annual report 2006 of the ‘Belgisch Mucoviscidose Register – Registre Belge de la 
Mucoviscidose (BMR-RBM)’ database, which is managed by the ‘Wetenschappelijk Instituut 
Volksgezondheid – Institut Scientifique de Santé Publique’.169  
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Table 15 shows the mutations found in CFTR genes of Belgian CF patients, as taken 
from the annual Belgisch Mucoviscidose Register – Registre Belge de la Mucoviscidose 
(BMR-RBM) 2006 report. It should be noted that even within a small country such as 
Belgium, and even within regions in the Flemish speaking region, and possibly also 
French speaking region, certain  mutations will be more frequent compared to the 
other regions. A total of 2072 CFTR genes of Belgian CF patients are included in this 
database. However, a CF-causing mutation has not been identified yet in 165 CFTR 
genes. Indeed, CFTR mutation testing is performed in different genetic centers in 
Belgium, and some of these laboratories only screen for the presence of a set of the 
more common known CF-causing mutations (which may even vary from lab to lab), 
while other laboratories continue complete scanning or sequencing of the CFTR gene 
for the presence of a mutation. A total of 104 CFTR genes were never referred for 
genetic testing and or missing. Without doubt, the latter two groups of mutant CFTR 
genes still carry a mutation that is found at a frequency of more than 0.5% in Belgian CF 
patients. In a total of 91.6 % (1801/1966) of the CFTR genes derived from Belgian CF 
patients, a CF-causing mutation has thus been identified according to this report. If one 
would screen for all mutations having a frequency of more than 0.5% in the Belgian CF 
population according to this report, one would need to screen for only 15 mutations 
and one would obtain a sensitivity of only 84.6%. The incomplete database thus 
underestimates the number of mutations that need to be tested and the sensitivity that 
would be obtained. Indeed, in Belgian studies in which the complete CFTR gene was 
studied in CF patients, a higher number of mutations were found to have an incidence 
of more than 0.5% and a higher cumulative sensitivity of 90-92% was obtained.283-285 All 
the CFTR mutations that are of relevance in Belgian CF patients can be detected when 
commercial available mutation-specific CFTR tests are used (Appendix 7). 
Innogenetics provides two RDB INNO-LiPA assays. For CFTR mutation testing they are 
usually used in a serial format. When a negative result is obtained with the first RDB 
INNO-LiPA CFTR17+Tn assay which tests for the most common mutations, the second 
RDB INNO-LiPA CFTR19 assay is performed. However, it should be noted that the 
second assay also contains mutations that are found at an incidence of more than 0.5% 
in the Belgian mutant CFTR genes, so that both tests should be used on IRT-positive 
samples rather than serial analysis. Indeed, many false-positive IRT samples are 
frequently CF carriers and found to carry a mutation in the first assay, so that the 
second assay will need to be performed anyway.  
Luminex provides two assays. The first xTAG® Cystic Fibrosis 71 kit v2 screens for 39 
mutations, while the second xTAG® Cystic Fibrosis 71 kit v2 screens for 71 mutations. 
All mutations included in the first assay are also included in the second assay. They are 
thus not used in a serial format, but one of these assays is selected for a given needed 
sensitivity or spectrum of mutations. The majority of the additional mutations in the 
second assay are very rare or not found in the Belgian population, but again a few of 
these mutations have an incidence of more than 0.5% in Belgian mutant CFTR genes. 
Abbott Molecular provides one assay which screens for 32 mutations. 
Elucigene provides 4 different assays. The selection of the assay is again based on the 
needed sensitivity, spectrum of mutations, but also on the activity (i.e. neonatal 
screening program). 
Elucigene  CF29 has been developed to provide laboratories with a simple and accurate 
means of routinely testing 29 of the most prevalent mutations in individuals of European 
Caucasian descent. 
Elucigene™ CF-EU1 has been specifically developed and approved for in vitro diagnostic 
testing within Europe.  Elucigene CF-EU1 identifies 32 of the most frequently observed 
CFTR gene mutations within populations of European origin. 
Elucigene  CF30 has been developed and approved for routine use in the French 
national neonatal cystic fibrosis screening program. The panel of mutations detected by 
Elucigene  CF30 are identified as the thirty most frequent within the French population.  
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Elucigene  CF30 is also relevant for screening other European populations, particularly 
those of Spanish and Scandinavian descent, and might be of interest in the French-
speaking region of Belgium. 
Elucigene  CF7 is particularly useful for cystic fibrosis screening in the Ashkenazi Jewish 
community.  
The obtained sentivitiy will depend on the commercial test which is used. For all, except 
the Tepnel diagnostics CF7 molecular kit, a sensitivity of 91 to 94% is obtained, which 
should be sufficient for CF NBS in Belgium (Table 15). It should be however noted, that 
even these CE-marked commercial CFTR tests, may have their pitfalls.286 In contrast to 
other in vitro diagnostics (eg  tests for screening of blood for viral agents), the CE label 
regulations do not specify minimal performance characteristics for genetic tests. It is 
therefore advised that these tests are only performed by laboratories which are well 
aware and have experience with these pitfalls. In practice, this experience is mostly only 
obtained if the laboratories perform a considerable number of these tests annually. 
Moreover, the genetic testing laboratories should participate in external annual quality 
protocols121, 257. 
About 3% of all mutant CFTR genes carry a large deletion or insertion, of which the 
majority or not included in these tests. The CF-causing nature of such large 
deletions/insertions can, however, be accurately predicted. Specific single tests, such as 
the MLPA® (Multiplex Ligation-dependent Probe Amplification) assay (MRC-Holland) 
tests for all possible large deletions or insertions. Although each of these 
deletions/insertions are rare and found at an incidence below 0.5% and would therefore 
be not tested, their combined incidence exceeds 0.5% which makes it still worthwhile 
to include a single MLPA assay in the screening program, since it improves the obtained 
sensitivity.  
Since these DNA tests thus have no 100% sensitivity, not in all IRT-positive individuals 
who will turn out to be true CF patients, a CF-causing mutation will be identified on 
both CFTR genes. Table 15 shows the fraction of CF patients in whom 2 CF-disease-
causing mutations, 1 CF-disease-causing mutation, or no CF-disease-causing mutations 
can be identified in function of the sensitivity of the CFTR mutation test. Of course, if 2 
CF-causing disease mutations are found, a CF diagnosis can be made. If no CF-disease-
causing mutation at all is found, a CF diagnosis becomes very unlikely. However, if only 
one CF-disease-causing mutation is found it will be not clear if the newborn carries 
another CF-causing mutation that is not included in the CFTR mutation test, or is truly a 
CF carrier. A further third tier test is advised in order to try to discriminate newborns 
who have CF from true CF carriers. A functional test, such as a new IRT test on a new 
sample or a sweat test in the baby, can be used as a third tier test. It should be noted 
that in the false-IRT-positive newborns, a higher proportion of CF carriers will be found 
to carry one CF-causing mutation than in the general population (CF carrier of 1/30). 
These individuals simple have hypertrypsinaemia but will not develop (severe) CF.287 It 
has also been observed that neonates who are heterozygous for a CF-disease-causing 
CFTR mutation with transient hypertrypsinaemia may even carry a second mild CFTR 
mutation, which mostly does not result in (severe) CF.247 
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Table 16. CFTR genotypes, with respect of finding a CF-causing CFTR 
mutation, or not, in CF patients depending on the sensitivity of the CFTR 
mutation test. 
Sensitivity MUT / MUT MUT / No MUT No MUT / No MUT 
90 % 81.0 % 18.0 % 1.0 % 
91 % 82.8 % 16.4 % 0.8 % 
92 % 84.6 % 14.7 % 0.6 % 
93 % 86.5 % 13.0 % 0.5 % 
94 % 88.4 % 11.3 % 0.4 % 
95 % 90.3 % 9.5 % 0.3 % 
96 % 92.2 % 7.7 % 0.2 % 
97 % 94.1 % 5.8 % 0.1 % 
98 % 96.0 % 3.9 % 0.04 % 
99 % 98.0 % 2.0 % 0.01 % 
100 % 100 % 0 % 0 % 
MUT = CF disease-causing CFTR mutation 
Given the technological progress in sequencing, and thereby reduction in sequencing 
cost, complete sequencing of the CFTR gene in IRT-positive newborns may be an 
option in the near future. Even then, it will be of utmost importance that only mutations 
of functional relevance are screened/reported. The clinical and functional consequences 
of 98% of the CF-causing CFTR mutations that are found worldwide in CF patients will 
be available from the CFTR2 database, and therefore the finding of such a mutation will 
allow a correct diagnosis. About a quarter of the remainder 2% mutations are nonsense 
and frame-shift mutations of which the deleterious consequences can be accurately 
predicted. Only for the remainder 1.5% mutations (missense mutations, small inframe 
deletions/insertions), the CF-causing defect may not be clear. However, less than 10 
mutations are expected in IRT-positive newborns in Belgium annually. More extensive in 
vitro functional characterization of these mutations may then be an option in order to 
establish the diagnosis. Here, it should then be investigated if CFTR carrying such a 
mutation does mature or not, and whether it can function as a chloride channel.288-290 
Given the needed expertise, which is even more relevant given the more limited 
number of samples involved, centralization of complete sequencing of the CFTR gene 
and in vitro functional characterization of CFTR carrying such mutations/variations in a 
single center or a few centers should be considered. 
In this way, complete sequencing of the CFTR gene thus indeed becomes a valuable 
option in newborn screening programs. Moreover, it may establish a diagnosis, or 
absence thereof, in newborns having borderline sweat values. Attention should be given 
to the turn around time for DNA analysis as this should fit into the overall screening 
timeline.  
7.2.3 Consideration of PAP measurement 
As discussed above, the concentration of pancreatitis associated protein (PAP), a stress 
protein synthesized by the diseased pancreas, is elevated in the blood of newborns with 
CF. PAP elevation is not strictly specific for CF and PAP alone as a biological marker 
would not perform better than IRT alone. However, newborns with CF have a raised 
level of both IRT and PAP while non-CF newborns may have an increased value for one 
but rarely for both markers. This combination of markers (IRT and PAP) may overcome 
the need for genetic testing in the content of a NBS programme.  To date, the number 
of published studies using PAP is however limited.   A Belgian study is ongoing277 with 
preliminary but yet unpublished data. Additional results from France will become 
available soon (Munck, Personal communication) and may impact the final choice of the 
algorithm. The algorithm suggested by A. Meulemans and coworkers (ULB and CHU-
Liège) is shown in Figure 10.  
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Figure 10. IRT-PAP-DNA algorithm 
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Results of a pilot trial recently resulted in a recommendation of the Health Council of 
the Netherlands to start CF NBS using the combination of IRT and PAP as illustrated in 
Figure 11. (http://www.gezondheidsraad.nl/en/publications/neonatal-screening-cystic-
fibrosis), 
 
Figure 11. IRT-PAP based algorithms as recommended recently by the 
Health Council in the Netherlands. 
 
MUT1: test for limited number of mutations using CF kits; MUTII: sequencing; Hielprik: blood 
sampling from heel prick  
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KEY POINTS 
• The decision about which method to use for CF NBS involves a compromise 
between sensitivity and specificity, and between cost and uptake. We need 
to make sure that the methodology achieves an equitable distribution of 
both the benefits (early diagnosis) and harms (false-positive and false 
negative results), particularly within racial and ethnic minorities.  
• Based on current study data, a NBS protocol based on IRT/DNA seems to 
be most appropriate for the Belgian situations. From a methodological point 
of view, the main issue remains the number and type of mutations to be 
reported. Different commercial CFTR genetic tests are available that screen 
for the most common mutations found in up to 92% of the CF patients. 
Given the establishment of the CFTR2 database and advances in sequencing, 
complete sequencing of the CFTR in IRT-positive newborns becomes a 
valuable option in the near future. In that case, in vitro characterisation of a 
small number of mutant/variant CFTR proteins will be also needed.  
• DNA testing involves certain ethical and legal issues. The drawback of this 
genetic analysis may be solved by combining IRT with a second biological 
marker like PAP. At present published data on the performance of NBS 
algorithms based on IRT/PAP are limited when taking numbers of screened 
infants into concern. Until clinical utility and validity of the IRT-PAP-DNA 
protocol have been established, the IRT-DNA-IRT may be the preferred 
solution. Recent pilot study results from the Netherlands support the IRT-
PAP-DNA approach. 
• It is important, that once a screening programme is started, close 
monitoring and regular review of data is needed. Based on data of 
performance of the initial algorithm, the screening procedure can be 
adapted where needed and according to new available techniques and/or 
knowledge. 
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8 STUDY OF ETHICAL AND LEGAL ASPECTS 
8.1 INTRODUCTION 
For this project  the explicit question is to formulate advice on a newborn screening 
program for CF. We do therefore not include in our text considerations regarding the 
challenges that occur in the case of screening programs for several diseases and the 
implications for informing (information overload) the participants in case of multiplex 
testing. 
For CF-NBS different screening algorithms can be used. Most algorithms currently in 
use consist of a multistep approach including DNA analysis to improve the sensitivity 
and specificity. Including genetic testing in a new born screening raises several ethical 
and legal issues. Therefore some programmes study the used of PAP (pancreatic 
associated protein) as second step to avoid these additional complexities. 
The last section of this chapter provides a tabular overview of the legislation applicable 
to CF NBS (legislation applicable to CF NBS 
Table 17). 
8.2 FREE CONSENT AND INFORMATION BEFORE AND 
AFTER SCREENING  
8.2.1 Free consent 
First of all it should be noted that when a newborn screening test is offered there will 
be always a form of pressure because there is an invitation of health authorities towards 
families who were not asking a test.291 
According to the report of the American Task Force on Newborn Screening,292 there 
are only three States in the USA that require consent for newborn screening (not 
involving genetic testing). In many other states however there is a right of ‘parental 
refusal’, mostly on religious grounds. Also the recent report of the President’s 
Commission293 recommends that mandatory newborn screening be recommended for 
those disorders that clearly meet the classical screening criteria. The Dutch Health 
Council recommends that parents should consent to the performance of screening in 
their child.294  The Health Council understands the notion of parental consent in the 
context of newborn screening as primarily founded in the principle of best interest for 
the child. 
In Belgium, there is no specific legislation concerning newborn screening. The general 
rules governing the practice of any medical activity and the rights of patients have to be 
respected.  The Belgian law on patients’ rights should in this respect be interpreted as: 
consent of one of the parents has to be given. In principle, express verbal consent 
should suffice. A written informed consent is only required if a specific legal rule exists 
in this respect. This is for instance the case for termination of pregnancy and organ 
removal. As such a specific legal rule does not exist for screening that involves DNA 
testing, written consent is not required. Opting out is only justified when a legal basis 
allows for this. This is for instance the case for removal of organs from deceased 
persons. There is no legal basis for an opting out system in case of screening. According 
to the law on the rights of patients an express, beit oral consent, is required.  In 
Flanders there is since December 12 2008 the ‘Besluit van de Vlaamse Regering 
betreffende bevolkingsonderzoek in het kader van ziektepreventie’.  But as the concrete 
interpretation and implementation of this Besluit is being studied by a Working Group 
(Vlaamse Werkgroep Bevolkingsonderzoek) it is too early to present here its modalities, 
forms, and scope.For the American ethicists Faden et al. the parental consent is not 
necessary in the case of early screening for treatable diseases: “if the principle 
consideration is the welfare of children, their welfare is best served in this case by a 
program of compulsory and exception less screening”.295  
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The Institute of Medicine296 on the other hand states that there are no indications that 
asking consent would lead to lower uptake rates and so would damage the interest of 
the children.  
The Health Council points out that the free participation and informed consent are 
important, because it commits the parents in the success of the newborn screening.  
De Wert does not exclude the possibility of impulsion: in the context of newborn 
screening for treatable diseases, the caregivers have in his opinion the moral duty to 
persuade parents to give their parental consent for the screening if applicable.297 The 
Health Council agrees with this view, but concludes as follows:” After an intensive 
dialogue of this type, however, the Committee feels that the decision ultimately reached 
by the parents will have to be respected, even if this entails a refusal to participate.” 
8.2.2 Information before the screening 
Information will have to be provided to the parents, even in the case of mandatory 
screening. The Health Council recommends that the information to be provided will 
need to include answers to the following questions: 
• What is the infant being screened for? 
• What does the screening entail? 
• What are the anticipated benefits and disadvantages? 
• How important is it that parents should have their child screened? 
• Is it possible that results have implications for us and for family members 
or previous children? 
• Are the data produced by heel prick testing confidential? 
• What happens to the blood spot cards once the testing has been 
completed? 
• What happens in the event of non-participation in the screening? 
• Who can we turn to with any additional questions? 
More specifically, this information could encompass the following issues: information 
about the nature, prevalence and severity of the disorders for which screening is to be 
carried out; the importance of early diagnosis; the possibilities for treatment and/or 
other benefits for the person concerned; the fact that some test results require 
confirmation or give rise to false alarm the fact that cases can be missed and that not all 
diseases are detectable; and further information about use of residual material from the 
heel prick for medical research and about protection of privacy. It is also relevant for 
the parents to know whether a test method may provide information about the 
implications of being a carrier. Last, but by no means least, it is important that parents 
should understand, based on the information provided, that they do, in fact, have a 
choice. 
Regarding the timing of providing the information the Health Council states that the 
first few days after the birth are unlikely to be a suitable time for the parents to digest 
information about neonatal screening. Interviews with 115 parents in 13 focus groups in 
Chicago revealed that only a tiny minority could remember postnatal information that 
was provided about neonatal screening and that in around one-third of the focus groups 
not a single parent could remember anything about neonatal screening.298 It makes more 
sense to discuss neonatal screening during antenatal check-ups. There is then still time 
to answer questions and, if necessary, to supply more information. In their systematic 
review, Hayeems et al.111 note that parents recommend about newborn screening 
during the prenatal period as well as during their hospital stay. Also others recommend 
that all state newborn screening programs should work proactively to ensure that all 
women receiving prenatal care are educated about newborn screening.299 As part of this 
educational process the distributed educational information should also be culturally 
appropriate.300 It implies that the educational material should be made available in the 
languages of the respective language groups/minorities.294 
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8.2.3 Information after the first screening test 
Health professionals are involved in providing parents with information at two main 
stages after the screening/diagnostic process. First, the information they give to parents 
following an abnormal screening test result, and second, the information they provide to 
carrier and affected families following sweat testing and DNA results. Tluczek et al.279 
described parents’ preferences for counselling content at the time of the infant’s sweat 
test appointment. Preferred content includes: factual information (i.e. probability of CF 
diagnosis, CF disease facts, CF genetics, sweat test procedure itself) and social support 
(i.e. providing choice about timing and amount of CF information, empathy, hope, 
person-centred counselling, and hospitality). Counselling strategies that matched 
parents’ preferences reduced distress whereas strategies that did not match parents’ 
preferences increased parental worry about their infant. 
Effective communication of abnormal results is important because psychosocial 
complications may be related to misunderstanding the information (see also further, the 
paragraph on carrier information). Tluczek et al.301 found that parents of newborn CF 
carriers were distressed when they were informed: (1) by telephone, (2) by an 
answering machine message, (3) before their infant was old enough to complete a sweat 
test, or (4) in a setting where there was insufficient time to discuss the information. 
Parents preferred learning results face-to-face from an experienced professional and 
understood the information better this way. 
The  review of Hayeems et al.111 found evidence suggesting that in the context of cystic 
fibrosis, uptake of genetic counselling services is higher if offered on the same day as 
confirmatory sweat testing. In practice, this may be a good timing for counselling in case 
on negative sweat test. However, if parents just received the news their child has CF 
genetic counselling is probably best postponed to a later time point. Challenges to 
follow-up relate to the fact that primary care physicians lack perceived competence to: 
discuss the meaning of positive screening results, determine which confirmatory test to 
order, access a convenient laboratory, interpret the meaning of the confirmatory test 
result, and make the necessary sub-specialty referrals. Their evidence suggests that face-
to-face counselling and the provision of simple, positive, and non-threatening language 
are associated with less distress among parents whose infants were identified as CF 
carriers. Also Parsons and Bradley107 conclude that in both the USA and UK, 
recommendations have been made all carrier families should receive genetic counselling 
to ensure that they understand the meaning of their carrier status. 
8.3 PRIVACY, STORING AND RESEARCH ON DNA  
8.3.1 Privacy 
Regarding the question “who should be informed about the test result”, the Belgian law 
is clear. Article 7 of the law on the rights of patients provides that a physician has to 
provide to his/ her patient all information regarding his/her health status and its 
prognosis. When the patient is minor, this information has to be provided to the 
parents of the minor.  For the ethical aspects of confidentiality regarding blood-spot 
cards in the Belgian context we refer to the opinion of the Belgian Advisory Committee 
on Bioethics nr 25 (only in Dutch and French): ”Advies nr. 25 van 17 november 2003 
betreffende de bewaartijd van de bloedkaartjes en het vertrouwelijk karakter van de 
gegevens voor het opsporen van aangeboren metabolische afwijkingen”. 
In Western countries the vast majority of newborns have their blood taken for 
screening. This blood is kept on blood-spot cards for various lengths of time, depending 
on the facility that stores them.302 As shown by Lysaught et al. it is possible to extract 
DNA from these samples.303 As such, collections of blood spot cards can be considered 
as ‘inchoate DNA banks’302: they form a possibly huge potential resource for genetic 
research, although they were originally gathered for diagnostic purposes. For example, 
Klotz304 describes how these samples can be used for DNA extraction, to study cancer 
susceptibility genes. Other uses include genetic research (e.g. Sudden Infant Death 
Syndrome), environmental studies and epidemiological studies of a variety of diseases 
that are now frequently associated with childhood, such as allergies, asthma, autism.305 
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8.3.2 Stocking the newborn’s tissue for research 
There are specific ethical issues associated with collections of human biological 
materials. The issue most discussed is the one of consent.306, 307 In most countries, such 
as Canada, USA and UK, consent for newborn screening is presumed: often no written 
or oral consent is sought and many parents are unaware that they could refuse 
screening of their newborn.308 Authors agree that screening for treatable disorders 
without consent can be defended because the benefits to the child are obvious. 
However, the same authors make a strong distinction between the diagnostic use of the 
samples, for which consent may not be needed as this is considered part of routine 
care, and further storage of these samples and their use for non-therapeutic research. 
For the latter, they do think explicit consent is needed 303, 308-315. Hence they suggest 
that, should blood spot cards be used for something other than diagnostic purposes, 
consent should be sought, a recommendation supported by empirical research.316 As an 
illustration of the importance of such consent, in Holland people were shocked to find 
that, in the aftermath of a disaster with fireworks blood spot cards were stored and 
used for identification purposes without consent. As a result, the policy of retention of 
blood spot cards was changed.317 
Another ethical issue associated with stored tissue samples is the issue of 
confidentiality.318 Such samples, including blood spot cards, are a potential source for 
genetic information. If insurers and employers could get access to this information this 
could lead to discrimination of the donors. It is imperative that proper privacy 
protections are in place and that the researchers only work with an anonymized version 
of a sample. Also, there should be policies what should happen if researchers find 
potentially relevant information about the donors: should such incidental research 
findings be returned to donors or not?319 
Blood on blood spot cards is de facto from children, which further complicates the 
issue. On the one hand, as the blood is stored when the children are infants, consent is 
given by the parents. However, the same blood may be stored until they are 16 or 18 
years old. Should the children be recontacted to give renewed consent? Who is 
responsible for making them aware of the research done on their blood? On the other 
hand, a major concern in paediatric research is that such research should not burden 
children320. Especially venepunctures are quoted as something children dislike very 
much.321 Using blood spot cards, which have been taken in a diagnostics context, would 
reduce the burden of non-therapeutic research. In how far does this weigh up against 
the more formal ethical requirements of consent and autonomy? 
Blood spot cards can form a good resource for research. This option however would 
implicate the need for written informed consent, which is less feasble in the context of 
population screening. In case of research studies, the use of such existing blood spot 
samples could even be preferred over taking new blood samples from children. Certain 
conditions should be fulfilled. First, parents should consent to any non-diagnostic uses of 
the cards. Midwifes should be trained to discuss these issues with mothers and, if 
possible, also fathers. Second, research on blood spot cards that were stored must be 
for the benefit of children. In the Flemish community the storage time has been defined 
at 5 years after which the blood spot cards have to be destroyed. Third, collections 
should be under scrutiny of external ethics committee to ensure adequate privacy 
protections. Researchers themselves should never be allowed to recontact donors 
directly or to have access to their identities. Also, an ethics committee should decide 
whether certain uses of the blood spot cards require reconsent of parents and/or 
children when they reach a certain age. Finally, we believe that, if a policy to reuse 
blood spot cards for research, is adopted, this should become common knowledge to 
the general public. Children have the right to be made aware of such use and be given 
the opportunity to opt out. This step is probably the hardest to implement. It is 
however a very important one to establish and maintain this and further generations’ 
trust in science and the medical profession. 
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8.4 UNAVOIDABLE DETECTION OF CARRIERS  
The results of neonatal screening for CF when DNA testing is used can be expressed in 
one of three ways: not affected-no carrier, not affected-carrier –affected. The two last 
possibilities mean that one or both parents are also carriers and therefore these 
diagnosis have implications with regard to information provision and further 
investigation involving the parents and their relatives.294 This part will present what the 
implications of detection of carrier status are for the child, and the parents. 
8.4.1 Implications for children 
The provision of information about CF carrier status has raised concerns about 
potential stigmatization and discrimination.322 To date, no studies have reported the 
long-term implications for individuals identified as carriers via newborn screening.41 
There is also little evidence that carriers feel stigmatized in their personal 
relationships.323, 324 As with true-positive cases, there is concern that the temporary 
distress caused by the abnormal test result might disrupt early maternal bonding.107 
However Parsons report that there was no evidence of any difference between the 
carrier group and a control group drawn from the general population, 6 months after 
sweat testing.107 In another study there was no evidence of any of the 57 parents had 
experienced withdrawal or distancing from their baby.325 
8.4.2 Implications for parents 
Regarding the communication of carrier results of the newborn to the parents, a 
consensus governs that carrier status information generated through newborn 
screening results cannot be withheld from parents.326 This would be an infringement of 
the rights of parents to manage important reproductive information about themselves 
and their children. 
Tluczek et al.279 found that prior to the confirmatory CF sweat test, parents of infants 
who had an abnormal newborn screen were more distressed than parents of infants 
who had a normal newborn screen. However, after the sweat test, parents whose 
infants were found to be CF carriers scored comparably with parents whose infants had 
normal newborn screens. While persistent concern about the carrier infant does not 
seem to apply to the majority, one to six years after identification, as many as 28-29% of 
parents worry about the physical health of their carrier child as well as the potential 
difficulties that being a carrier might have for future relationships. 
Evidence from quantitative survey data endorses newborn screening for CF and 
disclosure of carrier results; 68% of parents agreed that they felt better informed 
knowing their child’s CF carrier status. Evidence from qualitative interview studies 
corroborates this finding.111 Reasons parents wanted to have carrier testing include an 
interest in knowing their own carrier status and whether other family members might 
be at risk to be carriers. In the same review Hayeems et al. state also that “while it is 
suggested that the frequency of identifying non paternity by disclosing carrier results 
generated through newborn screening might be as low as 1.8%, there is no evidence 
specific to the context of newborn screening that reflects the harm(s) that this 
revelation is thought to cause”. 
8.4.3 Use of carrier status for parental reproductive decision-making 
In the literature, there is at the moment a vivid debate on the use of carrier status 
ascertained through newborn screening for CF to guide reproductive decision-
making.327 Lewis et al328 found that for 82-87%, their infant’s carrier status “made no 
difference” to their reproductive plans whereas 12-13% had decided to have “no more 
children” and 6% decided to have “fewer children”. Mischler et al.329 suggest in their 
study that “if the use of prenatal diagnosis is a surrogate marker for the value of genetic 
information obtained through newborn screening, then this is a benefit for only a 
minority of the individuals”.  
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Ciske et al.330 observed in their retrospective study that 78.7% of the parents said that 
the knowledge of their child’s carrier status had not caused them to change their 
reproductive plans. 
More fundamentally one should ask whether such (and other) benefit should play a role 
in the evaluation of the acceptability of newborn screening for CF. In clinical genetics  
the traditional stance is that carrier information belongs to the tested individuals who 
are positioned to make reproductive choices. This position is reflected in the guidelines 
that recommend not to proceed with carrier testing of asymptomatic children where 
such testing is not serving the health of the person involved.331 The traditional criterion 
of benefit for the child in newborn screening situations has been challenged by recent 
publications that describe this position as outdated. In their opinion newborn screening 
can be justified on the basis of secondary benefits (like the reproductive benefit).332, 333 
Others however do not agree and state that there should be a clear benefit to the 
newborn109, 296: in the reproductive benefit scenario (as primary goal) the child is being 
used as a means for the interests of others.  In a recent article Bombard et al.334 argue 
that reproductive benefit could remain a secondary goal of newborn screening 
(including an additional choice to receiving this information or not) but “that pursuing 
reproductive benefit through newborn screening programs is not appropriate and may 
be best achieved through traditional antenatal screening programs”.  
8.5 THE RISK FOR A LEGAL PURSUIT IN CASE OF FALSE 
POSITIVE/FALSE NEGATIVE TEST RESULTS  
8.5.1 Introductory remark 
When discussing the legal consequences of false positive or false negative test results in 
Belgian law one should be aware of the general features of medical liability law in 
general in Belgium. This is not without difficulties as this law is actually in a phase of 
transition.  The Act of 15th May 2007 on the compensation of damages resulting from 
health care has introduced a complete new system of compensation that is not based 
anymore on fault and liability but on solidarity. Since many years the Scandinavian 
countries have elaborated so called no-fault or no-blame insurance schemes to 
compensate victims in a medical context. Such a system has also been adopted in the 
Act of 15th May 2007. This Act had to come into force on 1st January 2009. Because of 
the fear that this scheme would not be financially viable, the Government decided to 
replace the Act of 15th of May 2007 by a new Act. A proposal has already been 
approved by the Government recently but still has to be approved in Parliament. This 
could be managed end 2009/begin 2010. The inspiration of the newly proposed system 
comes from French law: a combination of the classic liability compensation system 
based on fault and a system of compensation based on solidarity of severe damages not 
attributable to a fault. 
8.5.2 Liability for false positive/false negative test results: an exercise in the 
dark. 
At the moment of writing, Belgian medical liability law is still based on fault. This means 
that the victim of a pretended medical fault has to prove: a fault, the damages and the 
causal relationship between fault and damages. Regarding the medical fault, a distinction 
has to be made between the so called technical fault (typically called: medical 
malpractice) and not respecting the rights of the patients, notably the right to give 
informed consent. When a CF screening test has been applied according to all the 
professional standards at stake, it nonetheless can give a misleading, false positive or 
false negative result. In such a case the patient cannot sue the physician because he has 
made a technical fault. The only way for the patient to hold the physician liable, is to 
convince the judges that the physician was under an obligation to inform him, the 
patient of the possibility of false positive or false negative results of the test. This is 
information that should be given in the context of the consent (cfr first part). Whether 
the judges will accept the existence of such an obligation is not easy to predict. There 
are no legal precedents in Belgium in this regard.  
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The question that judges will have to answer is the following: would a prudent and 
careful physician (often referred to as a bonus medicus) placed in the same 
circumstances have given this kind of information. Judges cannot answer this question 
without asking the opinion of medical experts and paying attention to practice 
guidelines, professional standards and protocols, provided they exist. Even if judges 
accept the existence of an obligation for the physician to inform the patient of the 
possibility of false positive or false negative results of the test, the patient is faced with 
other serious difficulties. Under Belgian law the burden of proof that the information 
has not been given to him rests upon the patient (for example, in France and other 
countries the burden of proof rests upon the physician: he has to demonstrate that he 
has informed the patient in a satisfactory way). The proof of not being informed is an 
extremely difficult one because it relates to a negative fact. The chances of success are 
therefore very limited. And even if the patient would succeed in this proof, he still has 
to face another difficult hurdle. Indeed, even if the physician had to inform the patient 
and the patient demonstrates that he has not been informed, the question arises what 
the damages are.  Damages have to be evaluated not in abstracto but in concreto. This 
means: what are the damages if parents of a neonate have been told that their baby has 
CF while afterwards it appears that this is not the case? And vice versa: what are the 
damages if parents have been told that their baby has no CF while afterwards it appears 
this information was wrong? This way clinical diagnosis will be postponed which may 
lead to irreversible damage (see deliverable 1a, late diagnosis being related to worse 
prognosis. Even if the parents can make their damages in either case concrete they will 
have to prove the existence of a causal relationship between the improper information 
and their damages. Again, this is not easy. In case parents have been told that their baby 
has no CF, while afterwards it appears that this information was wrong, there is clearly 
no causal relationship between the improper information and the CF status of the child 
because this status is the result of nature. And what could parents have done if they had 
received immediately the correct information? Interruption of pregnancy is not possible 
anymore and “euthanasia” would be inacceptable both legally and ethically. In other 
words : parents confronted with a false positive or a false negative result of a CF 
screening test, face enormous difficulties when they want to sue the physicians 
responsible for the screening. 
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8.6 LEGISLATION APPLICABLE TO CF NBS 
Table 17. Tabular overview of legislation applicable to CF NBS 
Patients’ Rights 
Law Article Application to CF newborn screening 
Wet van 22 augustus 2002 betreffende de 
rechten van de patiënt, B.S. 26 september 2002 
 
Art. 8 §1 informed consent + art. 12 
parental authority 
 
Art. 373-374 Civil Code 
Informed oral consent of one parent is sufficient. The law defines a non-exhaustive and general list of 
information-elements  
Information has to be provided in advance, timely and in clear language  
If the physician presumes/knows that the parents are separated and that possibly the other parent 
would not consent, he/she should ask for consent of both parents.  
 
 
Art. 8 § 4: right to refuse 
 
The parent(s) has/have the right to refuse CF newborn screening 
 
 
Art. 7 § 1: right to information 
 
 
The parent(s) has/have the right to information of the test result and all information on the health status 
and probable evolution 
Persons responsible for the education of the newborn, not being the (legal) parents (e.g. step parent) 
can receive medical information regarding the minor’s health status if they are assigned as confident by 
the parents having the parental authority or by the guardian (Advies inzake de mededeling van 
information over de gezondheidstoestand van mindeerjarigen van 18 september 2009 van de Federale 
Commissie van de Rechten van de Patiënt)  
 
 
Art. 7 § 3: right not to know The parent(s) has/have the right not to know the test result at their explicit request, unless the non-
notification of information causes damage to the child or a third party and on condition that the 
physician consulted an other health care professional  
 
 
Art. 7 § 4: Therapeutic exception 
 
If the communication of the test result would cause obviously serious damage to the health condition of 
the child (e.g. because the parents get anxious and depressed) and on condition that the physician 
consulted an other health care professional, the physician can decide to not to communicate the 
negative test result to the parents. 
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Art. 9: right to access to the patient 
file and a copy 
The parent(s) has/have direct (implying without the assistance of a physician) access to the patient file 
and the right to have a copy of it  
Professional Secrecy and confidentiality  
Criminal Code, 8 juni 1867, B.S. 9 juni 1867 Art. 458: professional secrecy The treating physician, the nurses and paramedics taking part in the care process of CF screening are 
not allowed to disclose patient data unless specific exceptions described in law (see art. 458 Crim. 
Code); if the parent(s) consented to do so or when data are shared with colleagues (also bound by 
professional secrecy) of the medical team treating the patient (=shared professional secrecy). 
 
Wet van 8 december 1992 tot bescherming van 
de persoonlijke levensfeer ten opzichte van de 
verwerking van persoonsgegevens, B.S. 18 
maart 1993. (Data Protection Act- DPA)  
 
+  
Koninklijk Besluit van 13 februari 2001. - 
Koninklijk besluit ter uitvoering van de wet van 
8 december 1992 tot bescherming van de 
persoonlijke levenssfeer ten opzichte van de 
verwerking van persoonsgegevens, B.S. 13 
maart 2001 (Royal Decree Data Protection 
Act- RD DPA) 
 
Art. 7, § 4, section 3 DPA 
 
Art. 25, 3° RD DPA 
 
 
art. 16 §2 DPA 
The health care practitioner, his appointees and authorized representatives are bound by secrecy 
concerning the health data. 
The hospital is obliged to assure that the persons processing the health data respect the confidential 
character of the data by contractual clauses, or legal or statutory provisions  
 
 
The hospital needs to make sure that access to the data and possibilities of processing for the persons 
who are acting under his authority are limited to what is necessary for the exercise of their duties or 
for the requirement of the service. 
Privacy 
Wet van 8 december 1992 tot bescherming van 
de persoonlijke levensfeer ten opzichte van de 
verwerking van persoonsgegevens, B.S. 18 
maart 1993. (Data Protection Act, DPA)  
 
+  
Koninklijk Besluit van 13 februari 2001. - 
Koninklijk besluit ter uitvoering van de wet van 
8 december 1992 tot bescherming van de 
persoonlijke levenssfeer ten opzichte van de 
verwerking van persoonsgegevens, B.S. 13 
maart 2001 (Royal Decree Data Protection 
Act, RD DPA) 
Art. 1 DPA 
 
 
Art. 7, § 2 j) DPA 
 
 
 
Art. 9 DPA + art. 25 RD DPA 
Art. 10 DPA 
Art. 12 DPA 
 
Art. 4 § 1, 2° DPA + Chapter II RD 
DPA 
All information resulting from the CF screening is personal health data. DNA as such is not considered 
to be personal health data. The processing of the test results (e.g. integration in the patient file, 
invoicing, accounting,…) is subject to the dispositions of the Privacy Law  
Primary processing: Processing of the CF test results is allowed if this is required for the purposes of 
preventive medicine, medical diagnosis, the provision of care or treatment to the data subject or a 
relative, the management of health care services and the data are processed under the supervision of a 
health care professional. 
Right to information with regard to the processed data 
Right to access to the patient file 
Right to correct, erase data or object to processing 
 
 
Secondary processing  
If health data are further processed for scientific purposes that are incompatible with the original 
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purposes (= unforeseeable by the patient or  not considered as compatible by law), extra privacy 
measures (anonymising , encoding of data, unless consent of the patient, extra information etc.) must be 
taken into account. For details see Chapter II RD DPA 
 
Genetic testing and the relation employer-employee or the relation insurer-insured 
Wet van 28 januari 2003 betreffende de 
medische onderzoeken die binnen het kader 
van de arbeidsverhoudingen worden 
uitgevoerd, B.S. 9 april 2003. 
+  
Wet van 25 juni 1992 op de 
landverzekeringsovereenkomst, B.S. 20 
augustus 1992 
 
Art. 3 § 1 
 
 
 
 
 
Art. 95 
Predictive genetic testing by employers is prohibited 
 
 
 
 
Medical certificates needed for the contracting or executing of contracts delivered by the physician of an 
insured individual, may not contain predictive medical information. Genetic testing must be excluded 
from the medical examination for the contracting or the execution of the contract.   
Information exchange networks  
Decreet van 16 juni 2006 betreffende het 
gezondheidsinformatiesysteem., B.S. 7 
september 2006 
Art. 36 The epidemiological information system enables the exchange of health data among care providers and 
other institutions involved in the provision of health care for purposes of organizing the public health 
system. The data in this system are allowed to be further processed in the scope of population 
screening.  
 
Wet van 21 augustus 2008 houdende oprichting 
en organisatie van het eHealth-platform, B.S. 13 
oktober 2008 
 The eHealth Platform is a government institution, managed by representatives of several actors in the 
healthcare sector creating and managing a cooperation platform for secure electronic exchange of 
information about patients, provided care and the results of the provided care, and for the exchange of 
electronic care prescriptions between all relevant actors in the health care sector. Besides providing a 
network and basic services, it will also coordinate the development of functional and technical 
interoperability standards. The eHealth Platform can be useful in the scope of data processing in 
population screening 
 
Liability for false positive/false negative test results 
Wet van 31 maart 2010 betreffende de 
vergoeding van schade als gevolg van 
gezondheidszorg, B.S. 2 april 2010 (not yet 
came into force!) 
  
The parent(s) (or the patient), victims of damage above a certain degree of gravity that was caused by an 
act of healthcare do no longer need to prove the existence of fault by the health care professional and 
can be reimbursed by a Fund. 
It is doubtful if the damage that was caused by the effect of a false positive or a false negative result can 
reach the degrees of gravity specified in law. 
Damage linked to false positive tests will be mostly moral. In case of a false negative result the damage 
will consist of the loss of a chance to improve the health status of the child because of earlier treatment 
(resulting from the early detection). 
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Civil Code - Tort Liability  
or 
 contractual liabilty  
Art. 1382 Civil Code The parent(s) need(s) to prove the fault of the physician and a causal link between the damage and the 
fault. Solely if the parent(s) can prove that he/she/they would not have consented to CF screening if the 
physician informed them on the possibility of a false positive/false negative result, the physician can be 
held liable  
Liability for defective products 
Civil Code - Tort Liability  
or contractual liability, Wet van 25 februari 
1991 betreffende de aansprakelijkheid voor 
produkten met gebreken, B.S. 23 maart 1991 
 
1384 section 1, 1604, 1641 Civil 
Code 
If damage (e.g. a false test result) was caused because of defective material or equipment for CF 
screening the parent(s) can claim liability of different parties based on different legislations. The easiest 
way to get compensation is the application of the Product Liability law because the solely causal link 
between the damage and the defective product needs to be proven. No fault has to be established. 
Scientific research 
Wet van 19 december 2008 inzake het 
verkrijgen en het gebruik van menselijk 
lichaamsmateriaal met het oog op de 
geneeskundige toepassing op de mens of het 
wetenschappelijk onderzoek, B.S. 30 december 
2008 (see also executing Royal Decrees of 28 
september 2009, B.S. 23 oktober 2009). Did 
not yet come into force! 
 
Art. 3§3 b) 
 
Art. 10 §3, § 5 
 
Art. 11 
 
 
Art. 20 § 1 
 
 
 
 
Art. 20 § 2 
 
 
 
 
Art. 21 
 
 
 
Art. 22 
 
 
 
Art. 17 
The law is not applicable to the (sole) primary use of DNA or sweat for the CF diagnostic test (or 
screening). 
Primary use of DNA (except if exclusively for diagnosis): written informed consent of the parent(s) or 
of the minor (according to art. 12 Patients’ rights act) is needed. 
Right to information if analyses result in relevant medical information for the donor.   
 
Secondary use of DNA (e.g. for further scientific research): the patient (or parent(s) according to art. 
12 Patients’ rights act) needs to be informed + written informed consent of the patient (or parent(s) 
according to art. 12 Patients’ rights act) needs to be obtained by the physician-guardian of the DNA, 
unless this is impossible (e.g. patient deceased) or not appropriate. In the latter case the positive advise 
of an Ethical Committee is needed 
Secondary use with residual DNA samples: consent is presumed as far as the parent(s) or the patient 
(≥18 years old or allowed to consent according to art. 12 § 2 Patients’ rights act) did not refuse before 
the scientific research has started. The patient or the parent(s) has/have to be notified, preferably in 
written of the option to refuse  
 
The secondary use of the DNA sample as well as the specific purpose of the research necessitate the 
positive advice of an ethical committee (cfr. also art. 2, 4°, van de wet van 7 mei 2004 betreffende de 
experimenten op de menselijke persoon).  
 
The purposes and activities of biobanks (banks storing and providing human tissue for scientific 
research), as well as any provisions of blood spot cards need to be subject to a positive advice of an 
ethical committee. 
Biobanks are obliged to keep a register regarding the character, the source and the destination of the 
blood spot cards. 
Several obligations are foreseen in this article for entities storing, providing, analysing etc. the DNA.  
Wet van 7 mei 2004 inzake experimenten op 
de menselijke persoon, B.S. 18 mei 2004. 
 
 
 
Clinical trials on minors affected with CF are solely allowed   
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Art. 7 With the written informed consent of the parent(s) or the guardian, expressing the wish of the minor. 
The researcher has to ask for and respect the minor’s wish as far as the minor is capable to evaluate the 
information and the consequence of participation to the experiment; 
the clinical trial needs to be directly related to the health status of the neonatal or solely possible with 
minors; 
the trial is essential to confirm the results of trials with consenting individuals or other research 
methods and the trial grants a direct benefit for the patient group 
The risks are proportionate to the (expected) advantages 
Pain, fear, discomfort or any other foreseeable risk is minimised; 
 
A positive advice is given by an ethical committee, composed of at least 2 paediatrics or an ethical 
committee that consulted 2 paediatrics; 
The minor or the representatives do not get any financial incentives other than a remuneration; 
 
The scientific guidelines of the “Europees Bureau” were taken into account. 
Advies van 17 juli 2004 van de Nationale Raad 
van de Orde der Geneesheren betreffende het 
DNA onderzoek en farmacogenetica 
 
 Processing of genetic data is highly confidential and the use needs to be limited to the protocol to which 
the person consented. The use of these data for other purposes needs to be approved by the same 
ethical committee and an informed consent of the person concerned is needed.  
Population screening 
Besluit van 12 december 2008 de Vlaamse 
Regering betreffende bevolkingsonderzoek in 
het kader van ziektepreventie, B.S. 19 februari 
2009 
+ Protocolakkoord van 28 september 2009 
tussen de federale overheid en de overheden 
bedoeld in artikelen 128, 130 en 135 van de 
Grondwet inzake preventie, B.S. 29 oktober 
2009 
 
Art. 4 and 5  The Flemish government can organise population screening if  
The expected health gain in the target population and efficacy is evidence based; 
Participants will probably have more gain than disadvantage 
The screening programs guarantees the possibility to participate to the entire target group 
 
The working group Population screening advices on the proposition of the Flemish government. 
 
Modalities for the organisational elaboration of a population screening program are identified in law.   
 
 
Disclaimer: The information in the table is a summary of the respective legislation. We limited ourselves to highlight the dispositions that are obviously applicable to the CF 
newborn screening. Details regarding the specific legislations mentioned were not elaborated.  
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9 REVIEW OF THE COST-EFFECTIVENESS 
LITERATURE 
9.1 METHODS 
9.1.1 Literature search strategy 
The search for the economic literature on newborn screening for cystic fibrosis was 
performed by consulting electronic databases up to mid December 2009. The 
HTA(CRD) database and websites of Health Technology Assessment (HTA) institutes 
listed on the INAHTA (International Network of Agencies for Health Technology 
Assessment) website were consulted to retrieve HTA reports on this topic. The NHS 
EED(CRD), Medline(OVID), and EMBASE databases were searched to retrieve full 
economic evaluations and reviews of full economic evaluations on this topic. No 
restrictions on the time period and language were imposed. At this stage, 160 
potentially relevant references were identified. See Appendix 8 for an overview of the 
search strategies and results. 
9.1.2 Selection criteria 
All retrieved references were assessed against pre-defined selection criteria (in terms of 
population, intervention, comparator and design - Table 18) in a two-step procedure: 
initial assessment of the title, abstract and keywords; followed by full-text assessment of 
the selected references. When no abstract was available and the citation was unclear or 
ambiguous, the citation was assessed on the basis of keywords and/or full-text 
assessments. Reference lists of the selected studies were checked for additional relevant 
citations. The selected full economic evaluations (i.e. studies comparing at least two 
alternative treatments in terms of costs and outcomes - Figure 12) were critically 
assessed. 
Table 18: Economic evaluation selection criteria 
 Inclusion criteria Exclusion criteria 
Population newborn babies others 
Intervention screening for cystic fibrosis others 
Comparator non-screening alternative 
(traditional symptomatic 
diagnosis) 
Analyses only looking at other 
screening protocols without including 
the no-screening alternative 
Design full economic evaluations no full economic evaluations 
Figure 12: Classification of economic studies 
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Partial evaluation Partial evaluation 
Outcome 
description 
Cost 
description 
Cost-outcome description 
Yes 
Partial evaluation Full economic evaluation 
Efficacy or 
effectiveness 
evaluation 
Cost 
comparison 
Cost-minimisation analysis (CMA) 
Cost-effectiveness analysis (CEA) 
Cost-utility analysis (CUA) 
Cost-benefit analysis (CBA) 
Adapted from Drummond et al., 2005335 
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9.1.3 Selection process 
The searches of the HTA websites and databases returned 202 citations. After 
exclusion of 42 duplicates, 160 unique citations were left. Based on title, abstract and 
keywords (if available), 95 citations were excluded since they were no full economic 
evaluations. The 65 remaining citations were retained for full-text assessment. Six 
evaluations were selected and are reviewed in this manuscript.  
Further exploration of articles’ references did not bring additional citations.  
Figure 13. Flow chart of the literature selection process 
Potentially relevant citations 
identif ied (Medline, Embase, 
CRD): 160
Based on title, abstract, and keywords: 
citations excluded: 95
Reasons: design (95)
Studies retrieved for more 
detailed evaluation: 65
Based on full text evaluation:
studies excluded: 59
Reasons: 
design (53), intervention (4), language (1), 
not retrieved (1)
Relevant studies: 6
Inclusion of  relevant economic evaluations 
f rom websites HTA institutes, reference 
lists and hand searching: 0
6 full economic evaluation on 
the cost-ef fectiveness of  
newborn screening for cystic 
f ibrosis versus traditional 
(symptomatic) diagnosis.
 
Several studies were excluded because they were cost analyses not comparing 
screening with a no-screening situation, e.g. Farrell et al., 2007336 is a cost comparison of 
three different procedures for sweat testing in Ireland; Gregg et al., 1993337 is a cost 
comparison of two protocols (IRT and IRT/DNA) for newborn screening for cystic 
fibrosis; Rosenberg et al., 2005338 compares the costs of single CF mutation and CF 
multi-mutation test. The latter study338 mentions to compare with the traditional means 
to diagnose CF. However, no such results are presented in the manuscript and 
therefore it was withdrawn from our review.  
Several studies only mention the cost per diagnosed case.325, 339, 340 These results are not 
taken into account since they are merely cost analysis and are not considered being full 
economic evaluations. Such studies were included in the overview if there is a 
comparison with a no screening alternative and when the analysis shows that costs with 
screening are lower than without. These studies do not explicitly compare effects 
expressed as life-years gained or QALYs gained. However, we consider them since 
results can be interpreted as being located in the second quadrant of the cost-
effectiveness plane, i.e. being cheaper and better/not worse. 
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The following studies were selected and are summarized in this report: 
• Dauphinais RM. A cost analysis of blood-spot screening newborns for 
cystic fibrosis. Journal of Clinical Immunoassay 1992; 15(2):121-125.341 
• Farrell PM, Mischler EH. Newborn screening for cystic fibrosis. The Cystic 
Fibrosis Neonatal Screening Study Group. Advances in Pediatrics 1992; 
39:35-70.342 
• Lee DS, Rosenberg MA, Peterson A, Makholm L, Hoffman G, Laessig RH, 
Farrell PM. Analysis of the costs of diagnosing cystic fibrosis with a 
newborn screening program. Journal of Pediatrics 2003; 142(6):617-623.343 
• Simpson N, Anderson R, Sassi F, Pitman A, Lewis P, Tu K, et al. The cost-
effectiveness of neonatal screening for cystic fibrosis: An analysis of 
alternative scenarios using a decision model. Cost Effectiveness and 
Resource Allocation. 2005;3(8).344 
• Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Mehta G, et al. 
Economic implications of newborn screening for cystic fibrosis: a cost of 
illness retrospective cohort study.[see comment][erratum appears in 
Lancet. 2007 Jul 7;370(9581):28.]. Lancet. 2007;369(9568):1187-95.345 
• Van Den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse 
JE. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. 
Pediatrics. 2006;118(3):896-905.346 
9.2 OVERVIEW AND DISCUSSION OF ECONOMIC 
EVALUATIONS 
9.2.1 Dauphinais, 1992341 
This US (Connecticut) cost analysis questions whether it is more cost-effective to 
screen for CF or continue to rely on conventional methods of diagnosis by signs and 
symptoms. The authors mention that in Connecticut, roughly one half of the newborn 
population is screened for CF because of the voluntary nature of hospital participation. 
The average costs were compared between IRT screened and non-screened CF patients 
seen at their CF center. Only patients diagnosed between 1982 and 1990, both 
screened and non-screened, were included in this study. Costs of 16 non-screened 
patients with a delayed diagnosis of 1.5 months to 21 years were compared to IRT 
screening costs based on an incidence rate of 1/2700.341  
For non-screened patients, CF-related costs generated prior to diagnosis were 
evaluated. Hospital, physician (office visits, medications, and special needs such as air 
purifiers), and sweat test costs were included. These costs were obtained from 
physicians' offices, hospital billing and medical records, and by direct communication 
with families of affected children. Costs of sweat-testing non-CF children between 1982 
and 1990 because of non-specific signs and symptoms were added to non-screened CF 
patient costs.341 Screening costs were based on a detailed analysis of labour and 
materials used in the Connecticut program. Screening costs included those for kits, 
special collection blotters, disposables, materials used in generating and reporting 
results, and technical and non-technical labour costs. Costs were included from a health 
care payer’s perspective. Sweat-test charges were based on the 1988 average charge of 
three regional hospitals included in the Connecticut program, i.e. $119.60 (range: 
$93.40 – $138.11).341 
In this cost analysis, total costs (1988 prices) per year per CF patient diagnosed by 
screening and non-screening were $6,243.00 and $14,497.00, respectively. The authors 
conclude that the cost of diagnosing CF by IRT screening is more cost-effective than 
relying on signs and symptoms.341 
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9.2.2 Farrell et al., 1992342 
The cost analysis of Farrell et al. analyzed the costs of the Wisconsin screening 
program. Two potential approaches are considered, i.e. a one-tiered testing strategy 
(IRT analysis only) and a two-tiered method involving the IRT/DNA approach. This is 
compared with how much money is being spent to identify CF patients by the standard 
diagnostic approach. This includes performing a sweat test because of either a positive 
family history or the occurrence of signs/symptoms suggesting CF.342  
If laboratory supplies plus personnel (technician) budgets per year were combined and 
sweat tests included, one-tier testing (with an IRT cut-off 180 ng/mL or the 99.8 
percentile) would cost $130,400 to screen 75,000 newborns. IRT/DNA testing (using an 
IRT 100 ng/mL cut-off or the 99 percentile plus mutation analysis for the SF508 allele) 
would cost $126,770. This assumes 150 people would have a sweat test using the one-
tier screening strategy and about 50 people would need a sweat test using the two-tier 
method. In both groups, the researchers expected to identify 18 individuals with CF. 
Without screening, a total cost of $182,030 was revealed. This was based on a total 
number of 1,670 sweat tests, applying an average sweat test charge of $56, and 
assuming that the equivalent of at least one extra "sick visit" occurred (per sweat test) 
in the primary care physician's office at a usual and customary fee of $53.342 
Furthermore, delays in diagnosis can increase medical costs significantly because of 
unnecessary laboratory tests and hospitalizations. Farrell et al. mention that advocates 
of screening suggest that neonatal diagnosis would prevent these unnecessary costs and 
decrease the probability of hospitalization. On the other hand, they remark there is 
good reason to expect intuitively that diagnosing CF early will lead to an increased 
likelihood of more (rather than less) treatment and that physicians will be more likely to 
admit known CF patients to the hospital for parenteral antibiotic treatment and other 
types of inpatient management. Therefore, this is a difficult issue to address.342 
The authors conclude that if better treatments are developed that would prevent the 
need for hospitalizations in CF patients diagnosed through neonatal screening, the cost 
of care could be significantly reduced. In comparison to cumulative direct medical costs 
for patients requiring frequent or prolonged hospitalization, the expenses for screening 
are relatively small. However, at that time, the authors also mentioned that they cannot 
offer a treatment known to prevent hospitalization. They also did not know at that time 
if CF children diagnosed because of screening will be more healthy than those identified 
because of their symptoms.342 Early identification of children with cystic fibrosis may 
lead to increased cost in the short term because of a greater probability that children 
will be hospitalized for management of respiratory illnesses. On the other hand, it is 
possible that screening would decrease the total cost of the diagnostic process. This 
may be true if therapy in early childhood prevents progressive lung disease requiring 
fewer hospitalizations. 342 The authors conclude that the major gap in knowledge that 
must be closed before CF neonatal screening can be recommended generally in the US 
concerns the potential long-term medical benefits of initiating treatment in early infancy. 
In their opinion, in 1992, it would be premature to implement mass population 
screening of newborns for CF until the benefits and risks have been fully defined, and an 
adequate and logistically feasible testing system developed and/or highly effective 
therapy for CF lung disease becomes available.342 
9.2.3 Lee et al., 2003343 
This US (Wisconsin) study compares the cost of diagnosing CF through a newborn 
screening program with the traditional method. Total costs for a national newborn 
screening program were also calculated but are not discussed in this report. The 
following figure shows the pathways to CF diagnosis for both approaches.  
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Figure 14. Pathways to CF diagnosis in Wisconsin by neonatal screening 
during 2000 or by traditional methods (shown in the box).343 
 
Source: Lee et al., 2003 343 
Since 1994, the state of Wisconsin performs CF neonatal screening with the use of both IRT and 
DNA analysis tests. Newborn infants with IRT levels below the daily 96th percentile are reported 
as normal, whereas newborn infants with IRT levels above the daily 96th percentile are analyzed 
for the ΔF508 mutation. Unless two CF mutations are demonstrated, however, the sweat 
chloride test is still used to confirm the diagnosis of CF. Newborn infants with IRT levels >170 
ng/mL and no ΔF508 mutation are reported as possibly having CF. In this case, physicians are 
advised to refer the newborn for a sweat chloride test if any signs or symptoms of CF develop or 
if there is a positive family history.343 
The annual cost of a CF newborn screening program was calculated as a function of the 
cost per test for the IRT/DNA screening, the cost per test for the sweat chloride 
testing, and the annual numbers of newborn infants who undergo the IRT/DNA and 
sweat chloride tests. The costs for the tests were $1.50 for IRT, $18 for DNA analysis, 
and on average $161.40 for a sweat chloride test. The numbers of annual sweat tests 
performed in Wisconsin were determined by surveying hospital and clinic laboratories 
with a questionnaire. Two surveys were performed with similar methods during 1991 
(before routine CF neonatal screening) and for the year 2000.343 
In this study, the total cost of CF newborn screening was estimated to be $180,491, or 
$9025 per newly diagnosed patient with CF (n=20), or $2.66 per screened baby. 
However, the hospital survey in 2000 revealed that next to 134 follow-up evaluations in 
the screening program, another 804 sweat test were performed. Adding another 
$129,766 for these sweat tests to the total cost of screening and diagnosis results in an 
estimated annual costs in Wisconsin in 2000 of $310,257, or $15,513 per CF diagnosis 
or $4.58 per newborn infant.343 
The 1991 hospital survey (before routine CF NBS) determined that 1670 sweat tests 
were performed. Assuming a sweat chloride test charge of $161.40 and 20 newly 
diagnosed patients with CF, an estimated total cost for the traditional method was 
$336,923, or $16,846 per newly diagnosed CF child, or $4.97 per newborn infant.343 
The authors conclude that a CF newborn screening program provides a potentially 
cost-saving alternative to the traditional method of diagnosis of CF.343 
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9.2.4 Simpson et al., 2005344 
This paper explores the cost-effectiveness of adding CF screening to an existing routine 
neonatal screening programme. The analysis was performed from the perspective of a 
hypothetical UK Health Authority that has an existing routine neonatal screening 
programme for congenital hypothyroidism and phenylketonuria but not for cystic 
fibrosis.344 
Figure 15. Decision tree for no screening and neonatal screening strategies 
for cystic fibrosis.344 
 
Source: Simpson et al., 2005344 
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The study is based on a decision model (Figure 15) comparing lifetime cost-effectiveness 
of neonatal screening to no screening. Future treatment costs and QALYs were 
discounted at 6% and 2% per year, respectively. The screening programme used a two-
stage IRT combined with genetic testing strategy. A decision tree, incorporating Markov 
processes, was set up to model lifetime costs and quality of life. The health states 
included were (‘born’ into) the pre-symptomatic health state, the symptomatic disease 
state, the severe irreversible lung disease-state, and finally death. Probabilities of moving 
into the last two states changed over time.344 Under the "no screening" strategy infants 
would be diagnosed with CF symptomatically (late diagnosis). Under the screening 
strategy most CF cases would be detected by screening (early diagnosis), with the 
remainder, i.e. the false negatives, experiencing the disease under late diagnosis 
assumptions. The model excluded those cases (15% in the base case scenario) 
diagnosed at or shortly after birth, for example by meconium ileus or family history, 
since these infants would have received the same prognosis and treatment under both 
strategies.344 
The following screening costs were included in the model: counselling time required by 
midwives to obtain consent for testing, IRT test, DNA analysis and sweat chloride test. 
Other costs related to obtaining the blood spot and feedback of results by health 
visitors, were assumed to be sunk in the existing neonatal screening programmes for 
phenylketonuria and congenital hypothyroidism. Time for genetic counselling for 
carriers identified by the screening programme were excluded from the model because 
of difficulties to quantify the benefits of such counselling and because this cost would 
only be small in relation to total screening costs.344  
The following table provides an overview of all model parameters and values used in 
their model. The pre-diagnosis healthcare costs for children with late diagnosis (no-
screening) was estimated via an audit of the clinical notes of 25 children with cystic 
fibrosis. Disease state-specific costs of treatment were derived from the cost of care of 
161 patients at a large UK cystic fibrosis unit during 1996 which were based on annual 
medical costs for patients at different age groups and at different disease stages.344 
Quality of life values, based on Quality of Well-Being scores, were assigned to each 
Markov state (Table 19) and multiplied by survival time in the same state to produce 
quality-adjusted life expectancy.344 
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Table 19. Model parameters and values used in the model of Simpson et 
al.344 
Model parameters
Base case value Range used in 
sensitivity analysis
Probabilities
- Incidence of cystic fibrosis 0.0004 0.00067 – 0.00029
- % diagnosed at birth (MI & family history) 0.15 0.10 – 0.40
- IRT test sensitivity 0.9 0.99
- IRT test specificity 0.995 0.999
- DNA test: % of mutations detected 0.88 0.85 – 0.95
- DNA test sensitivity 0.9856 0.9975
- DNA test specificitya 1
0.1 10 – 40%
Costs (all inflated to reference year 1998)
Costs of screening
- Additional time to explain test £0.40 (2.1 mins) £0 – £1.44 (0 – 7.6 mins)
- Obtaining and transport of blood samplec £0
- IRT test £0.97 £0.50 – £1.50
- DNA test £79.48 £40.00 – £120.00
- Sweat test £29.40 £15.00 – £45.00
- Administration and feedback of resultsc £0
Cost of pre-diagnosis care in unscreened group
- Presumed GP visits (mean number of visits) £14.77 (1.27) £11.63 – £46.52 (1 – 4)
- Outpatient attendances (mean number) £129.07 (1.47) £0 – £263.40 (0 – 3)
£792.55 (0.87) (3.0 days) £0 – £1821.96 (0–2)
Costs of treatment per year in health state by age group
- Presymptomatic 0–5 £2,950
6–10 £3,995
11–15 £4,570
> 16 £4,275
- Symptomatic 0–5 £15,241
6–10 £15,704
11–15 £19,247
> 16 £19,291
- Severe irreversible symptoms 0–5 £28,722
6–10 £30,692
11–15 £37,224
> 16 £37,388
Utility values of symptom states
- Asymptomatic – lated 0.95 0.9
- Asymptomatic – earlye 0.95 0.9
- Symptoms (FEV1 – 60%, range 40%–80%) 0.75 0.65 – 0.90
- Severe irreversible symptoms (FEV1 – 30%, range 20–40%) 0.68 0.58 – 0.78
- Increased annual transition probability of remaining without 
symptoms (in early-diagnosed cases)b
- Inpatient admissions (mean number of admissions and days 
per admission)
a The authors assumed that there are no false positives (from the combined DNA and sweat tests), because all test results 
that are either homozygous or heterozygous for cystic fibrosis mutations, are confirmed using sweat tests; b Assumed effect 
of early diagnosis; c Assumed to be a shared cost with existing screening programmes; d utility value to reflect "taking 
regular medication or staying on a prescribed health diet for health reasons" derived from community surveys; e arbitrary 
utility weight to reflect the probable repeated visits to GP with undiagnosed CF.
 
Source: Simpson et al., 2005344 The sources of all parameter values are in the original 
manuscript. 
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Survival estimates were derived from the UK National Cystic Fibrosis Survey. The 
transition probabilities in the Markov model were estimated to achieve age-specific 
survival rates and other estimated parameters. Three alternative scenarios were 
modelled: conservative, balanced and optimistic. The authors mention the annual 
transition probabilities that best predicted these calibration data for the balanced 
scenario, 'late diagnosis': from asymptomatic to symptomatic, 0.491 per year (with the 
remainder all staying asymptomatic); symptomatic to severe irreversible lung disease, 
0.0064 increasing exponentially according the accumulated years with symptoms (with 
hazard rates derived from Dodge et al., 1997347); severe irreversible lung disease to 
death, 0.09 increasing according to the number of years spent in the severe irreversible 
disease stage.344 
Sensitivity analysis was restricted to one-way and two-way sensitivity analysis (due to 
absence of published data on the uncertainty surrounding the mean parameter 
estimates). A threshold analysis was also performed to calculate the needed delay in the 
emergence of symptoms to make the screening scenario less costly and better than no 
screening.344 Scenario analysis on whether or not explaining CF screening can be 
incorporated in the existing process (and how much time this takes of this is not the 
case) and the impact of reducing birth prevalence of CF due to introducing routine 
antenatal screening are also considered.344 For results of the latter, we refer to the 
original manuscript. 
Some of the assumptions made in the analysis are the following: 
• Coverage: The addition of CF screening does not increase refusals or 
insufficient blood samples and 100% of the neonatal population would be 
covered by the programme.344 
• Specificity: There are no false positives from the combined DNA and 
sweat tests because all test results that are either homozygous or 
heterozygous for CF mutations, are confirmed using sweat tests.344 
• Treatment effect: There is an increased annual transition probability of 
remaining without symptoms (in early-diagnosed cases) of 10% (range 10-
40%). This hypothetical benefit of early diagnosis through neonatal 
screening was modelled as a difference in the annual transition probability 
of remaining pre-symptomatic. In the initial model this probability was 
69% for those diagnosed through screening (compared with 59% for 
those diagnosed symptomatically) resulting in a delay of the emergence of 
symptoms of 6 months.344 
Under initial assumptions, the IRT/DNA two tier screening protocol costs £5,387 per 
infant diagnosed, or £1.83 per infant screened (1998 costs). 75% of these costs are due 
to performing the IRT test and the explanation of the test by midwives, i.e. the 
components of the screening process that are carried out for every infant screened. 
Based on these findings, the authors think it is unlikely that substantially different results 
would be obtained with other screening protocols because all employ an IRT test as the 
initial screening stage for all neonates.344 Screening resulted in an average of 0.36 QALYs 
gained per life with CF at an additional cost of £2,895. The incremental cost-
effectiveness ratio (ICER) for CF NBS versus no screening was £6,864 per QALY gained 
assuming a 6 month delay in the emergence of symptoms. Under the conservative and 
optimistic survival scenario, this would become £7,474 and £6,532 per QALY gained, 
respectively. If the delay in the emergence of symptoms would be 11 months or more, 
than CF NBS would be less costly and better than no screening.344 Results were most 
sensitive to the incidence of the disease, and the proportion of cases detected at birth 
by family history of MI.344 
The authors conclude that neonatal screening is expensive as a method of diagnosis and 
may be a cost-effective intervention if the hypothesised delays in the onset of symptoms 
are confirmed. Furthermore, they do not see good reasons to discontinue existing 
neonatal screening programmes on cost-effectiveness grounds since evidence of health 
benefits of early diagnosis is beginning to emerge. 
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9.2.5 Sims et al., 2007345 
This cross sectional UK cost analysis estimates the potential savings in treatment costs 
attributable to newborn screening. The cost of illness was based on a retrospective 
snapshot cohort study based on the UK Cystic Fibrosis Database (year 2002). Patients 
aged 1–9 years were divided into two groups: newborn screening, i.e. 184 patients 
identified by newborn screening within 2 months of birth; and clinically diagnosed, i.e. 
950 patients presented at any time by clinical diagnosis. Patients presenting with MI or 
with a CF family history were excluded. Yearly costs (no discounting) of long-term 
therapies and intravenous antibiotics were estimated. Assumptions were made on the 
used type of antibiotics. Subgroup analyses were performed according to age (3 age 
groups) and for homozygous ΔF508 newborn screening. It was also tested whether 
possible cost savings could off set the known costs of a national newborn screening 
programme (as used in Scotland), when scaled to the UK as a whole. Finally, a separate 
analysis was made restricting the cost estimates to patients diagnosed after the age of 2 
months (since newborn screening can only benefit patients who would otherwise have 
presented after 2 months of age), and to those diagnosable with a 31 CF 
transmembrane regulator (CFTR) mutation assay (as used in the Scottish Newborn 
Screening Laboratory).345 
Incremental cost estimates included staff costs (actual yearly salary costs adjusted for 
the proportion of time each member of staff devoted to CF screening), overheads 
(including equipment maintenance and capital charges), and consumables used in adding 
CF NBS to an established NBS programme (for phenylketonuria and congenital 
hypothyroidism) in Scotland. The costs of midwife or health visitor counselling, 
collection of blood spots, and health promotion are not included. Indirect costs 
(economic effects on carers, patients’ productivity, etc) were also not included.345 The 
perspective of the analysis was not explicitly mentioned. 
The main results were: 1) The cost of therapy for patients diagnosed by newborn 
screening was significantly lower than equivalent therapies for clinically diagnosed 
patients: mean $7228 vs $12 008 (95% CI of difference: −6736 to −2028, p<0·0001). 
Depending on the subgroup, this difference remained significant. And 2) When the 
clinically diagnosed group was limited to only those diagnosable with a 31 CFTR 
mutation assay and similar disease progression in the clinically diagnosed group as in the 
newborn screening group was assumed, the mean ($3 397 344) drug cost savings could 
have off set the estimated cost of adding CF to a UK national newborn screening 
service ($2 971 551). In other scenarios, these cost savings did not outweigh the CF 
NBS costs. The authors remark that CF NBS might have greater financial benefits to 
society than their estimate shows if indirect costs savings are included.345 
The authors conclude that newborn screening is associated with lower estimated 
treatment costs and reduced hospital admissions for invasive therapy than for clinically 
diagnosed patients. This also suggests that indirect costs and disruption to family life will 
also be less. According to these authors, universal newborn screening programmes for 
CF should be adopted internationally.345 
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9.2.6 Van den Akker et al., 2006346 
This economic evaluation, performed for the Netherlands, compares the cost and 
effects of 4 CF neonatal screening strategies and a no screening strategy. The four 
screening strategies are: IRT/IRT, IRT/DNA, IRT/DNA/IRT, and IRT/DNA/DGGE 
(denaturing gradient gel electrophoresis). Positive results and referral for sweat test are 
considered if:346 
• IRT/IRT: concentration of IRT from the second IRT measurement is 
above the cut-off level. 
• IRT/DNA: one or two CF mutations are detected. 
• IRT/DNA/IRT: two CF mutations are found or when the second IRT test 
is above the cut-off level (IRT performed if one mutation based on DNA). 
• IRT/DNA/DGGE: two CF mutations are identified, either by multiple 
mutation analysis or by the extensive gene analysis (DGGE if one 
mutation based on DNA). 
Results of the economic modelling exercise are expressed in costs per life-year gained. 
No CUA was performed since the authors did not find adequate estimates for health-
related quality of life in CF patients identified by screening compared with clinically 
detected patients. The model assessed the costs and number of life-years gained as a 
result of CF NBS for a hypothetical cohort of 200 000 neonates, i.e. the approximate 
number of children born annually in the Netherlands. The analysis was performed from 
a societal perspective. A lifetime time horizon was taken into account and all costs and 
effects were discounted at a 3% rate.346 
The following table provides an overview of the parameters used in their modeling 
exercise.  
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Table 20. Model parameters and values used in the model of Van den Akker 
et al.346 
Model parameters
Base case value Range used in 
sensitivity analysis
Probabilities
- Incidence of CF 0.0003 0.0002
- % newborns with meconium ileus 17 10 - 20
- Participation neonatal screening, % 99.5 95
- Sensitivity first IRT test, % 98 86 - 100
- Cutoff level first IRT test, daily percentile 99th
- Sensitivity second IRT test, % 92 88.5 - 95
- Specificity second IRT test, % 94 88.3 - 98
- % infants with positive IRT test who are carriers 6
- % CF patients with 1 mutation detected by DNA test 25
- % CF patients not detected by DGGE test 1
- CF mortality in childhood, % 6 3 - 10
- Reduction in childhood CF mortality because of screening, % 25 50
- % parents opting for genetic counseling 90
50
- Savings in lifetime costs of treatment because of screening, % 0 10
- % decrease in CF patients because of neonatal screening 10
50
- % pregnancies terminated when fetus affected with CF 69
Costs, € (2004 values)
- Adding CF screening to neonatal screening program 133116 75000 - 150000
- First IRT 4.79
- Second IRT 18.47
- DNA test 100 50
- DGGE test 500 300
- Sweat test 109.56
- Testing for carrier status 663.62
- Genetic counselling 449.24
- Clinical diagnosis CF 9096 7500 - 11 000
- Lifetime of treatment for clinically diagnosed patient 406266 812531
- Costs of prenatal diagnosis 1648
- Costs of terminating pregnancy 690
Others
- Annual No. of neonates 200000
40 (20.5) 35 (19.4) - 45 (21.8)
100
- % parents opting for carrier status testing after genetic 
counseling
- % decrease in CF patients in a situation with screening 
because of prenatal diagnosis
- No. of sweat tests for diagnosis of non-CF patients per 
clinically diagnosed CF patient
- No. of life-years gained per prevented death because of 
screening (3% discounting)
 
Source: Van den Akker et al., 2006346 
The model parameters were retrieved form literature, based on expert opinions or on primary 
data collection. We refer to the original manuscript for original sources of parameter values. 
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For the situation without screening, information about the number of hospital days and 
the medical procedures performed in the diagnostic process was reviewed in 36 
patients. Multiplying the numbers of hospital days (not mentioned) with the 
hospitalization cost (not mentioned) and adding the costs of medical procedures 
resulted in an average diagnostic cost of €9096 per patient diagnosed with CF. 
Furthermore, the non-screening scenario included the cost of 100 sweat tests for each 
clinical CF patient diagnosed.346 
The costs of including neonatal screening for CF in the existing neonatal screening 
program was based on the costs of adding screening for congenital adrenal hyperplasia 
to the neonatal screening program in the Netherlands (€133 116 per year). These costs 
include the costs of a medical consultant, administration costs, and evaluation costs. No 
costs were included for changing the information leaflet since it is updated regularly. For 
the second IRT test (€18.47), it was assumed that a new blood spot has to be collected 
by the district nurse at the child health clinic. This figure includes the cost of the 
laboratory, the cost of the district nurse (15 minutes), and travel and time (30 minutes) 
for one of the parents. The costs of the sweat test (€109.56) include pediatric 
consultation, laboratory costs, and parents’ travelling expenses and time (60 minutes). 
Also the costs of genetic counselling (€449 per couple) and testing parents for carrier 
status (€664) include parents’ travelling expenses and time (60 minutes). The costs of 
the multiple mutation tests (€100) and DGGE tests (€500) include the cost of DNA 
extraction, DNA analysis, laboratory space, equipment, reagents, supplies, licenses, 
technical and administrative personnel, and new technical advances. Costs incurred 
during life-years gained because of neonatal CF screening are not included in the 
analysis.346 
One of the main assumptions was a gain of 40 life-years per CF death prevented by 
neonatal screening (excluding benefits for CF patients with MI which do not benefit 
from neonatal screening). Furthermore, a 6% CF mortality (range 3% – 10%) in 
childhood and a 25% reduction (changed to 50% in sensitivity analysis) in childhood CF 
mortality because of screening were assumed.346 
Both univariate and multivariate sensitivity analyses were performed. In the probabilistic 
multivariate sensitivity analysis, a uniform distribution was assumed for the parameters 
between the lower and upper values. In a scenario analysis, the costs and effects of 
changes in reproductive decisions because of neonatal screening were also assessed.346 
The CEA finds the most favorable ICER for the IRT/IRT protocol: €24 800 per life-year 
gained. Compared to no screening the ICER for the other strategies is as follows: IRT-
DNA: €38 300/LYG; IRT-DNA-IRT: €39 800/LYG; and IRT-DNA-DGGE: 
€33 000/LYG. Working on the efficiency frontier (i.e. comparing with the previous most 
cost-effective alternative) IRT-DNA-IRT is excluded by extended dominance. The ICER 
of IRT-DNA-DGGE (compared with IRT-IRT) becomes €130 700/LYG and for IRT-
DNA (compared with IRT-DNA-DGGE) becomes €2 154 300/LYG.346 
Results were most sensitive to the uncertainty about whether screening for CF will lead 
to savings in lifelong costs of treatment, the lifelong costs of treatment of clinically 
diagnosed patients, mortality in early childhood because of CF in a situation without 
screening, and the reduction in childhood mortality as a result of screening for CF. 
Changing the CF mortality in childhood to 3% would result in a less favourable ICER of 
€49 600/LYG. Also changing the IRT threshold has a large impact on results. Changing 
the IRT threshold to the 95th daily percentile would result in an ICER of €40 400/LYG. 
Finally, in the scenario where changes in reproductive decisions as a result of neonatal 
screening were also taken into account, this study finds that CF neonatal screening may 
lead to financial savings (~€1.8 million annually, depending on the screening strategy 
used).346 
The authors conclude that NBS for CF is economically beneficial, and positive health 
effects are expected as a result of the screening. IRT/IRT and IRT/DNA/DGGE are the 
most cost-effective strategies. 
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9.2.7 Discussion 
In our overview, only studies comparing with the no-screening alternative were 
included. Exclusion of the no-screening alternative seems inappropriate, as the type and 
scale of the benefits of CF screening remain uncertain.344 The lack of data on CF 
screening benefits is a major problem to calculate the intervention’s cost effectiveness. 
Several studies solved this problem by only looking at the costs to diagnose CF cases 
without including the impact of (possible) benefits. We looked at studies that concluded 
that screening reduced the costs per diagnosed case. If this would be the case, then 
screening could be supported, i.e. an intervention that is cheaper, has potential benefits 
and risks or harms are limited. 
The first study of Dauphinais et al., 1992341 compared the costs of 16 non-screened 
patients with a delayed diagnosis of 1.5 months to 21 years versus IRT screening costs. 
A major problem with this study is the difference in time horizon between the two 
groups. The costs of the non-screened group of CF patients were accrued over a 
period of 1.5 to 253 months. In contrast, the time window is only a couple of months 
for the screening group. A comparison of costs over very different time periods is not 
appropriate and therefore, results are not reliable.341 Furthermore, the comparability of 
populations in the non-screened and screening group is questionable.  
The cost analysis of Farrell et al., 1992342 also finds that screening might be cheaper: a 
one-tier protocol (IRT) would cost $130,400 to screen 75,000 newborns, a two tier 
IRT/DNA protocol would cost $126,770 and without screening their analysis revealed a 
total cost of $182,030. The number of sweat tests was assumed to be 150 and 50 for 
the IRT and IRT/DNA protocol, respectively. Without screening this was 1,670. The 
latter was determined by a hospital survey in 1991. The costs of the IRT and IRT/DNA 
analysis are however underestimated. The 2000 hospital survey343 revealed that in the 
screening program, next to follow-up evaluations, still another 804 sweat tests were 
performed. Only looking at the laboratory costs, e.g. excluding the extra costs of 
genetic counselling, this would already make the screening protocols more expensive 
than no screening. This illustrates the difficulty in answering the question of whether or 
not neonatal screening for CF will reduce (direct) medical costs and that the in- or 
exclusion of certain cost data may completely alter the results.  
A more elaborated cost analysis of the same research group performed about 10 years 
later included the extra costs of these sweat tests.343 The previous analysis342 applied an 
average sweat test charge of $56 and assuming an extra "sick visit" per sweat test in the 
primary care physician's office ($53). In the more recent analysis, these costs increased 
to $161.40 for a sweat chloride test. The analysis indicated that a CF newborn 
screening program could be a potentially cost-saving alternative to the traditional 
method of diagnosis of CF. However, as for the other analysis, a lot of important cost 
factors are not included. For example, almost all studies did not include the expenses 
for genetic counselling.343-345 The same remark is true for a lot of other aspects such as 
the influence of false-positives and false-negatives with screening, the delay in diagnosis 
and expenses for other tests without screening, etc. 
The cost analysis of Sims et al.345 included in this review illustrates the problem of 
comparability between population. Children identified by use of newborn screening are 
not comparable with those identified by clinical presentation because the former 
probably includes more patients with mild disease.348 The same criticism applies to the 
other cost and cost-effectiveness studies. The models explicitly or implicitly assume that 
the CF diagnosed patients are a relatively homogeneous group. However, as mentioned 
by Simpson et al.344 the spectrum of cases ranges from neonates that are severely 
affected, to cases who live a normal life undiagnosed until adulthood. It is possible that 
the more severe but asymptomatic cases would benefit most from early diagnosis. 
Those with milder forms of the disease would be diagnosed later under the no-
screening strategy and would have their age at diagnosis advanced most under 
screening.344 The authors could not investigate this issue with the available data and 
ignored this issue. However, this may bias the outcome of analyses. Results and 
conclusions of analyses comparing costs of two possibly incomparable patient groups 
should be interpreted cautiously.  
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Only two analyses344, 346 performed a full economic evaluation including both costs and 
effects of one or more screening protocols versus the no-screening alternative. Only 
Simpson et al.344 include QoL for several health states. However, for the asymptomatic 
states, utility weights are arbitrary or derived from non-CF specific health surveys. For 
the symptomatic disease state and the severe irreversible lung disease-state, reference 
is made to two publications published about two decades ago.349, 350 The analysis of Van 
den Akker et al. did not perform a CUA since they did not find adequate estimates for 
health-related quality of life in CF patients identified by screening compared with 
clinically detected patients.346 Good information on the QoL impact of screening versus 
no screening is currently lacking. 
Similar to the other analysis, Simpson et al. do not include all relevant items that have an 
influence on costs and effects, mainly because information is still lacking. For example, 
they also excluded time for genetic counselling because of difficulties to quantify the 
impact and because they argue that this cost would only be small in relation to total 
screening costs. However, if the number of false positives is relatively large, this costs 
should not be underestimated. Furthermore, in their analysis they assume that there are 
no false positives. This is a rather optimistic scenario, probably not reflecting reality. 
Another very important assumption is the modelled treatment effect: an increased 
annual transition probability of remaining without symptoms (in early-diagnosed cases) 
of 10% (range 10-40%). This results in a 69% probability of remaining pre-symptomatic 
with screening versus 59% in the symptomatically diagnosed CF population. As the 
authors conclude, the intervention may be cost effective if the hypothesised delays are 
confirmed. In other words, the analysis has to be interpreted as a hypothetical analysis. 
The problem of lack of data is reflected in the absence of state-of-the art probabilistic 
sensitivity analysis. Simpson et al.344 mention they have not performed such analysis due 
to the lack of data reflecting the uncertainty around the mean estimates for input 
variables. Furthermore, the used ranges of values for some key variables may be 
unrealistic. For example, Simpson et al. only increased the hypothetical base case 
treatment effect up to 40% (no lower treatment effect was modelled). With a 59% 
transition probability for those diagnosed symptomatically, this results in a 99% 
transition probability of remaining without symptoms for the CF population diagnosed 
through screening.344 
The study of Van den Akker et al.346 has the same merits and shortcomings of the 
previous discussed study: it tries to make an estimation of CF screening’s cost 
effectiveness but it remains a hypothetical analysis. The main assumptions are: 1) there 
is a 25% reduction in childhood CF mortality because of screening; and 2) the number 
of life-years gained per prevented death because of screening is 40 years. With current 
available evidence, the impact on mortality is uncertain. Furthermore, the baseline risk 
for CF mortality in childhood was set at 6% in this analysis, ranging from 3% to 10%. 
Current treatments of CF are probably better than a decade ago. Lowering the 
mortality risk of the comparator lowers the possible gains by introducing screening. The 
ICER for the IRT/IRT protocol increased from €24 800/LYG to €49 600/LYG applying a 
6% or 3% CF mortality risk in childhood, respectively (note: ‘childhood’ is not defined). 
It would be interesting to know the real-world CF mortality risk (for the Belgian 
population) with current available treatment options and optimal/timely referral of 
patients to specialised centres. Currently, the estimated 10-year mortality would be 
about 2% with a very small percentage also being identified through screening. Reducing 
the baseline mortality risk without screening deteriorates the intervention’s cost 
effectiveness. Finally, the problem of reaching patients for a second IRT test was also 
not taken into account. Up to 20% of patients may be lost for this examination.250 In 
France this number was reduced to 3.2%. In the local CF screening initiative in Brussels  
this may be as high as 15% (personal communication, A. Meulemans). This will also have 
a negative impact on the intervention’s cost effectiveness. On the other hand, other 
possible positive effects are also not included in the analyses (e.g. the costs of the 
diagnostic odysseys). 
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The report of the Dutch Health Council 
(http://www.gezondheidsraad.nl/en/publications/neonatal-screening-cystic-fibrosis) 
mentions that some aspects of the cost calculation are uncertain. If screening results in 
a decrease in treatment costs, it might lead to costs savings. A related (but not-yet-
published) article assesses the costs of three neonatal screening strategies (IRT-PAP, 
IRT-DNA-EGA, IRT-PAP-DNA-EGA) for CF in relation to health effects (personal 
communication). It concludes that neonatal screening for CF leads to financial savings in 
comparison to a situation without screening. Similar as for the previous studies, the 
outcomes mainly depend on the assumptions that are made, based on expert opinion. 
For example, in this Dutch study, it is assumed that costs for about 3000 sweat tests 
without screening would disappear if screening is introduced. This can be questioned, 
especially because screening is not 100% sensitive eg cases with bronchitis suspected of 
CF, will still exist after screening is introduced. It is also assumed that CF treatment 
costs would decrease with about 0% - 5% due to screening. Nevertheless, CF treatment 
costs may both increase or decrease, depending on whether or not mild and/or severe 
cases are detected, how much morbidity actually decreases because of early referral to 
optimal treatment, etc. In short, there are many uncertain arguments/assumptions that 
may make the outcome of the cost-effectiveness calculation positive or negative. 
The published results on CF screening may look promising. However, results of the 
costs analyses depend on assumptions, the cost items included and their valuation. 
Furthermore, comparability of the screening and no-screening group remains a 
challenge and should be interpreted with caution. For the economic evaluations, results 
mainly depend on the assumed treatment effects. The models rather reflect hypothetical 
situations, not supported by reliable evidence. This lack of reliable data remains a major 
problem to calculate the intervention’s cost effectiveness. In the following chapter, 
several uncertain elements that may determine the intervention’s cost effectiveness are 
listed. 
Key points 
• Cost analyses face the problem of possible incomparability of CF patients 
diagnosed through screening versus symptomatic diagnosis. 
• Results of cost analysis depend on the included cost items and their 
valuation. 
• There is a lack of reliable evidence to feed the economic models. Especially 
the effect of screening without interference of an improved treatment over 
time is unclear. 
• The published economic evaluations should be interpreted as hypothetical 
analyses since the values of most important parameters (e.g. treatment 
effect) are based on assumptions. 
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10 ECONOMIC ASPECTS OF NEWBORN 
SCREENING FOR CYSTIC FIBROSIS IN 
BELGIUM 
10.1 COST EFFECTIVENESS 
The review of the economic literature has shown that there is a lack of reliable 
evidence to feed the economic models. Therefore, the published economic evaluations 
should be interpreted as hypothetical analyses since the values of most important 
parameters (e.g. treatment effect) are based on assumptions. There are both items that 
will/can increase or decrease costs and effects if CF NBS would be implemented. 
However, for most of these items it is difficult to quantify their exact impact in 
monetary terms or their influence on (quality-adjusted) life-years. Instead of making a 
hypothetical calculation of the incremental cost-effectiveness ratio for which most input 
parameters (and thus results) can be questioned, a non-exhaustive overview is given of 
elements that might have an influence on costs and/or effects (Table 21). A positive sign 
indicates the influence would be positive (i.e. decreases costs or increases effects) and 
vice versa. 
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Table 21. Items which might have a positive or negative effect on costs and/or 
effects if screening is introduced 
Item Impact on costs Impact on effects
cost/effect neutral
education of midwives/nurses no incremental cost
information leaflet no incremental cost
Guthrie cards no incremental cost
informed consent no incremental cost
taking blood sample no incremental cost
follow‐up of patients in registry no incremental cost if already present
etc.
negative impact on costs and/or effects
tests in screening protocol ‐: incremental cost
false positives ‐: retesting, counselling ‐: psychosocial effects
false negatives ‐: diagnostic odysseus ‐: relatively late diagnosis
counselling ‐: incremental cost
genetic counselling (e.g. IRT/DNA 
protocol)
‐: incremental cost ‐: psychosocial effects
recall (e.g. IRT/IRT protocol) ‐: incremental cost
contacting physician for patients with 
abnormal test result
‐: incremental cost
coordination of screening programme ‐: incremental cost
supervision of screening programme ‐: incremental cost
set up an audit/control system ‐: incremental cost
etc.
positive impact on costs and/or effects
tests for undiagnosed patients with 
symptoms
+: less sweat tests if (most) patients 
already identified through screening
avoiding diagnostic odysseus +: avoidance of other (expensive) 
diagnostic tests and/or treatments
+: psychosocial effects
future pregnancies +: decrease in CF prevalence (and thus 
treatment costs)
+/‐: psychosocial effects
burden of care +: could be lower if symptoms are more 
under control
+: less severe treatment
‐: could be higher if 'overdiagnosis' of 
cases (that otherwise would never be 
identified)
‐: overly aggressive treatment 
(medicalisation of society)
hospitalisations +: could be reduced +: positive impact on QoL if less 
hospitalisations
‐: could increase due to more planned 
hospitalisations (e.g. for administration 
intravenous antibiotics)
‐: negative impact on QoL if more 
hospitalisations
pulmonary status, nutritional benefits, 
cognitive development
+: possibly less treatment costs +: possibly positive impact on QoL if 
improved situation
mortality +: possibility to gain life years
etc.
Determining factors
Incidence
Part of MI or mild CF No/less benefit of screening
Current situation without screening
Screening protocol
(timely) referral identified patients to 
treatment centres
Cost of tests
Heterogeneity of population
Carrier screening (on a large scale)
etc.
Less benefit for neonatal screening if parents already screened.
Possibility of overshooting with screening
The better the identification of patients (based on e.g. family history or symptoms) , 
Lower incidence will result in a lower possible impact on a population level of 
Tests included, cut‐off levels, etc. will influence both costs and effects.
Necessary to have a positive impact of identifying patients.
Importance of low cost, scale and scope effects
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Some of these items would very probably not be an incremental cost, such as: education 
of midwives/nurses if this is included in the training sessions for other screened 
diseases, adaptation and distribution of the existing information leaflet if it is made up-
to-date and reprinted on a regular basis, purchase of the Guthrie cards, providing 
informed consent and taking the blood sample since this already happens in the 
currently running screening programme. It is clear that the presence of an existing 
screening programme reduces the incremental costs of an extra test. Of course the 
pro’s and con’s, both from a medical and economic point of view, should be regarded. 
Explicitly doing so is currently not possible due to a lack of reliable data for most of 
these elements.  
10.2 BUDGET IMPACT 
In this part, the budget impact of NBS CF is calculated. This exercise is performed for 
the proposed Belgian CF NBS algorithm (Figure 9) and the IRT-PAP-DNA algorithm 
(Figure 10). Cost data are gathered for the tests that occur in these protocols. Cost 
estimates are based on data received from two laboratories (AZ Brugge-Oostende and 
ULB). We would like to acknowledge Dr. Dirk Bernard and Dr. Ann Meulemans for 
their willingness, time and efforts to gather relevant cost data.  
We would like to remark that this exercise is a simplified costing exercise. Data for 
each test is based on input data from one laboratory. Certain data are based on 
invoices, and thus reflect real-world situation. However, other data are based on expert 
opinion (e.g. time needed for certain acts), while better and more reliable but also more 
time-consuming approaches exist (e.g. timekeeping of the necessary time to perform a 
certain activity). Some costs are based on information received from the producer, 
while for other items included costs reflect negotiated prices. For some of these items, 
(further) price negotiations may be possible if implemented on a larger scale. 
Uncertainty around cost parameters, estimated equipment service life, and other 
parameters was left out of consideration. Once there is more certainty on whether or 
not to introduce NBS CF and the preferred protocol, more detailed cost data (from 
several laboratories) may be gathered and an improved costing exercise including 
parameter uncertainty could be performed. Nevertheless, this budget impact exercise 
provides a first general idea of the possible budget impact. 
10.2.1 Costs for individual tests 
Costs were expressed in 2010 (April) values using the Health Index (Table 22). 
Table 22. CPI and Health Index 
Year CPI Health Index
1996 100.00 99.97
1997 101.63 101.29
1998 102.60 102.58
1999 103.75 103.54
2000 106.39 105.49
2001 109.02 108.38
2002 110.81 110.32
2003 112.57 111.92
2004 114.93 113.74
2005 118.13 116.21
2006 120.25 118.26
2007 122.44 120.35
2008 127.94 125.44
2009 127.87 126.18
2010* 130.25 127.81  
*: April 2010; CPI: Consumer Price Index 
Source: http://statbel.fgov.be/ 
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The tests that occur in (one of) the two screening protocols are the following: IRT, 
DNA, PAP and sweat test.  
For the IRT test, both a calculation of a manual and automatic test are provided. For the 
manual test, it is assumed that the equipment was used for a total of 10100 tests per 
year (AZ Brugge-Oostende laboratory). For the automatic test, 75740 tests were 
performed (ULB laboratory: T4: 2585 patients, 17a-OH: 18828 patients, TSH: 30001 
patients and IRT: 24326) 
The estimated cost for a ‘manual’ IRT test is €2.55 if the equipment costs are not 
included (i.e. if they are not interpreted as an incremental cost), and otherwise €3.95: 
i.e. €1.28 (reagents), €1.27 personnel, and €1.40 equipment ((€8 761 + €5 127 + 
€234)/10100) (Table 23). For an ‘automatic’ IRT test the cost is €2.00 if the equipment 
costs are not included (i.e. if they are not interpreted as an incremental cost), and 
otherwise €2.19: i.e. €1.33 (reagents and consumables), €0.40 (software), €0.27 
personnel, and €0.19 equipment ((€7 829 + €6 455 + €234)/75740) (Table 24). 
Whether or not the equipment is already used for (several) other tests and whether or 
not these costs  are interpreted as incremental costs clearly has an impact on the 
calculated costs per test. The costs for reagents represent a relatively large part in the 
calculated incremental costs. There was some disagreement about the time needed for 
validation and communication of results which might be underestimated. More refined 
costing approaches might provide more reliable data. Furthermore, other approaches to 
perform this test are also possible, e.g. Elisa Classic, but not regarded in our 
calculations. 
Table 23. IRT test (manual) 
Cost items Cost
Year of 
information
Indexation to 
2010 (April)
Estimated 
longevity
Source
Equipment
Investment cost & depreciation € 8761/year
Puncher € 20 651 2007 € 21 931 5 years invoice
Diskwasher & remover € 7 556 2008 € 7 699 5 years invoice
Shaker € 1 805 2003 € 2 061 10 years invoice
Victor D fluorometer € 22 688 2002 € 26 284 10 years invoice
Maintenance of equipment € 5127/year
Puncher € 2 275 2010 € 2 275 yearly invoice
Diskwasher & remover /
Shaker /
Victor D fluorometer € 2 853 2010 € 2 853 yearly invoice
Disposables substances € 234/year
Head of puncher € 1 171 2010 € 1 171 5 years inquiry
reagents € 1.28a 2010 € 1.28 per test
Personnel
Estimated 
time
Time on 
yearly basis
Time/test Cost/hour Source
MLT ~70 minutes/76 samplesb 1 minute/test € 37.5 expert opinion
Clinical biologistc 1h/week 52 hours 0.31 minute/test € 125.0 expert opinion
€ 1.27/test
Personnel cost Yearly cost Hours/yeard
MLT € 60 000 1600 hours
Clinical biologist € 200 000 1600 hours
estimate HR 
departmente
invoice and 
expert opinion
 
MLT: Medical laboratory technologist 
a: (€995 x 13kits)/10100 patients = €1.28 per patient. The cost per IRT kit is €995 (incl. 
21%TAV). 13 kits (960 tests per kit) would be used for 10100 patients (based on the number of 
TSH kits used for this number of patients). The surplus of tests (960 x 13 = 12480) is used for 
calibration and checks. 
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b: The time needed by the MLT was measured for 76 samples (starting the test, punching the 
cards, adding reagents, etc.). The MLT needed about 70 minutes, i.e. on average less than one 
minute per sample. 
c: One hour per week, 52 weeks, for 10100 patients (Validating results, checking protocol, 
communicating results, staff meeting, etc.). 
d: One full-time equivalent equals about 1650 hours per year. Taking into account sickness, 
absence, reduction of working hours, seniority, etc. this becomes about 1600 hours. 
e: Personnel costs are a rough estimate. Data can vary widely across hospitals. 
Table 24. IRT test (automatic) 
Cost items Cost
Year of 
information
Indexation to 
2010 (April)
Estimated 
longevity
Source
Equipment
Investment cost & depreciation € 7829/year
AutoDelfia and puncher € 76 835 2008 € 78 287 10 years invoice
Maintenance of equipment € 6455/year
AutoDelfia and puncher € 6 373 2009 € 6 455 yearly invoice
Disposables substances € 234/year
Head of puncher € 1 171 2010 € 1 171 5 years inquiry
€ 1.33/test
neonaltal IRT kit, Whatman 904 € 1 119 2010 € 1 119 for 1008 testsa,b invoice
Eppendorf pipette tips € 143 2010 € 143 for 1008 testsc invoice
autodelfia wash concentrate € 519 2010 € 519 for 1008 testsd invoice
autodelfia enhancement solution € 1 198 2010 € 1 198 for 1008 testse invoice
new dilution vessels (100/package) € 114 2010 € 114 for 1008 testsf invoice
€ 0.40/test
Others: softwareg € 30 000 yearly rough estimate
Personnel
Estimated 
time
Time on 
yearly basis
Time/test Cost/hour Source
MLT ~4 hours/1008 samplesh 0.24 minute/test € 37.5 expert opinion
Clinical biologist ~1 hour/1008 samplesi 0.06 minute/test € 125.0 expert opinion
€ 0.27/test
Personnel cost Yearly cost Hours/yearj
MLT € 60 000 1600 hours
Clinical biologist € 200 000 1600 hours
estimate HR 
departmentk  
MLT: Medical laboratory technologist 
a: 168 samples per run, i.e. 96 samples per plate, two plates each time, 12 for checking and 12 for 
calibration. Six runs (i.e. 12 plates per kit), i.e.168 x 6 = 1008 samples per kit. 
b: €1.11/test, i.e. €1119.25/1008. 
c: €0.01/test, i.e. ((€142.78/960)x48)/1008. €142.78 is the price for 960 tips, 8 tips needed for 
two plates (or 48 tips needed for 1008 samples). 
d: €0.05/test, i.e. ((€519.09x7)/75.1)/1008. €519.09 per kit and 7 kits needed for four tests (T4, 
17a-OH, TSH and IRT). For these four tests, 75.1 kits are needed (T4: 2.6 kits (2585 
patients/1008), 17a-OH: 18.7 kits (18828 patients/1008), TSH: 29.8 kits (30001 patients/1008) and 
IRT: 24.1 kits (24326 patients/1008). 
e: €0.16/test, i.e. ((€1197.90x10)/75.1)/1008. €1197.90 per kit and 10 kits needed for four tests 
(T4, 17a-OH, TSH and IRT). For these four tests, 75.1 kits are needed (see previous remark). 
f: €0.01/test, i.e. ((€113.74/100)x6)/1008. €142.78 is the price for 100 vessels, 6 vessels needed 
for 6 runs (i.e. for 1008 samples). 
g: €0.40 per test, i.e. €30000/75740. 75740 tests are performed (T4: 2585 patients, 17a-OH: 
18828 patients, TSH: 30001 patients and IRT: 24326). 
h: ~40 minutes for 168 samples (punching, starting PC, reporting abnormal results, etc.) 
i: 10 minutes for 168 samples (Validating results, checking protocol, communicating results, staff 
meeting, etc.). 
j: One full-time equivalent equals about 1650 hours per year. Taking into account sickness, 
absence, reduction of working hours, seniority, etc. this becomes about 1600 hours. 
k: Personnel costs are a rough estimate. Data can vary widely across hospitals. 
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For DNA, the costs items are provided in Table 25. The cost per test will, among 
others, depend on the total number of tests and the number of tests per batch 
The latter depends on how many centres will perform this test and if this happens e.g. 
weekly or every two weeks. For example, if about 600 tests are needed on a yearly 
basis, one centre can handle this and the costs per test will be somewhere between the 
costs calculated in scenario 2 and 3 (in which on average 650 tests are provided). This 
results in an average estimated cost per DNA test of €150 or €196, depending on 
whether or not the equipment costs are interpreted as incremental costs. This would 
be on average €150 or €242 if two centres perform about half of these tests (the 
average cost of scenario 6 and 7 which also provides an average of 650 tests if two 
centres are performing the test). This has an influence on the average costs if the 
equipment costs are included (i.e. being interpreted as incremental costs). In other 
words, whether or not the equipment is already available will have a relatively large 
impact on costs per test and thus total costs. 
If 170 DNA tests are needed, and taking into account a small overcapacity, one centre 
could handle this. The average of scenario 5 and 6 results in 195 yearly samples with an 
average cost of €176 or €342, again depending on ex- or inclusion of equipment costs.  
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Table 25. DNA test (part A) 
Cost items Cost
Year of 
information
Indexation to 
2010 (April)
Estimated 
longevity
Source
Equipment
Investment cost & depreciation € 16588/year
qiasymphony € 75 988 2009 € 76 970 7 years invoice
incubator € 12 100 2010 € 12 100 10 years expert opinion
ABI9700 € 6 733 2010 € 6 733 5 years invoice
autolipa € 30 353 2010 € 30 353 10 years invoice
Maintenance of equipment € 12079/year
qiasymphony 10% € 7 697 yearly expert opinion
incubator / / / expert opinion
ABI9700 20% € 1 347 yearly expert opinion
autolipa 10% € 3 035 yearly expert opinion
Disposables substances € 85.89/test
qiasymphonya € 9.44 2010 € 9.44 per test expert opinion
incubator / / / expert opinion
ABI9700 € 1.00 2010 € 1.00 per test expert opinion
autolipa CFTR19 testb € 60.25 2010 € 60.25 per test invoice
traysc € 10.20 2010 € 10.20 per test invoice
template stripsd € 3.00 2010 € 3.00 per test invoice
TAQ-polymerase € 2.00 2010 € 2.00 per test expert opinion
Personnel
Estimated 
time
Cost/hour total cost Source
MLT sampling 2.5h/batche € 37.5 € 93.8 expert opinion
amplification 1.5h/batch € 37.5 € 56.3 expert opinion
autolipa 1.5h/batch € 37.5 € 56.3 expert opinion
Clinical biologist 1.5h/week € 125.0 € 187.5 expert opinion
Molecular biologist 15minutes/sample € 125.0 € 31.3 expert opinion
Personnel cost Yearly cost Hours/yearf
MLT € 60 000 1600 hours
Clinical/molecular biologist € 200 000 1600 hours
estimate HR 
departmentg  
MLT: Medical laboratory technologist 
a: €9.44/test, i.e. (€7.5x1.21)x1.04 (i.e. €7.5 excl. 21%TAV and another 4% for checking). 
b: €60.25/test, i.e. €1205 (incl. TAV) for 20 tests (19 mutations). 
c: €10.20/test, i.e. €255 (incl. TAV) for 25 trays. 
d: €3/test, i.e. 75€ (incl. TAV) for 25 strips. 
e: Scale effect: it is assumed that 5 to 20 samples can be incorporated per batch and processed in 
about the same time. 
f: One full-time equivalent equals about 1650 hours per year. Taking into account sickness, 
absence, reduction of working hours, seniority, etc. this becomes about 1600 hours. 
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Table 26. DNA test (part B) 
Cost per 
analysis
samples/ 
batch
batches/ 
year
samples/ 
year
equipment
a
disposables
b
personnel
c
Total 
(incl. eq.)
Total 
(excl. eq.)
scenario 1 5 52 260 € 110 € 86 € 110 € 306 € 196
scenario 2 10 52 520 € 55 € 86 € 71 € 212 € 157
scenario 3 15 52 780 € 37 € 86 € 58 € 180 € 143
scenario 4 20 52 1040 € 28 € 86 € 51 € 164 € 137
scenario 5 5 26 130 € 221 € 86 € 110 € 416 € 196
scenario 6 10 26 260 € 110 € 86 € 71 € 267 € 157
scenario 7 15 26 390 € 74 € 86 € 58 € 217 € 143
scenario 8 20 26 520 € 55 € 86 € 51 € 192 € 137  
a: Total equipment cost is €28667 (€16588 + €12079). This amount is divided by the number of 
yearly test (e.g. €28667/260=€110) 
b: see previous table 
c: personnel costs: (((cost per batch x batches per year) + (cost per week x batches per 
year))/samples per year) + cost per sample (see cost items in previous table). E.g. €110 = 
((€93.8+€56.3+€56.3+€187.5)x52)/260 + €15.6 
The costs for the PAP test exclude equipment costs (both investment and 
maintenance), again not being interpreted as incremental costs. As such, total costs per 
test would be about €7.59 per test. The test kit represent the largest part of this cost. 
Table 27. PAP test 
Cost items Cost
Year of 
information
Indexation to 
2010 (April)
Estimated 
longevity
Source
Equipment
Investment cost & depreciation no incremental cost expert opinion
Maintenance of equipment no incremental cost expert opinion
Disposables substances € 6.08/test
MucoPAP ELISA kits € 12 015 2010 € 12 015 for 1975 testsa invoice and 
expert opinion
Personnel
Estimated 
time
Time/test Cost/hour Source
MLT 2h38minutes/79 samplesb 2 minutes/test € 37.5 expert opinion
Clinical biologist 10minutes/79 samples 0.13 minute/test € 125.0 expert opinion
€ 1.51/test
Personnel cost Yearly cost Hours/yearc
MLT € 60 000 1600 hours
Clinical biologist € 200 000 1600 hours
estimate HR 
departmentd  
MLT: Medical laboratory technologist 
a: €6.08/test, i.e. €12015/1975. The total cost for 25 kits was €12015 (€9930 excl. 21% TAV). 
Each kit contains 96 samples of which 79 are used (i.e. excluding controls). 
c: One full-time equivalent equals about 1650 hours per year. Taking into account sickness, 
absence, reduction of working hours, seniority, etc. this becomes about 1600 hours. 
d: Personnel costs are a rough estimate. Data can vary widely across hospitals. 
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For the sweat test, the costs are calculated relying on the assumption that the number 
of yearly analyses would be about 400, i.e. 50 weeks of testing, four patients per week 
and two tests per patient. Accounting the cost of €29 336 (€1 759 + €3 147 + €7 139 
+ 18 333 (Table 28)) to these 400 test results in an estimated cost of €76.94. Adding 
another €1 for small material like recipient and gauze (rough estimate, expert opinion) 
and providing two tests per patient results in €204.30 per patient. Excluding the 
equipment costs this would become €125.85. In contrast, the nomenclature provides 
the following codes: 545753-545764 (€15.55 per act, 2 times), 593154 (€32.87) and 
593176 (€7.68), or a total fee of €71.65 per patient. Note that the wording of the 
nomenclature code 545753-545764 is not clear with regard to the testing of two 
independent samples, as is recommended by international guidelines. Health insurers 
however commonly accept to reimburse two such acts. 
Table 28. Cost sweat test 
Cost items Cost
Year of 
information
Indexation to 
2010 (April)
Estimated 
longevity
Source
Equipment
Investment cost & depreciation € 1759/year
Flame photometer € 6 749 2001 € 7 959 10 years invoice
Cl-titrator € 6 000 2010 € 6 000 10 years inquiry
Collectora € 3 630 2010 € 3 630 10 years inquiry
Maintenance of equipment € 3147/year
Flame photometer - contract € 1 321 2009 € 1 338 yearly invoice
- work € 834 2009 € 845 yearly invoice
Cl-titrator 10% € 600 yearly expert opinion
Collector 10% € 363 yearly expert opinion
Disposables substances € 7139/year
Flame photometer € 363 2009 € 368 yearly invoice
€ 261 2009 € 265 yearly invoice
€ 162 2009 € 164 yearly invoice
Cl-titrator € 55 2009 € 56 yearly invoice
€ 2 723 2009 € 2 758 yearly invoice
€ 69 2009 € 70 yearly invoice
€ 2 723 2009 € 2 758 yearly invoice
Collectorb € 50.42 2010 € 50.42 per patient inquiry
Others: Checking € 1 384 2009 € 1 402 2 years invoice
Personnel
Estimated 
time
Time on 
yearly basis
Cost/hour Source
MLT sampling 4h/week 200 hours € 37.5 expert opinion
measurements 4h/week 200 hours € 37.5 expert opinion
otherc 40min/week 33 hours € 37.5 expert opinion
Clinical biologistd 20min/week 17 hours € 125.0 expert opinion
€ 18333/year
Personnel cost Yearly cost Hours/yeare
MLT € 60 000 1600 hours
Clinical biologist € 200 000 1600 hours
estimate HR 
departmentf  
MLT: Medical laboratory technologist; a: Macroduct sweat collection system 
b: Macroduct supply kit: € 125 (excl. 21% taxes) for 6 samples and 2 samples are needed per 
patient. 
c: Weighing samples, ordering reagents, writing/adjusting protocol, etc. 
d: Validating results, checking protocol, communicating results, staff meeting, etc. 
e: One full-time equivalent equals about 1650 hours per year. Taking into account sickness, 
absence, reduction of working hours, seniority, etc. this becomes about 1600 hours. 
f: Personnel costs are a rough estimate. Data can vary widely across hospitals. 
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10.2.2 Costs for NBS CF protocols 
The total costs to perform several tests are shown in Table 29. Only the calculated 
costs to perform the tests are included in these tables. Ex- or inclusion of equipment 
costs (i.e. interpreting them as incremental costs or not) clearly has an important 
impact on total costs. Relying on existing infrastructure might limit extra costs. The 
alternative screening algorithm with PAP testing might lower total costs if this results in 
less DNA and sweat tests. 
Table 29. Budget impact 
Proposed Belgian CF NBS algorithm (see also Figure 9) 
Number 
of tests
excl. eq. incl. eq. excl. eq. incl. eq.
IRT manual 120000 € 2.55 € 3.95 € 305 852 € 473 642
automatic € 2.00 € 2.19 € 240 283 € 262 914
excl. eq. incl. eq. excl. eq. incl. eq.
DNA 1 centre, once a week 600 € 150 € 196 € 89 970 € 117 534
2 centres, every 2 weeks € 150 € 242 € 89 970 € 145 098
excl. eq. incl. eq. excl. eq. incl. eq.
IRT manual 120 € 2.55 € 3.95 € 306 € 474
automatic € 2.00 € 2.19 € 240 € 263
excl. eq. incl. eq. excl. eq. incl. eq.
sweat test 75 € 126 € 204 € 9 439 € 15 323
min max
Total € 339 932 € 634 536
Type of test Cost per testa Budget impact
 
IRT-PAP-DNA algorithm 
Number 
of tests
excl. eq. incl. eq. excl. eq. incl. eq.
IRT manual 120000 € 2.55 € 3.95 € 305 852 € 473 642
automatic € 2.00 € 2.19 € 240 283 € 262 914
PAP 6000
excl. eq. incl. eq. excl. eq. incl. eq.
DNA 1 centre, every 2 weeks 170 € 176 € 342 € 29 954 € 58 069
excl. eq. incl. eq. excl. eq. incl. eq.
sweat test 24 € 126 € 204 € 3 021 € 4 903
min max
Total € 318 842 € 582 198
€ 7.60 € 45 584
Type of test Cost per test Budget impact
 
a: excl. eq.: equipment is already present (and also used for other purposes) and not considered 
as incremental cost; incl. eq.: equipment cost is considered as incremental cost. 
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The costs for the Guthrie cards (€9414,25 incl. 21% TAV for 16 042 cards (in 2009)) 
are not included since these are not interpreted as incremental costs if another test is 
added to the current screening programme. Other costs, however, should also be taken 
into account and might increase or decrease these costs (see Table 21). For example, 
from the patient’s perspective, transport and time/productivity costs of patient and 
family might be important. From the payer’s perspective, there are also costs for the 
coordination and supervision of the programme, costs for genetic counselling, etc. Price 
negotiations and scale effects might also further influence total budget impact.  
Therefore, these cost estimates can only be considered as a rough estimate of real 
costs. This can provide an idea of screening programme costs, depending on the 
suggested protocol (which tests are included, what are the used cut-off values, who will 
perform these tests (centralised or not), etc.). If the decision would be taken to 
introduce a certain screening protocol, or if new evidence becomes available, more 
detailed cost estimations could be considered.  
An important remark concerns the reimbursed amount for tests with a billing code (CF 
DNA and sweat test), which does not reflect the current real cost. In Belgium, DNA 
tests in general are reimbursed at about €320, which is about double the real cost. In 
France, CF DNA tests are reimbursed at €128.1. In Belgium, a sweat test conducted in 
duplo costs about €126 while it is only reimbursed at €72. Of note is also the high 
volume of 15 000 CF DNA tests (see KCE report no 65) and 6400 single sweat tests 
currently reimbursed (RIZIV/INAMI) per year in Belgium. 
Key points: 
• There is not enough reliable data to calculate incremental cost and benefits 
of NBS CF, nor to conclude on the possibility that NBS CF is cost saving. 
Therefore, the incremental cost-effectiveness ratio of NBS CF compared to 
no screening can only be calculated hypothetically (i.e. largely depends on 
assumptions).  
• The budgetary impact of NBS CF in Belgium was roughly estimated to be 
about €340 000 – €635 000, including only costs to perform IRT, DNA, 2nd 
IRT and sweat tests. A lot of other items (e.g. costs for coordination and 
supervision, including costs for genetic counselling, price negotiations, etc.) 
might increase/decrease this budget impact. 
• Real costs of tests and nomenclature values may differ largely. 
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11 APPENDIXES 
APPENDIX 1: SEARCH STRATEGY 
We attempted to identify all potential sources of data about CF newborn screening 
recorded in MEDLINE and EMBASE database from 1985 till end of June 2009. We used 
MESH (MEDLINE) or EMTREE terms (EMBASE) and general keywords to retrieve the 
maximum number of references. EMBASE, Ovid Medline and Pubmed Medline were 
searched. Major terms used were "cystic fibrosis” in combination with "neonatal 
screening" OR "screening" OR "newborn" OR "newborn screening".  
Table 1. First EMBASE search strategy details 
Date 24/06/2009 
Database  EMBASE .com 
Search 
Strategy 
 
Session Results....................................................... 
No.  Query                                                      Results    Date 
#1.  cystic AND fibrosis                                    37,685  24 Jun 2009 
#2.  cystic AND ('fibrosis'/exp OR 'fibrosis')     37,701  24 Jun 2009 
#3.  'cystic fibrosis'/exp                                    32,250  24 Jun 2009 
#4.  mucoviscidosis                                            1,460  24 Jun 2009 
#5.  #4 NOT #3                                                     110  24 Jun 2009 
#6.  #4 NOT #1                                                     103  24 Jun 2009 
#7.  'newborn screening'/exp                             7,169  24 Jun 2009 
#8.  'genetic screening'/exp                             25,175  24 Jun 2009 
#9.  'newborn'/exp                                         392,103  24 Jun 2009 
#10. #8 AND #9                                                   847  24 Jun 2009 
#11. #7 OR #10                                                 7,792  24 Jun 2009 
#12. #1 OR #3 OR #4 OR #7 OR #10             44,798  24 Jun 2009 
#13. #1 OR #3 OR #4                                      37,788  24 Jun 2009 
#14. #11 AND #13                                                782  24 Jun 2009 
#15. #11 AND #13 AND [1985-2009]/py              740  24 Jun 2009 
#16. #11 AND #13  
AND ([cochrane review]/lim OR [control                18  24 Jun 2009 
 led clinical trial]/lim OR [meta analysis]/lim OR  
 [randomized controlled trial]/lim OR [systematic r 
 eview]/lim) AND [review]/lim AND [1985-2009]/py    
#17. #3 OR #4                                                 32,360  24 Jun 2009 
#18. #3 AND #4 AND #11 AND #17                       13  24 Jun 2009 
#19. #11 AND #17                                                750  24 Jun 2009 
#20. #11 AND #17 AND [embase]/lim                  610  24 Jun 2009 
#21. #7 AND #17                                                  709  24 Jun 2009 
#22. #7 AND #17 AND [embase]/lim                    599  24 Jun 2009 
#23. #3 AND #7                                                   709    24 Jun 2009 
#24. #3 AND #7 AND [embase]/lim                     599    24 Jun 2009 
#25. #3 AND #7 AND [embase]/lim  
AND [1985-2009]/py                                            565   24 Jun 2009 
Note that only searches in bold typeface were used. Other searches were used to verify the 
completeness of the search strategy. 
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Table 2. Ovid MEDLINE search strategy details 
Date 24/06/2009 
Database  Ovid MEDLINE(R) 1950 to Present with Daily Update 
Search Strategy 
 
No.  Query                                                  Results     
1     Cystic Fibrosis/                                    (23442) 
2     Neonatal Screening/                              (4827) 
3     Mass Screening/                                  (63762) 
4     exp Infant, Newborn/                         (423905) 
5     4 and 3                                                  (4169) 
6     2 or 5                                                     (8828) 
7     6 and 1                                                    (572) 
8     limit 7 to yr="1985 -Current"                (463) 
9     mucoviscidosis.mp.                                (1362) 
10     9 not 1                                                     (92) 
Table 3. Second EMBASE search strategy details 
Date 23/07/2009 
Database  EMBASE .com 
Search 
Strategy 
 
....................................................... 
No.  Query                                                   Results     Date 
#1.  'cystic fibrosis'/exp                               32,372      23 Jul 2009 
#2.  'newborn screening'/exp                      7,207        23 Jul 2009 
#3.  #1 AND #2                                           711          23 Jul 2009 
#4.  'evaluation and follow up'/exp              1,902       23 Jul 2009 
#5.  #1 AND #2 AND [1985-2009]/py        678          23 Jul 2009 
#6.  #4 AND #5                                           117          23 Jul 2009 
#7.  'quality of life'/exp                                134,749    23 Jul 2009 
#8.  #1 AND #7                                           666          23 Jul 2009 
#9.  #1 AND #7 AND [1985-2009]/py          666          23 Jul 2009 
#10. #2 AND #8                                          14            23 Jul 2009 
#11. #5 AND #7                                          14            23 Jul 2009 
#12. 'mental development'/exp                   18,305     23 Jul 2009 
#13. #1 AND #12                                        11            23 Jul 2009 
#14. #3 AND #12                                        1              23 Jul 2009 
#15. 'cognitive development'/exp                2,390       23 Jul 2009 
#16. #5 AND #15                                        1              23 Jul 2009 
#17. 'outcome assessment'/exp                  70,273     23 Jul 2009 
#18. #5 AND #17                                        18            23 Jul 2009 
#19. #4 AND #5 AND [1985-2009]/py         117          23 Jul 2009 
#20. #1 AND #17                                        194          23 Jul 2009 
Note that the search in bold was used. Other search were used to verify the completeness of the 
search strategy. 
Table 4. PUBMED Medline search strategy details 
Date 07/08/2009 
Database  MEDLINE via PUBMED 
Search Strategy 
(details) 
 
("cystic fibrosis"[MeSH Terms] OR ("cystic"[All Fields] AND "fibrosis"[All 
Fields]) OR "cystic fibrosis"[All Fields]) AND ("neonatal screening"[MeSH 
Terms] OR ("neonatal"[All Fields] AND "screening"[All Fields]) OR "neonatal 
screening"[All Fields] OR ("newborn"[All Fields] AND "screening"[All Fields]) 
OR "newborn screening"[All Fields]) 
Æ862 articles 
Note Electronic research performed again for last updating of database in order to get 
all articles theoretically available by end of June 2009 according to selection 
criteria. Cross-checking of database manually performed. 
Note that this search was only used to check for recent publications. However, no additional 
publications were identified. 
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847 abstracts or title of publications were identified by the search strategy as described 
when combining Medline results with Embase results in Endnote library. Table 5 
provides the inclusion criteria raised accordingly to HTA guidelines. 
Table 5. Inclusion criteria 
 Inclusion criteria 
Population Cystic fibrosis newborn infants screened by NBS program 
Intervention Follow-up of screened CF patients 
Outcome Effect of early diagnosis on nutritional parameters, on respiratory outcomes, on 
mortality and possible harms(Pseudomonas acquisition), psychological harm effects 
Design Large population based observational studies, review studies, randomized,  control-
randomized or not 
Language Data published in English, except French or Dutch if about very large scale 
population (case by case discussion) 
‘PICO’ definition 
Based on the large amount of data available from 1985 to end of June 2009, it was 
decided to mainly focus on the recent data available and outstanding older data. A cut-
off date of 2004 was decided after agreement between both major authors and any new 
relevant article published after end of June 2009 was to be taken into account till the 
redaction of the report. The Table 6 presents the exclusion criteria defined. 
Table 6. Exclusion criteria 
 Exclusion criteria 
Population Not fulfilling inclusion criteria 
Intervention Not fulfilling inclusion criteria 
Outcome Not fulfilling inclusion criteria 
Design Not fulfilling inclusion criteria 
Language Not fulfilling inclusion criteria 
Other  Articles published in review with impact factor < 1 
Other  Published before 2004 (except if keystone study) 
Other  General statement about NBS 
Other  Redundant data 
Other  True duplicated data 
Table 7: Reasons for exclusion expressed by number 
Reason for exclusion    n = 
Population 41 
Intervention 8 
Outcome 106 
Design 2 
Language 0 
Impact factor <1  32 
Published before 2004  478 
Generalities about topic 62 
Redundant data  38  
Duplicated data missed by endnote program  30 
Total number:  792 
Full publications were retrieved based on abstracts or title (when abstract not available) 
if at least one reviewer suspected they were relevant to this report. Exclusion of a 
reference was decided after agreement between both major authors. From the 847 
references identified, 792 references were excluded; remaining 55 articles.  
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These 55 abstracts were selected and the full texts were read. In the references of 
these articles 17 additional references were found as possibly relevant. For these 
55+17=72 references (read as full text) the following selection criteria were used: 
studies comparing outcome parameters of a screened versus a non screened group, 
RCT (1), non-RCT (2), and reports form CF registries (3). Additionally, systematic 
reviews were kept together with articles on guidelines after screening. Were not 
selected: non-systematic reviews, letters and comments, studies not specific on 
screening, studies not comparing a screened versus an non screened group.  
With this selection criteria 29 articles were selected for the chapter on effectiveness. 
After a quality appraisal (see text and tables chapter 2), 4 articles were rejected leaving 
25 articles. In a later phase 3 articles were selected after the initial search (see tables 
below).  
Table 8. Inclusion and exclusion of references read as full text. 
 Type of study number 
1 Reports from RCT’s comparing outcome of screened versus 
non screened 
10 
2 Reports from retrospective cohort studies comparing 
outcome of screened versus non screened 
9: 4 rejected (see text) 
3 Reports from CF registries comparing outcome from 
screened versus non screened 
5 
4 Systematic reviews 2 
5 Guidelines on NBS and CF, FU after screening 3 
 TOTAL 29 (-4) = 25 
Three articles were added to the 25 articles after the search was performed: 
 reason number 
Castellani et al 2009 
JAMA 
Association between carrier screening and incidence 
of cystic fibrosis. This publications appeared months 
after the initial search and was considered as 
important in the context of benefits after screening 
1 
Grosse  references of Grosse after contacting the author on 
the systematic review on mortality 
2 
Remarks:  
• non systematic review were read to check for eventual new references 
but not quoted 
•  publications on possible harms, psychological and other were not selected 
and discussed in the chapter on benefits 
•  the other references in this chapter (n=17) are quoted in order to give 
background information on the topic (meaning of early diagnosis, data on 
the development of early disease in CF, background on vitamin deficiency 
in CF etc)  
•  quality appraisal was performed on the non-RCT data (5+5) by two 
reviewers; for the RCTs the Cochrane quality appraisal was taken 
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APPENDIX 2: FIVE KEY REFERENCES 
Grosse S, Boyle C, Botkin J et al. Newborn Screening for Cystic Fibrosis. Evaluation of Benefits 
and Risks and recommendations for State Newborn Screening Programs. MMWR 2004; 53: 1-
36. 
This exhaustive document (156 references) summarizes a workshop cosponsored in 
November 2003 by the CDC and the US Cystic Fibrosis Foundation. Peer-reviewed 
evidence is presented. The CDC concludes that CF NBS is justified. In 2004, CF NBS 
was implemented in 5 out of the 50 US states. At the end of 2009, all but one have 
developed a national CF NBS program. 
Southern K, Mérelle M, Dankert-Roelse J, Nagelkerke A. Newborn screening for cystic fibrosis. 
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001402. Review. 
This recent paper comprehensively analyses current evidence for the effectiveness of 
CF NBS from randomised controlled trials (RCTs) in CF, and could be used as the basis 
for the effectiveness chapter. Table 1 summarizes detailed data derived from this work. 
In contrast to many Cochrane reviews, the author’s conclusions about implications for 
practice, are so clear and positive that we found it useful to reproduce them below: 
“Newborn screening for CF benefits growth and prevents malnutrition in people with 
CF. Malnutrition may adversely influence cognitive function. From the available RCTs at 
this time, pulmonary benefits from CF newborn screening are likely in early childhood. 
Results on long-term pulmonary prognosis were biased by confounding factors such as 
infection and pancreatic status. The expense of CF newborn screening is similar to the 
costs for other screening tests such as phenylketonuria and is less expensive than when 
diagnosed clinically.” 
Castellani C, Southern K, Brownlee K et al. European best practice guidelines for cystic fibrosis 
neonatal screening. J Cyst Fibros. 2009; 8: 153-173 
This third major paper (126 references) is a summary of the consensus achieved by 31 
international experts having attended a meeting which took place on March 2008 in 
Italy. This meeting was organized by the European Cystic Fibrosis Society, the European 
Coordination Action for research in Cystic Fibrosis (Eurocare CF) in partnership with 
The International Society for Neonatal Screening, the EU EuroGentest Network of 
Excellence and the European Molecular Genetics Quality Network. This text 
comprehensively addresses the following issues: 1) The rationale for CF neonatal 
screening (benefits, hazards and costs) 2) Protocols and technical issues 3) Diagnosis 
through CF neonatal screening (including inconclusive cases) 4) Information to families. 
Comeau A, Accurso F, White T et al. Guidelines for Implementation of Cystic Fibrosis Newborn 
Screening Programs: Cystic fibrosis Foundation Workshop Report. Pediatrics 2007; 119: e495-
e518. 
This document (96 references) details step by step the components of a successful CF 
NBS program. Difficult situations (mild forms of the disease and diagnostic dilemmas) 
are also discussed. 
Haute Autorité de Santé. Le dépistage néonatal systématique de la Mucoviscidose en France: 
état des lieux et perspectives après 5 ans de fonctionnement, 2009. http://www.has-
sante.fr/portail/jcms/c_765713/le-depistage-neonatal-systematique-de-la-mucovsicidose-en-
france-etat-des-lieux-et-perspectives-apres-5-ans-de-fonctionnement 
This report (174 pages - 156 references) carefully analyses the results of the French CF 
NBS program 5 years after its nationwide implementation. It includes an updated review 
of the medical literature on this topic, specifically addresses problems encountered in 
relation to the current strategy and provides recommendations to improve it. 
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APPENDIX 3: EFFICACY AND EFFECTIVENESS 
Table 1: Randomized controlled studies 
Author Study 
Protocol 
Number 
CF SG/CG 
Aim Follow-up Results Time period 
NBS test 
{Chatfield,  
1991 
#526} 
 
UK 
 
464,586 babies 
screened on 
alternate weeks MI 
excluded 
  
230,076  
screened 
Æ58 CF 
 
234,510 
control  
Æ44 CF 
 
clinical benefit of 
NBS : growth,  
hospitalisation 
survival, 
 
5 years 
 
n  assessed 
at  age of : 
1y 34+22 
2y 33+21 
3y 23+13  
4y 12+7 
* mean age at diagnosis 9.1 (3.1) weeks  for SG and 50.5 (60.5) for CG 
(p< 0.001) 
* H en W sds: no difference  
* 3 non MI deaths in CG, no deaths in SG 
* Chrispin-Norman and  Shwachman scores: no difference  
* mean n  (sd) of admission in first year:  
1.3 (1.9) for SG and 3.3 (2.7) for CG (p< 0.01) 
1985-1989 
 
 
IRT 
56 
 
UK 
same cohort as 
above 
source data  
Pediatrician 
UK CF Survey 
 
176 CF 
registered 
 
NBS and  
death rate 
< 5 years 
 
5 years 
 
CF deaths reported in first 5 years: 
*7 CF children died 
-3 MI (before NBS diagnosis possibility) 
-4 non MI related  in the CG compare to  0 in the SG (p< 0.05)  
1985-1989 
 
 
IRT 
{Farrell, 
1997 
#431} 
 
USA 
650,341 babies 
Randomized , MI 
excluded 
SG 
Æ325,171  
Æ 74 CF 
(5 false-negative) 
CG : 
Æ325,170 
Æ 40 CF 
 
SG 56 
CG 40 
 
  
clinical benefit of 
NBS: 
 
weight/ 
height, 
head 
circumference 
 
 
10 years 
 
at 1year :  
52 / 26  
at 10years : 
14 / 9 
 
*90% PI in SG and 72% in CG (p=0.04); F508del homozygous 58% and 
50% (p=0.001) 
*HC at diagnosis better in SG (p= 0.003) 
*W and H better in SG:   
at diagnosis ( W z score p=  0.008 L z score p < 0.001;  at 1y: W z score 
p = 0.001 H z score p = 0.002; at 10y: W z score P=0.04+ H p= 0.02 
*Shwachman-Kulczycki score: no difference 
 
1985-1995 
 
 
IRT  
 
after 1995: 
IRT/DNA 
{Farrell, 
1997 
#732} 
 
USA 
same as above 
 + 1 year 
 
 
SG 67 
CG 56 
Pseudomonas 
aeruginosa acquis- 
ition 
10 years * overall no difference in Pa acquisition between SG and CG 
* in 1 centre  median time to chronic Pa lower for the SG: 52 weeks 
versus 234 weeks;  
p = 0,0003  
* other centre median time to Pa acquisition 130 weeks in the CG 
versus 289 weeks (NS) 
1985-1996 
 
IRT  
 
after 1995: 
IRT/DNA 
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Author Study 
Protocol 
Number 
CF SG/CG 
Aim Follow-up Results  
Farrell, 
200154 
 
USA 
same cohort as 
above 
 
SG 56 
CG 48 
 
clinical outcome 
after NBS : 
weight 
height 
 
13 years 
assessed at : 
1y 52+26 
5y 45+32 
10y 17+13 
13y 2+5 
* OR for W + H < P10 in the CG compared to SG:   
For W 4.12 (95%CI 1.64-10.38) and for H 4.62 (1.70-12.61) 
* Repeated measurement analysis until age 13y:W z score better in SG  but 
ns ( p= 0.06) H z score better in SG (P=0.009) 
1985-1994 
Farrell, 
200378 
 
USA 
same cohort as 
above 
 
 
 
SG 56 
CG 47 
 
 
pulmonary 
outcome after 
NBS 
FEV1, 
chest Xray. 
 
 
16 years 
 
assessed 
at 7- 16y 
 
* at diagnosis (14.3  SG weeks compared with 108 weeks CG (p<0.001), 
better WCXR and BCXR mean scores for SG 
* LF (FVC,FEV1) no difference : at 7 y, 88% of SG and 75% of CG LF had  
FEV1 of ≥ 89%  
* Wisconsin X-ray score progressively worse in the SG after 10 years  
 
1985-1995 
Farrell, 
200560 
 
USA 
same cohort as 
above 
 
 
SG 49 
CG 31 
 
 
clinical outcome 
after NBS : 
weight/ height 
chest Xray 
 
16 years 
 
assessed at : 
10y 32+19,  
13y 11+11, 
16y 3+5 
 
*  advantage for H and W for the SG persist long term 
*  Wisconsin and Brasfield X-ray score better in SG at diagnosis but 
declining after age 10y (ns) 
 
1985-1995 
Koscik, 
200472 
 
USA 
same cohort as 
above 
 
 
 
SG 42 
CG 47 
 
 
effect of NBS on 
cognitive function 
and Vit E  
 
17 years 
 
CSI at 7.3-17 
y 
 
 
* Cognitive skill index: 104.4 (14.4) SG versus 99.8 (18.5) CG (p=0.24) 
* lower CSI correlate with growth deficit: height <P10 at 6 months: CSI 
86.1(18.5) vs. 99.9(16.9) p=0.02 
* CSI lower in patients  with Vit E deficiency at diagnosis (p< 0.05)  
 
1985-1995 
Koscik, 
200573 
 
USA 
same cohort as 
above 
 
 
SG 37 
CG 34 
effect of NBS on 
cognitive 
function 
Head CF and  
Vit E  
 
 
16 years 
 
head PC at 0-
3y 
CSI at 7-16y 
 
* HC z score significantly lower in CG up to age 3 p=0.019 
* HC at diagnosis correlate with <300E r= 0.328 p = 0.025 
* higher % of low CSI score < 84 in CG<300 E at diagnosis (p=0.003)  
 
1985-1994 
 
KCE Reports 132 Cystic Fibrosis Neonatal Screening 119 
Table 2: Retrospective cohort studies comparing outcome of CF patients after clinical diagnosed and NBS 
Author Study 
protocol 
Number 
assessed 
Follow-
up 
Aim Results Time period 
Waters, 
199965 
Australia 
historical 
controls 
SG 60 
 
CG 57 
10 years clinical 
outcome 
growth 
respiratory  
* W and H sds better in the SG at all ages 
*10y : W sds  0.4 (95%CI -0.1-0.8) and H sds 0.3 (95%CI -0.1-0.7)(1.7 kg and H 2.7 
cm) 
* FVC, FEV1 % significantly better in SG: at 10 years mean diff 9.4% (95%CI 0.8-17.9) 
* X rays score not different 
* Shwachman score at 10y was 5.3 points higher in SG (95%CI 1.2-9.4)  
1978-81 CG 
1981-84 SG 
Siret, 
2003{Sire
t,  
2003 
#303} 
 
France 
contem 
-porary  
controls 
SG 77 
CG 36 
At 5y 
27+17 
At 10y 
 9+7 
10 years growth 
lung 
age at 
diagnosis 
* age at diagnosis 38 days SG vs 472 in CG (p < 0.005) 
* W z score better in SG age 1 and 8y (p<0.005); H z score better in SG at age 1, 3 + 
5 (p<0.005) 
* LF no diff 
* Brasfield score (p<0.001) and Shwachman score (p<0.05) higher for SG 
* Pa infection : no diff 
* % hospitalization:  86% CG vs. 49% SG (p< 0.001) 
1989-1998 
 
McKay, 
2005{Mc
Kay, 
2005 
#197} 
 
Australia 
historical 
controls 
SG 52 
CG 48 
 
15 years clinical 
outcome 
growth 
respiratory 
 
death 
outcome at 15y 
* 7 deaths in the NSG, out of 57 children enrolled (12.3%) compare to 4 deaths in the 
SG, out of 60 enrolled (6.7%).  
*  significant difference in cumulative mortality  at age 10 (0 in the SG and 9.1% in 
CG)7 deaths in CG vs. 4 in SG (ns): deaths at age 10 higher in CG 
* age at death in SG significantly older: mean difference of 48 months; p < .05 
* W and H: not different 
* Shwachman-Kulczycki score better in SG: X-ray score  (diff 2.3 (95%CI 0.3-4.2) 
composite score  7.0 (0.2-13.8) (p< 0.05) 
* FEV1 better in SG: 12.3 % (95%CI 2.9-21.7%)( p< 0.001) 
 
1978-1981 
CG 
 
1981-1984  
SG 
Baussano, 
200697 
 
Italy 
historicalco
ntrols 
SG 52 
NS 32 
untill 2005 risk of Pa 
infection  
* overall annual Pa infection rate similar for the 2  groups 21.% (95%CI 15.4-30.1)   
* survival estimates: no difference in risk for Pa infection 
* median time between diagnosis and first Pa shorter in SG 183 (range 35-951) vs. 448 
(range 53-2170) days 
* Pa within 60 days after diagnosis excluded from analysis 
1997-2000 CG 
2000-2004 SG 
Collins, 
200868 
 
USA 
Contempo
rary 
controls 
from same 
CF centre 
SG 
48 
Æ34 
CG 50 
Æ 21 
 
untill 2005 BMI 
Pa infection 
rate 
FEV1 
* BMI higher in SG from age 3 , diff increasing with age (p=0.01) 
* Brasfield score: not different 
* Pa acquisition: not different 
* LF not different by univariate analysis except at age 15y (Fev1 90% SG vs. 74% CG 
p=0.08) 
* by multivariate analysis FEV1 better in SG at all ages 
* between age 6-15 years: CG FEV1 decline of 14% , SG FEV1 increase of 4% (p=0.01) 
1983-1997 
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Table 3: Registry data comparing outcome of CF patients after clinical diagnosed and NBS 
Author, 
reference 
Time period Number 
studied 
Length of Follow-up Aim Results 
Sims, 200585 
 
UK registry 
 
diagnosed 
1994  
aged 1-9 years 
in 2002 
 
SG 184 
CG 950 
 
untill 2002 
 
evaluate if NBS is 
associated with a 
higher treatment 
intensity 
 
SG versus CG: 
* H sds (-0. 41 vs. -0.81) p= 0.05 
* W: comparable 
* LF: no difference 
* Northern and Shwachman score: better in SG 
* N° of long term therapies: 2 vs. 3 (p=0.005) 
* % receiving low intensity treatment: 65% vs. 47% (p<0.005) 
* % without neb therapy: 65% vs. 47 (p< 0.005) 
* % with ≥2 neb therapies: 9 vs. 19 (p< 0.005) 
 
Sims, 200570 
 
UK registry 
diagnosed 
1994,  
aged 1-9 years 
in 2002 
 
SG 183 
CG 950 
 
untill 2002 
 
evaluate outcome 
after NBS in the 
context of modern 
CF treatment 
 
SG versus CG 
* better H z scores 
* W: no difference 
* Northern X-ray score and Shwachman score: better in SG at all ages 
* LF : no difference 
* Pa infection: % with ≥Pa positive infection lower in SG between 1-3 years 
 
Accurso, 
2005 69 
 
US registry 
* diagnosed 
2000 through 
2002 < age 1  
* all  
patients in data 
base up to age 
20y 
* MI excluded 
1. CG 
1760,  
SG 256 
 
2.14647 
 
NA 
 
complications and 
hospitalizations by 
mode of diagnosis 
 
SG versus CG 
* less stunting: 9% vs. 26% L < P3 (OR 3.7 CI 2.3-5.9) 
* less wasting: 11% vs. 33% W < P3 (OR 4.0 (2.6-4.2) 
* less Pa: mucoid Pa 0.46% vs. 3% (OR5.9 (0.8-43.8) 
* less complications: 29% vs. 70% OR 5.6 (4.1-7.7) 
* days in hospital: no difference 
Lai, 200587 
 
US registry 
patients 
diagnosed > 
1986 
 
n=13687 
NA Impact of age and 
type of diagnosis on 
mortality 
 
% of deaths (p< 0.05) 
* SG 1.4% 
* family history 0.9% 
* MI 3.9% 
* CG 3.5% 
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Table 4: Summary of the Wisconsin trial- Demographic data 
Study Wisconsin CF NBS  P value/ Adjusted P 
value 
Comment 
Number of babies  
650 341 randomized 
 Parents in cohort group aware about 
CF disease and CF screening. Only 
0.03% of parents requested screening 
test result. Screened 
325 171 
Unscreened 
325 170 
 
NBS positive 501 Not mentioned  
CF diagnosis 74  
(15 MI)  
(5 false- negatives) 
( - 3 not enrolled) 
67  
(18 MI) 
(9 positive NBS) 
(9 not enrolled) 
 At 4 years, unblinding of NBS result in 
cohort group revealed 9 undiagnosed 
CF on the 40 previously clinically 
diagnosed, apart the 18 MI. 
DF508/DF508 homozygote: 
Farrell, 199753 
Farrell, 200154 
Farrell, 200560 
Pancreatic insufficiency: 
Farrell, 199753 
Farrell, 200154 
Characteristic of patients:  
32 (58%) 
41 (53%) 
32 (63%) 
 
46 (90%) 
61 (79%) 
19 (50%) 
35 (43%) 
22 (71%) 
 
26 (72%) 
47 (58%) 
0.001 
0.031/0.323 
0.12 
0.04 
0.012 /0.164 
Screened group more severe than 
cohort group based on DF508 
homozygote and PI in 1997.  
Not confirmed with P value adjusted in 
2001. 
 Sample size (Meconium ileus excluded)  
Farrell, 199753 56  40   
Farrell, 200154 75  76   
Farrell, 200378 56  47   
Farrell, 200560 49  31 0.82 Mean age of diagnosis do not differ in 
cohort group(72weeks compared to 73 
weeks) but median age is reduced 
compared to ‘usual’ time before 
randomization(median age 23 weeks 
compared to 36 weeks ) 
Mean age of 
diagnosis 
(Weeks) 
 
 Median 
 (range) 
Farrell, 199753 
 
12 +/- 37 
7 (4–281) 
72+/- 106 
23 (3–372) 
< 0,001 
Before the screening trial: 
Mean age diagnosis was 73 weeks; Median, 36 weeks 
Farrell, 200154 13.6 +/- 37 
7 (4–281) 
100.6+/- 117 
28 (3–372) 
< 0.001 
Farrell, 200378 12.4 weeks 95.8  weeks  
Farrell, 200560 7.4 ± 2.5 
6.9 (3.6-14.4) 
60.1 ± 89.8 
22 (5.4- 329.9) 
0.0001 
Mean age diagnosis for false-negative of 
screening 
7, 8, 21, 84, and 287 weeks Farrell, 199753 
7,19, 21, 124, and 281 weeks Farrell, 200154 
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Table 5: Summary of the Wisconsin trial- Anthropometric data and pulmonary outcomes 
Outcome Study NBS Control  P value Comment 
Weight/ Height 
% of < 10 th 
Percentile(OR) 
Farrell, 2001 54 W< 10th :  4.12 (95% CI: 1.64 –10.38) 
H<10th :  4.62 (95% CI: 1.70 –12.61) 
0.007 
0.004 
Significantly worse 
in the control 
group 
Height z-score 
 
No.%< 10th Per 
Farrell, 1997 53  
Farrell, 2005 60 
 
 
 
 
- 0.2 +/- 1 
-0.40 ± 0.16  
5 (10%) 
- 1.2 +/- 1.1 
-1.35 ± 0.21 
14 (45%) 
0.001 
<0.001 
<0.001 
A reduced growth 
is always the sign 
of severe disease, 
energy intake 
always going first 
in growth at the 
price of a reduced 
weight gain as 
observed in these 
groups. 
Weight z-score 
 
No.%< 10th Per 
- 0.5 +/-1.1 
-0.96 ± 0.18  
20 (41%) 
- 1.2 +/- 1.1 
-1.84 ± 0.23 
19 (61%) 
0.008 
0.003 
0.074 
Head 
circumference 
Z-score 
No% <10th Per 
-0.55 ± 0.12  
7 (17%) 
-1.07 ± 0.19 
10 (40%) 
0.021 
0.039 
Severe reduction 
in head size in late 
diagnosed group 
Head 
circumference 
Percentile 
Farrell, 1997 53  52+/- 28 32+/- 24 0.003 
Lung function  
Farrell, 200378 
 
FEV1  94 +/- 1.8% 95 +/-1.3% 0.54 But very little 
deterioration with 
age in both groups 
despite PA 
acquisition 
% > at 89% FEV1 
predicted 
88% 75% ns 
13% more in SG 
despite PA 
FEV1/ FVC; FEV1; 
FEF25−75; RV/TLC 
  ns Ns despite PA 
Shwachman–
Kulczycki score 
Farrell, 1997 53 
92+/- 1 87+/- 2 0.006 
Activity, Physical 
examination, 
Growth, nutrition, 
Chest film 
Brasfield X ray 
score 
 
No. (%) with 
Brasfield score  
Farrell, 2003 78 
Farrell, 2005 60 
20.1 (1.4)  
21.8 ± 0.3 (38) 
 
8 (21%) 
18.9 (1.8) 
20.5 ± 0.6 (25) 
 
10 (40%) 
0.01  
0.038 
 
0.103 
Trend of better 
chest x-ray score  
in SG despite 
more PA 
acquisition in one 
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< 21 group 
Wisconsin X 
ray score 
 
No. (%) with 
Wisconsin CXR 
score > 5 
Farrell, 2003 78 
Farrell, 2005 60 
8.3 (3.3) 
4.1 ± 0.6 (38) 
 
11 (29%) 
12.3 ( 8.3) 
7.4 ± 1.5 (25) 
 
12 (48%) 
0.01 
0.022 
 
0.124 
Pseudomonas 
acquisition 
Farrell, 1997 84 n CF Center A Center B P value Median 
pseudomonas-free 
survival period 
was 52 weeks 
contrasted with 
289 weeks in the 
other center  
Center A better 
for PA than 
control group 
n Screened G, % 
Prevalence PA % 
Control% 
 
Incidence rate/ person 
_year 
Median PA_ free 
survival period(Weeks) 
67 (54.5%) 
62.7 % 
53,6% 
 
0.240  
 
SG 
CG 
34 (53.1%) 
41.2% 
56,7% 
 
0.138 
 
289  
130 
33 (55.9%) 
84.8% 
50,0% 
 
0.389 
 
52  
234 
NS 
0.001 
NS 
 
0.004 
 
<0.001 
Farrell, 2003 78           45 (80%)             28(60%) 0.021 Same cohort as 
1997 
 No other lung function assessment since 2003 except Lai,2009 (responders vs non- responders)  
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Table 6: Summary of the Wisconsin trial- Cognitive assessment72, 73 
Author Sample size NBS Control cohort P value Comment 
Koscik, 2004 72 89 children non-meconium ileusÆ 
67 without missing data 
The screened group had a 5-point higher mean CSI score 
relative to the control group, which is equivalent to one third 
SD, controlling for confounding variables. No association was 
identified with any anthropometric indicator, including head 
circumference, height, and weight 41 
NS  
Koscik, 200573 
 
 
71 children non-meconium ileus  n = 37 n = 34  False-negative not diagnosed 
later than clinically diagnosed53. 
1 false-negative not in 
calculations; CF diagnosis done 
at 287 weeks 
CF with Pancreatic insufficiency n = 33 n= 21  
Mean age at diagnosis(Weeks) 8 (2-21) 
 
54 (5-373) <0.001 
Patients 
categorized into 4 
groups 
1) control patients with an a-T level<300 mg/dL at diagnosis (C<300E); 2) control patients with an a-T level >300 
mg/dL (C>300E); 3) screened patients with an a-T level <300 mg/dL (S<300E); 4) screened patients with an a-T 
level >300 mg/dL (S>300E) 
Alphatocopherol (a-T)  
Outcomes Results  Verbal skills, short-term 
memory function, and the 
ability to perceive relationships. 
Differences in cognitive ability 
of 1SD are perceptible to 
patients; a reduction of 1 SD in 
cognitive scores is associated 
with a decrement in reported 
HRQoL 
Cognitive skill 
test 
(CSI) 
n = 49 CSI was not significantly correlated with HC z-scores obtained 
at diagnosis (r = .119)  
0.42 
n = 71 Or at the time of cognitive assessment (r = .191)  0.11 
Scoring < 84 for patients <300E 0 7 (41.2%)  0.003 
CSI 
(mean = 100; SD = 16) 
CG had adjusted CSI scores 12.5 points lower than scores for 
the 17 screened subjects who also had vitamin E deficiency at 
diagnosis (- 1 SD) 
< 0.05 
Head 
circumference 
HC  
z-score 
n = 49  (30 S+19 C) 
  
From  6 weeks to 3 years of age (time of 
cognitive assessment) 
S<300E >300E C<300E >300E  
n=17 n=20 n=17 n=14 
- 0.7 (0.7) - 0.2 (0.7) - 1.2 (1.1) - 0.2 (0.9) 0.014 
0.7 (0.8) 0.4 (0.9) - 0.2 (1.0)   0.6 (1.2) 0.047  
Vitamin E 
 
At diagnosis, <300E 17 (46%) 17 (55%) 0.47 
CF with PI, <300E 16 (48%)  16 (76%) 0.04 
C<300E group were diagnosed an average of 29.4 weeks later than their peers in the S<300E group. 
Thus, the duration of deficiency, is significantly longer for the control group.  
0.049 
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Table 7: Impact of Weight z score recovery on Lung function Lai, 2009351 
Design 80 CF patients with pancreatic insufficiency 
Sample size: 80Æ 63Æ 51 for final analysis 
P value Comment 
Responders  n=  41 
28 NBS diagnosed 
Non responders  n= 22 
14 NBS diagnosed 
 From 80 patients, 41 were defined responders. > 30 % excluded 
from analysis- 10% because no FEV record validated- More 
responders in CF diagnosed by NBS (Trend?). 
Mean age diagnosis 
(Month) 
4.0+/-6.2 2.6+/3.2 0.39 Non responders trend to be diagnosed earlier than responders-  
more severe if earlier clinically involved? 
Weight z 0.28+/-0.93 _1.23+/-0.81 < 0.0001  
Height z 0.06+/-0.89 _1.03+/-0.79 < 0.0001 
BMI z 0.43+/-0.92 _0.38+/-0.90 0.001 
FEV1 99.5% +/- 13.9% 88.3% +/-18.5% 0.015 Improvement in lung function results from improvement in growth. 
The nutrition had no impact on infections rate for instance 
Shwachman-Kulczycki 
scores 
95.7+/- 3.8 90.7+/- 7.3 0.001  
Clinical signs 10% daytime cough;  
7% nighttime cough 
5 % wheezing 
27% daytime cough;  
36% nighttime cough 
9% wheezing 
 0.25 
0.09 
0.61 
 
Nutritional energy 
Intake over age 2--6 
Confirmed Lessened Improved Unchanged  0.009 Higher energy intake correlates with improved or maintain growth 
in group. In non responders, no response despite high energy intake 124+/-26 108+/-22 148+/-17   136+/-29 
Linoleic acid (% total 
plasma fatty acids) 
over ages 2–6 
27.4+/-3.1 26.7+/-5.0 27.6+/-4.4 27.0+/-3.4 0.9 Higher energy intake but same dosage Fat level- Non responders are 
more severe? 
Brasfield X ray score 
Wisconsin X ray score  
21.1+/- 1.5 
5.9+/- 3.5 
20.5+/- 2.2 
8.0+/_ 5.8 
0.16 
0.08 
 
Pseudomonas 
acquisition 
6 (15%) 6 (27%)  0.24 Trend of more PA and SA in non responders. Role of infection in 
‘non-responding’ state? 
Staphylococcus Aureus 7 (18%)  6 (27%)   0.37 
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Table 8: Summary of the UK trials 199155, 56 
Study UK CF NBS  P value Comment 
Number of babies 464 586 
screened on 
alternate week 
 
 Practical organisation? 
Administrative management of follow-up of screened 
patients? 
Meconium ileus(MI) excluded because CF diagnosis 
made within first days in both group. 
 
 
 
“Because no screening was performed in the control 
group, an unknown number of undiagnosed cases of 
CF in this group were not ascertained”41 
Screened 
230 076  
Unscreened 
234 510 
CF diagnosis 
  
MI excluded 
Chatfield, 199155 58  44 
Doull, 200156 42 86 (16 false 
negative) thus, 
70 identified by 
screening 
90 
Mean age of diagnosis (SD) 
 
9,1weeks 55 
8 weeks 42 
(3 to 22 weeks) 
50,5 weeks 
 
(6 to 22 months) 
< 0,001 Median ages were not reported42 
Sample size of 
babies assessed 
1 year old 34 22   
2 years old 33 21 
3 years old 23 13 
4 years old 12 7 
Mean number of hospitalisation at one year 1.3 3.3 < 0,01  
Weight/ Height NS NS  No support CF care prescribed after NBS 
Chrispin-Norman/ Shwachman scores  NS NS  
Death in first 
5 years after 
birth 
3 death related on meconium 
ileus on 7 deaths reported on 
176 CF registered.  
0  4 on? < 0,05  “A review of registry data revealed previously 
unknown CF-related deaths among children in the 
unscreened group” 41, 56 
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APPENDIX 4: QUALITY ASSESSMENT OF THE 
NON RCT TRIALS DISCUSSED 
Waters et al 199965, McKay 200566 
 
1. Groups compared: In this retrospective cohort study clinical outcome is compared for a group 
of CF patients clinically diagnosed from ’78-81 with a group of CF –NBS diagnosed between ’81 
and ’84. MI patients are included in the 2 cohorts. Clinical outcome parameters are compared at 
fixed ages. 
2. Evaluation of selection bias: Age at diagnosis was lower in the SG group as expected. The 2 
groups were comparable in other disease aspects like PI, presentation with MI etc. This excludes a 
large bias due to a higher proportion of less severe CF in the SG.  
3. Length of follow-up: Until age 10 (15 years for McKay) 
4. Loss to follow-up: Comparable in the 2 groups. For the analysis reported in Mc Kay et al: 2 out 
of 57 patients in the CG and 4 out of 60 in the SG. 
5. Possible confounders: The mean possible confounder in this study is the use of an historical 
comparison group. The authors are aware of this possible confounder and clearly state the 
therapeutic changes that occurred over the time course of the study.  
6.  General evaluation: The results of the study have to be interpreted with caution mainly because 
of the comparison on historical cohorts. Because on all other points the quality of the study was 
evaluated as good, and the follow-up was long-term, the study results are included in this report. 
 
 
Siret et al 200367 
 
1. Groups compared: In this retrospective cohort study clinical outcome is compared for a group 
of CF clinically diagnosed versus a group diagnosed after NBS. Patients are born in the same 
period (1989-1998). Patients with MI are excluded for both groups. Clinical outcome data are 
cross-sectional. 
2. Evaluation of selection bias: Age at diagnosis was lower in the SG group as expected.  In other 
disease aspects like PI, frequency F508del etc groups were comparable. Also the incidence of CF 
was similar for the 2 regions. This excludes a large bias based on a higher representation of less 
severe CF in the SG. False negative diagnoses in the SG are excluded from the analysis (5 cases 
with 77 positive screening cases) which could be criticized in the context of an intention to treat 
analysis. 
3. Length of follow-up: Follow-up until 1999 which is age 10 for the oldest patients only. Therefore 
the number of evaluable patients at later ages is limited. 
4. Loss to follow-up: 15 children in the SG (excluded). 
5. Possible confounders: Patient treated in 2 different CF centers although with similar treatment 
protocol. 
6.  General evaluation: Patients born in the same time period are compared. Similar treatment 
protocols are used. Therefore this study is evaluated as valid. Care has to be taken in interpreting 
data for the older children since numbers are very limited. Exclusion of false negative screening 
cases may be a confounder. 
 
Collins 200868 
 
1. Groups compared: In this retrospective cohort study clinical outcome is compared for a group 
of CF clinically diagnosed versus a group diagnosed after NBS. Patients are born in the same 
period (1983-1997) in Connecticut. In this period some hospital in the region offer NBS while 
others do not. Patients with MI are excluded for both groups. Clinical outcome data are cross-
sectional. 
2. Evaluation of selection bias:  Only patients with FU in the CF center until 2005 and if consent 
was obtained were included in this analysis. Of the 48 CF patients of the SG and 50 of the CG 
only data from 34 and 21 were analyzed. Insufficient data are provided to exclude a possible 
selection bias here. No data are given on the data of false negative screening patients. 
3. Length of follow-up: Until 2005 or age 15 for the oldest patients. Therefore the number of 
evaluable patients at later ages is limited. 
4. Loss to follow-up: 8 of 63 patients (proportion of SG versus CG not stated) 
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5. Possible confounders: Patients attending the screening hospitals reflected the racial diversity of 
the Connecticut area and also represented patients from similar socio-economic background 
compared to patients attending the hospitals were no NBS was offered. Age at diagnosis was 
lower in the SG group as expected.  In other disease aspects like PI, F508del frequency etc groups 
were comparable. This excludes a large bias based on a higher representation of less severe CF in 
the SG.   
6.  General evaluation: Care has to be taken in interpreting data because of a possible selection 
bias. No information is given on analysis of data of false negative screening cases. However, 
patients of both groups born in the same time period and are and are treated in the same CF 
center. Therefore this study is evaluated as valid.  
 
 
Baussano 200697 
 
1. Groups compared: In this retrospective cohort study clinical outcome is compared for a group 
of CF clinically diagnosed between 1997-2000 versus a group diagnosed after NS (2000-2004) in 
Piemonte Italy and followed in the same CF center.  Patients with MI are included for both groups.  
2. Evaluation of selection bias: SG and CG were comparable for pancreatic status, F 508 del 
frequency and gender. This excludes a large bias based on a higher representation of less severe 
CF in the SG. False negative diagnoses in the SG are excluded from the analysis (5 cases with 47 
positive screening cases). 
3. Length of follow-up: Follow-up until 1999 which is age 10 for the oldest patients only. Therefore 
the number of evaluable patients at later ages is limited. 
4. Loss to follow-up: 4 children in the SG (excluded) 
5. Possible confounders: Patients with PA positive culture within 60 days from clinical diagnosis 
were excluded from the analysis. This may be in favor of the data on Pa acquisition in the CG.  
6.  General evaluation: Patients from both groups are born in the same region and treated in the 
same CF center. Care has to be taken in interpreting data since the CG groups are born earlier. 
However, no major changes in therapy have been reported for this time period. Major 
confounders may be exclusion of false negative screening cases in the SG and exclusion of Pa 
positive patients in the SG within 60 days after diagnosis. Despite these limitations, the study was 
included in the analysis because it studies the important topic of Pa acquisition. 
 
Sims 2005 J Pediatrics, Sims (bis ) J Pediatrics 200570, 85 
 
1. Groups compared: Comparison of UK CF registry data of CF patients diagnosed after NBS (12% 
of UK CF patients) versus clinical diagnosis. Registry data of 2002 were analyzed in a cross-
sectional way of all patients aged 1-9 years if data of annual review were available.  
2. Evaluation of selection bias: Of all registered UK CF patients, data of 73% of patients was 
available for analysis. This group was comparable to the whole group when looking at sex 
distribution, age at diagnosis for the CG and occurrence of F508del mutation. Important selection 
bias at this stage can be excluded. No information is given on the number of non registered CF 
patients in the UK.  
The definition of NBS group in the text is: diagnosed within 3 months of age after NBS. It is unclear 
where the false negative screen CF patients are analyzed 
3. Length of follow-up:  NA 
4. Loss to follow-up: NA 
5. Possible confounders:   All patients in studied in this report are diagnosed after 1994. They all 
received CF center care and were treated with acid resistant enzymes. 
As discussed in this article the % of NBS patients was different for the CF centers in the UK. 
Outcome after NBS may thus be influenced by center quality and this could not be measured. 
Some geographical regions like Scotland and Wales have no screening programs. It cannot be 
excluded that these geographical (remote) areas also differ in quality of CF care. The only 
evaluation reported was that mean age at diagnosis for the CG was not influenced by the % NBS 
patients in the respective center. Since outcome difference where comparable to the Farrell RCT, 
the authors suggest that important bias based on center quality differences is unlikely.  
In the second report by Sims et al, the potential geographical confounding was addressed by a patient 
matching procedure. Social deprivation as confounder was excluded by measuring an ‘Index of 
multiple deprivation score’ for the different groups. 
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6.  General evaluation:  Possible bias and confounders cannot be excluded but are unlikely (see 
above). Therefore these UK registry data were included in this report. Possible confounders were 
addressed in the second report. However, the exact matching procedure not fully clear.  
 
 
Accurso J Pediatr 200569 
 
1. Groups compared: Two different patient group data were analyzed. 
 A. All new CF diagnosis (age 0-20) reported in the 2000, 2001 and 2002 registry (n = 2566) split 
up in diagnostic categories (prenatal, MI, NBS, symptoms). The % of homozygous F 508del patients 
was comparable for the symptomatic and NBS group.  
 B. A cross sectional analysis of complications was performed for all patients registered in the 2002 
data base. Patient were split up in diagnostic and age categories.  
2. Evaluation of selection bias:  It is estimated that data of 90% of US CF patients are registered. 
Since the cross sectional analysis concerns 14647 patients, this large sample covers a wide sample 
of CF patients. 
3. Length of follow-up: NA   
4. Loss to follow-up: NA   
5. Possible confounders:  No detailed data are given on deaths in each group over the years, 
making it difficult to evaluate a possible survival effect in certain subgroups. The only information 
given is that neither the age at death nor the proportion of deaths in each diagnostic category and 
age group were statistically different.  
6.  General evaluation: Cross sectional analysis of very large data set; no major bias or confounder 
suspected.  
 
Lai 2004, 2005, J Pediatrics82, 87 
 
1. Groups compared: Analysis of all patient data reported during 1986-2000. Patients with 
insufficient data or born before 1960 were excluded.  Patients are categorized in 4 groups (Screen, 
family history, MI and symptoms). Groups are well defined. MI, screen and symptom group are 
further classified according to type of symptoms at time of presentation. 
2. Evaluation of selection bias: After exclusion (see above) 27 692 patients from the initial 32 229 
are available for analysis. No data on genotype or other parameters are given for the group 
excluded. Selective selection bias in unlikely based on the reported exclusion criteria.  
Analyses are performed for all patients and for the subgroup of patients diagnosed after 1986. 
3. Length of follow-up:  NA 
4. Loss to follow-up:  not specifically reported 
5. Possible confounders: To reduce a potential cohort effect (advances in CF treatment) a 
subgroup analysis was reported, only including the patients diagnosed after 1986. The age range of 
patients in each diagnostic category is however not explicitly reported. In case median age would 
be different in subgroups, treatment advances could bias outcome.   
6.  General evaluation:  The value of this study is to analysis the effect of diagnostic categories and 
age at diagnosis separately.  Age distribution bias cannot be excluded. However large differences in 
age and year of diagnosis in this large data set are unlikely. 
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APPENDIX 5: TABLES AND FIGURE FOR CHAPTER 3 
Table 1- Summary of findings regarding knowledge and information from studying parents after neonatal screening results for cystic 
fibrosis  
Authors Location Findings Note 
Mischler et al., 
1998  329 
USA False-positive:   95% understood that their child definitely did not have CF (92% at 1 year).  
True positives: at 3 months, 90% could correctly identify recurrence risk (97% at I year). Most parents of 
carriers, but not all, retained and understood this information. 
Recall risks 
Tluczek et al., 
1992352 
USA The majority of families (73%) knew about neonatal screening. There is a significant relationship between 
knowledge and the level of education. Telephone communication leads to more misunderstanding than 
face-to-face communication. 
Phone call 
Tluczek et al., 
1991353 
 
USA Parents of children in early disclosure group were much more knowledgeable than those told 4years 
later. Parents informed of negative sweat test result by telephone had significantly lower understanding 
than those informed face-to-face. 
Time delay 
Phone call 
Reprinted as authorized from HTA report 2004 - Green108  
 [a] Mischler EH et al. Cystic fibrosis newborn screening: Impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998; 102: 44-52. 
[b] Tluczek A et al. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr 1992; 13: 181-186. 
[c] Tluczek A et al. l. Psychological impact of false-positive results when screening for cystic fibrosis. Pediatric Pulmonol 1991; Supplement 7: 29-37. 
Table 2  - Parents attitudes toward true positive test compared to parents with clinically diagnosed CF child  
Study Location Findings Notes 
Baroni, 
1997354 
USA 
Wisconsin 
Parents of children diagnosed through screening were more likely to have ‘at risk’ scores (Severe 
anxiety).  
 
Boland and 
Thomp-son,  
1990355 
New 
South 
Wales 
UK 
Mothers in screened symptomatic group scored significantly lower on ‘fostering dependency’ scale.  
Mothers in screened asymptomatic group scored significantly higher on intrusiveness scale. Absence of 
observable symptoms at diagnosis did not appear to increase mothers’ protectiveness as indicated by 
anxiety scale. 
In unscreened infants, mothers desire to foster dependency decreased with length of delay in diagnosis.  
Three groups of children 
with CF: Symptomatic SG 
Asymptomatic SG and  
Unscreened clinically 
diagnosed 
Al- 
Jader, 
1990356 
Wales 
UK 
A total of 11 out of 29 parents experienced diagnostic delays resulting in ‘extreme anxiety’ – nine were 
in the screened group.  
 
Helton, 
1991357 
Colorado 
USA 
No significant differences between groups on their report of depression and anxiety at the time of 
diagnosis, most rated it a time of high anxiety whenever it occurred.  
 
Reprinted as authorized from HTA report 2004 - Green108  
[a] Baroni MA et al. Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatr Nurs 1997; 23: 143-151. 
[b] Boland C et al. Effects of newborn screening of cystic fibrosis on reported maternal behaviour. Arch Dis Child. 1990; 65: 1240-1244. 
[c] Al-Jader LN et al. Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin Genet 1990; 38: 460-465. 
[d] Helton JL et al. Parental attitudes toward newborn screening for cystic fibrosis. Pediatric Pulmonol. 1991; Supplement 7: 23-28. 
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Table 3 : Summary of Psychological impacts reported at true-positive NBS results and comparison to parents with clinically CF diagnosis 
Psychological impact NBS Clinical  
Diagnosis 
Difference 
between groups 
Comment 
All 
studies 
Cochrane 
2009-OR 
Depression ++ + NS 1.73 [0.54, 5.51] No lasting depression reported 
Strong emotional shock ++ + Trend 14.42  [4.99, 41.68] Reported in high IRT level as well 
Anxiety 
 
+++ + NS 
 
161.45 [21.57, 1208.60] Much stronger in NBS group but no lasting (Peak of anxiety)-Young 
mothers at risk. 
Stress +++ + NS / Diagnosis never expected 
Anger 0 ++  / No anger reported in NBS 
Disruption in mother-baby  
relationship 
0 
 
0  / No stigmatization or excessive maternal behavior reported 
Failure in medical confidence 0 +  / Only Observed in delayed diagnosis 
‘Fostering’ to dependency 0 + / / However, this feeling decrease while waiting period increased – Reflect 
loss of confidence on reliability of health care? 
Feeling of ‘Intrusiveness’ + Not reported  NA Only for mother with child totally asymptomatic 
‘Relief’ 0 +  NA We hope that no other mother will have to say that... 
Mischler EH eta l. Cystic fibrosis newborn screening: Impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998; 102: 44-52. 
Tluczek A et al. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr 1992; 13: 181-186. 
Tluczek A et al. Psychological impact of false-positive results when screening for cystic fibrosis. Pediatr Pulmonol. 1991; Supplement 7: 29-37. 
Tluczek A et al. Psychosocial risk associated with newborn screening for cystic fibrosis: Parents' experience while awaiting the sweat-test appointment. Pediatrics 2005; 115: 
1692-1703. 
Baroni MA et al. Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatr Nurs 1997; 23: 143-151. 
Boland C et al. Effects of newborn screening of cystic fibrosis on reported maternal behaviour. Arch Dis Childh.  1990; 65: 1240-1244. 
Al-Jader LN et al. Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin. Genet. 1990; 38: 460-465. 
Helton JL et al. Parental attitudes toward newborn screening for cystic fibrosis. Pediatr Pulmonol. 1991; Supplement 7: 23-28. 
Parsons EP et al. Psychosocial issues in newborn screening for cystic fibrosis. Paediatr Respir Rev 2003; 4: 285-292. 
Green JM et al. Psychosocial aspects of genetic screening of pregnant women and newborns: A systematic review. Health Technol Assess. 2004; 8: iii-87. 
Lewis SL et al. Parental attitudes to the identification of their infants as carriers of cystic fibrosis by newborn screening. J  Paediatr Child Health 2006;  42: 533-537. 
Hayeems RZ et al. A systematic review of the effects of disclosing carrier results generated through newborn screening. J Genet Couns 2008; 17: 538-549. 
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Table 4  - Summary of parental affects while awaiting sweat test results 
Author Sample Size Study Harm effect After normal sweat test 
Distress Anxiety Mother-baby 
Relationship 
Tluczek et al. (2005) 301 14 (IRT), 29 
(IRT/DNA) 
Wisconsin, USA Mixed methods 43%   All Relieved 
Interview 
Lewis et al. (2006) 328 31 (IRT) 
35 (IRT-DNA) 
Victoria, Australia 
Cross-sectional 
 74%  64% Relieved 
Interview 76%  71% Relieved 
Baroni et al. (1997) 354 14 
14a 
Wisconsin, USA Case-control  +  Other 
Questionnaire 
Mischler et al. (1998) 329 206;109b 
106;63c 
Wisconsin, USA, 
Case-control 
 +  Other 
Questionnaire 
Parsons et al. (2003) 358 99 UK, Mixed-Methods   No effect Other 
Adapted from Hayeems RZ (30)  
 [a] Tluczek A et al . Psychosocial risk associated with newborn screening for cystic fibrosis: Parents' experience while awaiting the sweat-test appointment. Pediatrics 2005; 
115: 1692-1703. 
[b] Lewis S et al. Parental attitudes to the identification of their infants as carriers of cystic fibrosis by newborn screening. J Paediatr Child Health 2006; 42: 533-537. 
[c] Baroni M et al. Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatr Nurs 1997; 23: 143-151. 
[d] Mischler EH et al. Cystic fibrosis newborn screening: Impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998; 102: 44-52. 
[e]Parsons EP et al. Psychosocial issues in newborn screening for cystic fibrosis.  Paediatr Resp Rev 2003; 4: 285-292. 
Table 5  - Psychological effects of disclosing carrier status: Long-term follow-up 
Author Long term follow-up  (to 6 months to  6 years after disclosing result) 
Lewis et al. (2006)  328 28–29% of parents worry about the physical health of their carrier child and about potential difficulties that being a carrier might have 
for future relationships. 12–17% of parents worry more about the health of their carrier child than that child’s siblings 
Baroni et al.(1997)  354 Stress score one year post-disclosure higher among parents who received CF carrier results compared to parents’ who received 
negative results. 
Mischler et  al.(1998) ) 329 10% of parents of carrier infants thought about the results once a week or more after 1 year 
Parsons et  al.(2003)  358 6 months post-disclosure, there was no evidence that the mother–baby relationship had been affected by carrier identification or that 
carrier status was seen by parents as a problem in terms of spoiled identity. 
Adapted from Hayeems RZ (30)  
[a] Lewis S et al. Parental attitudes to the identification of their infants as carriers of cystic fibrosis by newborn screening. J Paediatr Child Health 2006; 42: 533-537. 
[b] Baroni MA et al.  Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatr Nurs 1997; 23: 143-151. 
[c] Mischler EH et al. Cystic fibrosis newborn screening: Impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998; 102: 44-52. 
[d] Parsons EP et al. Psychosocial issues in newborn screening for cystic fibrosis. Paediatr Resp Rev 2003; 4: 285-292.
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Figure 1 – Suggested approach to sensitive communication at different steps 
of the CF NBS process  
  
 
Adapted from Hayeems RZ (30)  
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APPENDIX 6. IMPLEMENTATION OF SCREENING 
Table 1: The Australasian experience 
Country/continent Australasia 
Source Australasian Paediatric Respiratory Group 
Methodology Consensus – Working group (n=52) 
Consensus/publication 2003/2005 
Pages 7 
Number of references 40 
Experience   
 Duration >20 y (≥1981) 
 Screened NB 5.301.040 
 Algorithm IRT (D3) / DNA  
  IRT cutoff (centile) P99 
  DNA - 83% of newborns screened for a few class I,II or III mutations 
only (1 to 5 class I, II or III mutations in 5 out the 6 territories; 8 
mutations including R117H in the  Queensland). 
- Extended analysis if one mutation + positive or borderline sweat 
chloride value 
 False positive rate (-) 
 False negative rate ± 5% 
 Excess detection of carriers x  1.5-1.8 
Topics covered Practical points 
- recall process - identify a CF screening coordinator for each screening centre 
- clinical features  - ± 50 % asymptomatic at the time of diagnosis 
- 25% of infants with Meconium ileus have an IRT value below the 
cutoff level 
- sweat testing - reliable after 1 week of age in  a term infant 
- sodium measured too  
- [Cl]<30 : nl, 30-59: borderline                                                          
- quality-assurance programs 
- conductivity not accepted 
- equivocal cases - 1-2% (1 CFTR mutation after extensive analysis and intermediate 
sweat chloride values) 
- Repeat assessment at 3-6 months of age (including sweat test) 
- genetic counselling - CF + carriers  
- carrier testing of parents, estimation of recurrence risk, offer of a 
cascade family testing 
- older siblings of infants 
detected with CF 
- at least sweat test 
- Consensus statement on 
diagnosis of CF after NBS in 
infants 
1) 2 CFTR CF-causing mutations 
2) or 1 CFTR mutation + positive sweat test                                       
3) or 1 CFTR mutation + intermediate sweat chloride values + 
recognized clinical features  
 
Massie J, Clements B; Australian Paediatric Respiratory Group. Diagnosis of cystic 
fibrosis after newborn screening: the Australasian experience--twenty years and five 
million babies later: a consensus statement from the Australasian Paediatric Respiratory 
Group. Pediatr Pulmonol 2005; 39: 440-446.. 
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Table 2: The French experience 
Contents 1) Review of the literature *                                                                      
• CF NBS : the evidence towards benefits                                               
• international recommendations                                                           
• CFNBS programs outside France                                                         
2)  Analysis of the French data                                                                  
• results                                                                                               
• identification of practical problems **                                                   
• suggestions for improvement 
Methodology * Literature: search strategy,  ** Questionnaires, National Data 
analysis, Working group (n=17) + reading committee (n=38)   
Pages 174 
Number of references 151 
Experience   
 Duration 5 ans (2002 -2006) 
 Screened NB 3.527.353 
 Identified CF 808 
 Carriers 1.763 
 Algorithm  IRT D3 (± D21) / DNA  
  IRT cutoffs  D3: 60 µg/l → 65 (2003);                                                                      
D21 for infants with ↑ IRT D3 and without DNA testing:  30 µg/l → 
40 (2003)                       D21 for  infants with ↑ IRT D3 and negative 
DNA testing: 30 µg/l → 100 µg/l. 
  DNA 20 mutations → 30 (2004) 
 False positive rate “± 0.6” 
 False negative rate ± 3.4 % 
 Excess detection of carriers x 3.1 
 Median age at diagnosis 35 days 
Identified practical problems - ↑IRT (D3): lost at follow-up (%): 1.4% 
 - ↑IRT (D3) & no available consent for DNA testing (%): 2.2% 
 - equivocal cases: ± 15% (!),inconsistencies in the management, lack 
of assessment of psychological impact 
Suggestions for improvement - consider the withdrawal of R117H mutation from the initial panel         
 - consider including only Class I, II or III mutations in the initial panel       
 - further study the PAP analysis mainly in order to reduce the ret of 
carrier detection   
 - identify a screening coordinator for each maternity       
 - consider prenatal information of parents about CF NBS 
 - clarify the ethical point of obtaining consent for DNA testing from  
both parents 
 - need for (external) quality assessment of CF centres not only for 
technical aspects (sweat test, IRT dosage, DNA testing) but also in 
terms of diagnostic process … 
 - track and publish data related to infants lost at follow-up, false-
negatives, lack of consent for DNA testing, clinical symptoms at the 
moment of diagnosis.     
  
Varia - leaflet redacted by the AFDPHE about all NBS was the single source 
of information for 32 % of the hospitals (about 40% of nurses and 
paediatricians did not respond to the questionnaire) and by far the 
most used information for parents.  
 - total cost of CF NBS/ newborn: 2.24 € - cost of NBD/ detected CF: 
9.974 €   
 - a strategy for assessing the CF NBS program should have been 
defined a priori 
Haute Autorité de Santé. Le dépistage néonatal systématique de la Mucoviscidose en     
France: état des lieux et perspectives après 5 ans de fonctionnement, 2009. 
http://www.has-sante.fr/portail/jcms/c_765713/le-depistage-neonatal-systematique-de-la-
mucovsicidose-en-france-etat-des-lieux-et-perspectives-apres-5-ans-de-fonctionnement 
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Table 3: US guidelines for implementation of CF NBS programs (table of 
contents) 
Systematic  planning for CF NBS  
components of successful CF NBS programs 
CF NBS workgroups Topics for successful CF NBS programs 
Specifications for successful CF NBS programs 
Prescreen education 
• notice to parents of availability of CF NBS 
• notice to pediatric health care providers of CF NBS 
• standardized presentations 
Blood spots testing algorithms for CF NBS 
• IRT analysis: a cautionary note 
• IRT/IRT algorithms 
• IRT/DNA algorithms  
o reagents availability 
o CF genotype variation 
o Genotype/phenotype relationships 
• fail-safe for IRT/DNA protocols 
Postscreening report and education 
• positive CF NBS Report 
• negative CF NS Report 
Diagnostic testing of infants after a positive CF NBS Result: the sweat test 
•  sweat laboratory qualifications 
• minimum age and weight of the infant for valid sweat testing 
Diagnostic interpretation after the sweat test 
•  positive sweat test results 
• negative sweat test results 
• borderline sweat test results 
Communicating Diagnostic-evaluation results to the parents 
• positive CF diagnosis  
• negative CF diagnosis 
• insufficient sweat for analysis  
• diagnostic dilemmas 
Genetic counseling 
Quality assurance of CF NBS: tracking and outcome assessments  
Financing CF NBS and care 
Research opportunities 
Special considerations 
• community-customized mutation panel 
• CFTR mutations and mild disease  
• diagnostic dilemmas  
o borderline sweat-test results 
o negative sweat tests results 
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Comeau AM, Accurso FJ, White TB et al. Guidelines for implementation of cystic 
fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. 
Pediatrics. 2007; 119: e495-518 
  
Consensus / publication 
(year) 
2004/2007 
Organizing Group Cystic Fibrosis Foundation 
Contributors (n) 41 
Contributors (country of 
origin) 
US (40) , Australia 
Number of references 97 
Table 4: US guidelines for diagnosis of cystic fibrosis in newborns through 
older adults  (table of contents) 
Phenotypic features consistent with a diagnosis of CF  
Methods 
• Sweat chloride test 
o test methodology 
o test interpretation  
o sweat chloride values in infancy  
o recommended sweat chloride reference values in infancy 
o sweat chloride values beyond infancy  
o recommended sweat chloride reference values beyond infancy  
• Role of DNA analysis in CF diagnosis  
o recommended panel of CF-causing mutations 
• Role of ancillary tests in CF diagnosis 
Diagnosis of CF : consensus statement 
• Recommended CF diagnosis process for screened newborns 
• Recommended general process for diagnosing CF  
Farrell PM, Rosenstein BJ, White TB et al. Guidelines for diagnosis of cystic fibrosis in 
newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 
2008 ; 153: S4-S14 
Consensus / publication 
(year) 
2007/2008 
Organizing Group Cystic Fibrosis Foundation  
Contributors (n) 18 
Contributors (country of 
origin) 
US, Canada (1), Australia (1), Europa (1) 
Number of references 80 
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Table 5: European best guidelines for CF NBS (table of contents) 
1. The rationale for CF neonatal screening 
1.1 Benefits 
• pancreatic disease 
• growth 
• nutritional deficiencies  
• lung involvement 
• burden of care 
• psychosocial effects 
• survival 
1.2 Hazards 
• anxiety 
• knowledge of carrier status 
• inconclusive NBS results 
• infection with Pseudomaonas aeruginosa 
• potential for ethnic discrimination 
2. Protocols and technical issues 
2.1 The first tiers: IRT 
• IRT cut offs  
• quality control 
• age at sampling 
• stability of IRT in blood spots 
• non CF causes of increased IRT  
2.2 Intermediate tiers 
• second sample IRT assay 
• CFTR mutation analysis 
• PAP analysis 
3. Diagnosis through CF NBS 
3.1 Sweat test 
3.2 Inconclusive diagnosis 
3.3 Clinical follow-up 
4. Information to families 
4.1 Before CF NBS 
4.2 After a positive NBS test 
4.3 At diagnosis 
4.4 For parents of carrier infants  
Castellani C, Southern K, Brownlee K et al. European best practice guidelines for cystic 
fibrosis neonatal screening.                                                                                               
J Cyst Fibros. 2009; 8: 153-173. 
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Consensus / publication 
(year) 
2008/2009 
Organizing Group European Cystic Fibrosis Society  
Contributors (n) 34 
Contributors (country of 
origin) 
Europa, US (2), Australia (2)  
Number of references 126 
Flowchart 1:  The CF diagnostic process for screened newborns 
 
Source : Farrell PM, Rosenstein BJ, White TB et al.   Guidelines for diagnosis of cystic fibrosis in 
newborns through older adults: Cystic Fibrosis    Foundation consensus report. J Pediatr. 2008 ; 
153: S4-S14   
140 Cystic Fibrosis Neonatal Screening KCE Reports 132   
Table 6: Components of successful CF NBS programs 
 
Source : Comeau AM,  Accurso FJ, White TB et al. Guidelines for implementation of cystic 
fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics. 
2007; 119: e495-518  
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Table 7: Suggested CF NBS Workgroups topics for successful CF NBS 
programs 
 
Source : Comeau AM,  Accurso FJ, White TB et al. Guidelines for implementation of cystic 
fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. 
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Table 8: Suggested items to be recorded for quality control of a CF NBS 
program 
 
Source : Comeau AM,  Accurso FJ, White TB et al. Guidelines for implementation of cystic 
fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. 
KCE Reports 132 Cystic Fibrosis Neonatal Screening 143 
Table 9: Recommendations for counselling about positive NBS results 
  
Source : Castellani C, Southern K, Brownlee K et al. European best practice guidelines for cystic 
fibrosis neonatal screening. J Cyst Fibros. 2009; 8: 153-173. 
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Table 10: Recommendations for counselling parents when CF NBS identifies 
carrier infants  
 
Source : Castellani C, Southern K, Brownlee K et al. European best practice guidelines for cystic 
fibrosis neonatal screening. J Cyst Fibros. 2009; 8: 153-173. 
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Figure 2. General scheme. 
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Figure 3. Suggested role of supervising structure. 
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Figure 4. Suggested role of newborn screening laboratories. 
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Figure 5. Suggested role of the CF centres. 
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APPENDIX 7. CFTR MUTATION TEST KITS   
Innogenetics Luminex Corporation 
RDB-INNO LiPA 
CFTR17+Tn Update 
RDB-INNO LiPA 
CFTR19 
xTAG® Cystic 
Fibrosis 39 kit v2 
xTAG® Cystic 
Fibrosis 71 kit v2 
E60X I148T F508del F508del 
G85E 711+1G>T I507del I507del 
394delTT I507del G542X G542X 
R117H F508del G85E G85E 
621+1G>T 1717-1G>A R117H R117H 
711+5G>A G542X 621+1G>T 621+1G>T 
1078delT G551D 711+1G>T 711+1G>T 
R334W Q552X R334W R334W 
R347P R553X R347P R347P 
A455E R560T A455E A455E 
2143delT 1898+1G>A 1717-1G>A 1717-1G>A 
2183AA>G 3120+1G>A R560T R560T 
2184delA S1251N R553X R553X 
2789+5G>A 3905insT G551D G551D 
R1162X W1282X 1898+1G>A 1898+1G>A 
3659delC N1303K 2184delA 2184delA 
3849+10kbC>T 3272-26A>G 2789+5G>A 2789+5G>A 
5T CFTRdele2,3 3120+1G>A 3120+1G>A 
7T 3199del6 R1162X R1162X 
9T   3659delC 3659delC 
    3849+10kbC>T 3849+10kbC>T 
    W1282X W1282X 
    N1303K N1303K 
    5T 5T 
    7T 7T 
    9T 9T 
    F508C F508C 
    I507V I507V 
    I506V I506V 
    1078delT 1078delT 
    394delTT 394delTT 
    Y122X Y122X 
    R347H R347H 
    V520F V520F 
    A559T A559T 
    S549N S549N 
    S549R S549R 
    1898+5G>T 1898+5G>T 
    2183AA>G 2183AA>G 
    2307insA 2307insA 
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    Y1092X Y1092X 
    M1101K M1101K 
    S1255X S1255X 
    3876delA 3876delA 
    3905insT 3905insT 
      E60X 
      R352Q 
      2869insG 
      R75X 
      S364P 
      3120G>A 
      405+3A>C 
      G480C 
      3199del6 
      406-1G>A 
      Q493X 
      444delA 
      G622D 
      W1089X 
      R117C 
      1677delTA 
      D1152H 
      R1158X 
      G178R 
      1812-1G>A 
      3791delC 
      L206W 
      2055del9>A 
      S1196X 
      935delA 
      2143delT 
      CFTRdel2,3 
      F311del 
      K710X 
      R1066C 
      G330X 
      Q890X 
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Abbott 
Molecular 
Tepnel Molecular Diagnostics - Gen-Probe Life Sciences 
Cystic Fibrosis 
Genotyping 
Assay CF29v.2 CF-EU1 CF30 CF7 
G85E E60X CFTRdele2,3 E60X F508del 
394delTT G85E E60X G85E 1717-1G>A 
R117H R117H P67L 394delTT G542X 
621+1G>T 621+1G>T G85E R117H D1152H 
711+1G>T 711+1G>T R117H Y122X 3849+10kbC>T 
1078delT 1078delT 621+1G>T 621+1G>T W1282X 
R334W R334W 711+1G>T 711+1G>T N1303K 
R347H R347P 1078delT 1078delT   
R347P A455E R334W R334W   
A455E I507del R347P R347P   
I507del F508del A455E A455E   
F508del 1717-1G>A I507del I507del   
V520F G542X F508del F508del   
1717-1G>A G551D 1717-1G>A 1717-1G>A   
G542X R553X G542X G542X   
S549N 2183AA>G G551D G551D   
S549R(T>G) 2789+5G>A R553X R553X   
G551D 3120+1G>A R560T 2183AA>G   
R553X R1162X 1898+1G>A 2789+5G>A   
R560T 3659delC 2184delA 3120+1G>A   
1898+1G>A 3849+10kbC>T 2789+5G>A R1162X   
2183AA>G S1251N 3120+1G>A 3659delC   
2184delA W1282X M1101K 3849+10kbC>T   
2789+5G>A N1303K D1152H S1251N   
3120+1G>A 2184delA R1162X W1282X   
R1162X R560T 3659delC N1303K   
3659delC 1898+1G>A 3849+10kbC>T 3272-26A>G   
3849+10kbC>T D1152H S1251N 1811+1.6kbA>G   
3905insT 394delTT 3905insT Y1092X   
W1282X   W1282X W846X   
N1303K   N1303K     
3876delA   S549RT>G       
          
    5T (incl. TGm)     
    7T     
    9T     
Mutations shown in italics are polymorphisms. Some of them are included in some assays since 
these polymorphisms may either result in a false positive signal for a mutation because of cross-
reactivity with the corresponding mutant probe and which can be controlled in this way. I148T 
was initially assigned as a CF-causing mutation, but later turned out to be a polymorphism (I148T) 
359, 360. Data are provided by the kit instruction manuals or the respective company websites. 
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APPENDIX 8. REVIEW ECONOMIC LITERATURE 
PUBLISHED LITERATURE – SEARCH STRATEGY 
Search for cost-effectiveness studies 
On December 19, 2009, the websites of HTA institutes (Table ) and following databases 
were searched: Centre for Reviews and Dissemination (CRD) databases (Health 
Technology Assessments (HTA) and NHS Economic Evaluation Database (NHS EED)) 
Medline (indexed and non-indexed citations), and Embase. The following four tables 
(Table  to Table ) provide an overview of the search strategy. 
Table 1: List of INAHTA member websites searched for HTA reports 
Agency Country 
AETMIS - Agence d´Évaluation des Technologies et des Modes 
d´Intervention en Santé 
Canada 
AETS - Agencia de Evaluación de Tecnologias Sanitarias Spain 
AETSA - Andalusian Agency for Health Technology Assessment Spain 
AGENAS - L'Agenzia nazionale per i servizi sanitari regionali - The Agency 
for Regional Healthcare 
Italy 
AHRQ - Agency for Healthcare Research and Quality USA 
AHTA - Adelaide Health Technology Assessment Australia 
AHTAPol - Agency for Health Technology Assessment in Poland Poland 
ASERNIP-S - Australian Safety and Efficacy Register of New Interventional 
Procedures -Surgical 
Australia 
AVALIA-T - Galician Agency for Health Technology Assessment Spain 
CADTH - Canadian Agency for Drugs and Technologies in Health Canada 
CAHTA - Catalan Agency for Health Technology Assessment and 
Research 
Spain 
CDE - Center for Drug Evaluation Taiwan 
CEDIT - Comité dÉvaluation et de Diffusion des Innovations 
Technologiques  
France 
CENETEC - Centro Nacional de Excelencia Tecnológica en Salud Reforma Mexico 
CRD - Centre for Reviews and Dissemination United Kingdom 
CVZ - College voor Zorgverzekeringen The Netherlands 
DACEHTA - Danish Centre for Evaluation and Health Technology 
Assessment 
Denmark 
DAHTA @DIMDI - German Agency for HTA at the German Institute for 
Medical Documentation and Information 
Germany 
DECIT-CGATS - Secretaria de Ciëncia, Tecnologia e Insumos 
Estratégicos, Departamento de Ciência e Tecnologia 
Brazil 
DSI - Danish Institute for Health Services Research Denmark 
ETESA - Department of Quality and Patient Safety of the Ministry Health 
of Chile 
Chile 
FinOHTA - Finnish Office for Health Care Technology Assessment Finland 
GÖG - Gesunheit Österreich GmbH Austria 
GR - Gezondheidsraad The Netherlands 
HAS - Haute Autorité de Santé France 
HIQA - Health Information and Quality Authority Ireland 
HSAC - Health Services Assessment Collaboration New Zealand 
ICTAHC - Israel Center for Technology Assessment in Health Care Israel 
IECS - Institute for Clinical Effectiveness and Health Policy Argentina 
IHE - Institute of Health Economics Canada 
IMSS - Mexican Institute of Social Security Mexico 
IQWiG - Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Germany 
KCE - Belgian Federal Health Care Knowledge Centre Belgium 
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LBI of HTA - Ludwig Boltzmann Institut für Health Technonoly 
Assessment 
Austria 
MaHTAS - Health Technology Assessment Section, Ministry of Health 
Malaysia 
Malaysia 
MAS - Medical Advisory Secretariat Canada 
MSAC - Medicare Services Advisory Committee Australia 
MTU-SFOPH - Medical Technology Unit - Swiss Federal Office of Public 
Health 
Switzerland 
NCCHTA - National Coordinating Centre for Health Technology 
Assessment 
United Kingdom 
NHS QIS - Quality Improvement Scotland United Kingdom 
NHSC - National Horizon Scanning Centre United Kingdom 
NOKC - Norwegian Knowledge Centre for Health Services Norway 
OSTEBA - Basque Office for Health Technology Assessment Spain 
SBU - Swedish Council on Technology Assessment in Health Care Sweden 
UETS - Unidad de evaluacíon Technologias Santarias Spain 
UVT - HTA Unit in A.Gemelli University Hospital Italy 
VASPVT - State Health Care Accreditation Agency under the Ministry of 
Health of the Republic of Lithuania 
Lithuania 
VATAP - VA Technology Assessment Program USA 
ZonMw - The Medical and Health Research Council of The Netherlands The Netherlands 
Table 2: Search strategy and results for CRD 
Date December 19, 2009 
Database  CRD (HTA & NHS EED) 
Date covered No restrictions 
Search Strategy # Search History Results 
1 MeSH Cystic Fibrosis EXPLODE 111 
2 MeSH Neonatal Screening EXPLODE 169 
3 #1 and #2 15 
Note 15 references were found in CRD, of which 4 were from the HTA database 
and 9 from the NHS EED database. The other two references were identified 
in the DARE (Database of Abstracts of Reviews of Effectiveness) database and 
thus not included in this search for economic literature. 
Table 3: Search strategy and results for Medline (OVID) (part I) 
Date December 19, 2009 
Database Medline (OVID) 
Date covered 1996 to November Week 3 2009 
Search Strategy 
 
# Search History Results 
1 economics/ 5197 
2 exp "Costs and Cost Analysis"/ 85445 
3 "Value of Life"/ec [Economics] 190 
4 Economics, Dental/ 150 
5 exp Economics, Hospital/ 7770 
6 Economics, Medical/ 690 
7 Economics, Nursing/ 437 
8 Economics, Pharmaceutical/ 1707 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 94164 
10 (econom$ or cost$ or pric$ or 
pharmacoeconomic$).tw. 221337 
11 (expenditure$ not energy).tw. 8042 
12 (value adj1 money).tw. 6 
13 budget$.tw. 7868 
14 10 or 11 or 12 or 13 229073 
15 9 or 14 266657 
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16 letter.pt. 358796 
17 editorial.pt. 166047 
18 historical article.pt. 91459 
19 16 or 17 or 18 608734 
20 15 not 19 252634 
21 Animals/ 1929502 
22 human/ 5235629 
23 21 not (21 and 22) 1280513 
24 20 not 23 231814 
25 (metabolic adj cost).ti,ab,sh. 344 
26 ((energy or oxygen) adj cost).ti,ab,sh. 1104 
27 24 not (25 or 26) 230720 
28 exp Cystic Fibrosis/ 10886 
29 exp Neonatal Screening/ 4067 
30 28 and 29 305 
31 27 and 30 41 
Note  
Table 4: Search strategy and results for Medline (OVID) (part II) 
Date December 19, 2009 
Database Medline (OVID), In-Process & Other Non-Indexed Citations 
Date covered No restrictions 
Search Strategy 
 
# Search History Results 
1 cost$.mp. 18466 
2 economic$.mp 7845 
3 budget$.mp. 930 
4 expenditure$.mp. 1514 
5 1 or 2 or 3 or 4 25865 
6 cystic fibrosis {Including Related Terms} 2520 
7 screening {Including Related Terms} 28775 
8 newborn {Including Related Terms} 7849 
9 neonatal {Including Related Terms} 7265 
10 8 or 9 8015 
11 6 and 7 and 10 24 
Note  
Table 5: Search strategy and results for EMBASE 
Date December 19, 2009 
Database  EMBASE 
Date covered No restrictions 
Search Strategy 
 
# Search History Results 
1 socioeconomics'/exp 119571 
2 'cost benefit analysis'/exp 51280 
3 'cost effectiveness analysis'/exp 63016 
4 'cost of illness'/exp 10000 
5 'cost control'/exp 34899 
6 'economic aspect'/exp 832197 
7 'financial management'/exp 215570 
8 'health care cost'/exp 144133 
9 'health care financing'/exp 9756 
10 'health economics'/exp 453519 
11 'hospital cost'/exp 19115 
12 'finance'/exp 8156 
13 'funding'/exp 5714 
14 fiscal 4983 
15 financial 245565 
16 #12 OR #13 OR #14 OR #15 253890 
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17 'cost minimization analysis'/exp 1615 
18 estimate*:ti,ab,de,cl 445891 
19 cost*:ti,ab,de,cl 446949 
20 variable*:ti,ab,de,cl 419922 
21 unit:ti,ab,de,cl 277494 
22 '#19 *4 #18' OR '#18 *4 #19' 441333 
23 '#19 *4 #20' OR '#20 *4 #19' 416796 
24 '#19 *4 #21' OR '#21 *4 #19' 32639 
25 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 
OR #9 OR #10 OR #11 OR #16 OR #17 OR #22 OR 
#23 OR #24 1691747 
26 'cystic fibrosis'/exp 33329 
27 'newborn screening'/exp 7359 
28 #26 AND #27 728 
29 #25 AND #28 124 
Note  
RESULTS OF SEARCH STRATEGY 
A total of 202 manuscripts were identified in several databases: 65 with Medline, 124 
with Embase, and 13 with the CRD NHS EED and HTA databases (Table ). After 
removing 42 duplicates, 160 articles were left. These were considered for further 
inclusion in two rounds; a first round based on title, abstract (if available), and keywords 
(if available); a second round based on full text evaluation. 
Table 6: search for cost-effectiveness studies: summary 
Database Search date or 
Years included 
References 
identified 
CRD Dec. 19, 2009  
   HTA 4 
   NHS EED 9 
MEDLINE 1996 to Nov. Week 
3 2009 
41 
MEDLINE In-Process & Other 
Non-Indexed Citations 
Dec. 19, 2009 24 
EMBASE Dec. 19, 2009 124 
Total references identified  202 
Duplicates  42 
Total  160 
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